Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders by Ahmad, Rabia
 
DOCTORAL THESIS
Effects of glucocorticoid overload on central regulatory systems involved in responses








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.










“Effects of glucocorticoid overload on central 
regulatory systems involved in responses to stress – 
preclinical investigations into putative molecular 












Rabia Ahmad, BSc (Hons). 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of PhD 
Department of Life Sciences 






Irregularities of the Hypothalamic Pituitary Adrenal (HPA) axis are 
implicated in stress-related mood disorders. The ensuing long-term elevations in 
circulating glucocorticoids are associated with neurobiological changes seen in 
depression. This thesis aims to identify some of the brain mechanisms by which 
exposure to chronic stress may lead to depression using a preclinical 
experimental approach.  
The role of the serotonin system in the aetiology of mood disorders is 
well established, although this is not considered to be the only factor which 
causes these mood disorders. Interactions between the serotoninergic, 
peptidergic and endocannabinoid systems in response to glucocorticoids have 
been proposed. As all three neurotransmitter systems are involved in the 
regulation of the HPA axis, they are implicated in the dysfunction which is seen 
in depression. Furthermore, oxytocin, vasopressin and endocannabinoids are 
known to influence serotonergic neurotransmission and therefore it is pertinent 
to understand how glucocorticoids directly and indirectly impact serotonergic 
neurotransmission. In this thesis, the effect of chronic exposure to corticosterone 
on the serotonergic system is determined and also the relative contribution of the 
peptidergic and endocannabinoid systems to stress-induced mood disorders is 
considered. In addition, glucocorticoid-dependant receptor changes in these 
systems are related to neurotransmitter activity in brain regions involved in 
responses to stress. This has not previously been studied nor have the 
simultaneous effects of glucocorticoids on the serotonergic, peptidergic and 
endocannabinoid systems.  
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Here, preclinical approaches are applied to investigate the above 
mentioned receptor systems and their involvement in depression resulting from 
exposure to chronic stress.  Administration of exogenous corticosterone (400 
µg/mL) to rats for 21 days, via addition to drinking water, resulted in changes in 
expression of central 5-HT1A, oxytocin, vasopressin 1a and CB1 receptors. This 
dose was selected as it has previously shown to induce depression-like behaviour 
in rats and also hippocampal atrophy similar to that seen in depressed patients 
(Magarinos et al 1998; Donner et al., 2012). In order to understand how these 
changes relate to the central concentrations of endogenous ligands, the 
concentration of serotonin, 5-HIAA, oxytocin and vasopressin was also 
measured in brain tissue.  
Here, circulating corticosterone concentration was increased, as it is in 
chronic stress and in some depressed patients. Binding of the post synaptic 5-
HT1A receptor was upregulated in response to chronic stress in the form of 
elevated corticosterone concentration without a concomitant change in serotonin 
turnover suggesting that elevated corticosterone exposure modulates the 5-HT1A  
receptor independently of serotonin turnover. Whereas presynaptic 5-HT1A 
receptor binding was unaffected.  In addition, chronic corticosterone exposure, 
as can be seen in depression, resulted in a decrease in binding to the oxytocin 
receptor in the hypothalamus associated with an increase in oxytocin 
concentration suggesting possible internalisation of the oxytocin receptor in this 
region. Conversely, there was an upregulation of the oxytocin receptor in the 
septal nuclei and raphé, with no associated change in oxytocin content in the 
same regions. Moreover, vasopressin 1a receptor binding was increased in septal 
nuclei and PODG subregion of the dorsal hippocampus, but decreased in the 
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hypothalamus. There was no change in vasopressin content in any brain region 
sampled, suggesting that these may be independent of peptide concentration. For 
the CB1 receptor, elevated corticosterone concentration, indicative of chronic 
stress, resulted in a decrease in receptor binding was found in the striata and 
raphé after chronic corticosterone treatment.  
Taken together, in particular the effect on receptor binding in the raphé, 
the present data suggest that elevated corticosterone exposure may modulate 
serotonergic neurotransmission via the oxytocin and CB1 receptor.  In addition, 
the hypothalamic peptidergic responses imply a potential role in glucocorticoid-
induced dysregulation of the HPA axis. These changes may help further 
elucidate their respective roles in depression and stress related mood disorders. 
In conclusion, the work presented in this thesis shows that the response 
to glucocorticoids is multifaceted and that there are changes observed in multiple 
neurotransmitter systems which regulate the HPA axis. Thus, the combined 
effect of the neurotransmitter systems studied here is of relevance to stress 
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In 1965 Schildkraut and Ketty introduced the monoamine hypothesis for 
the aetiology of depression, which suggests that the disorder is a resultant effect 
of decreased concentrations of neurotransmitters, particularly monoamines 
(serotonin, noradrenalin and dopamine), in the brain (Raap et al., 1999). More 
specifically, the serotonergic system has been implicated in the aetiology of 
depression, as the major symptoms of the disorder, such as disturbances in 
mood, sleep and appetite, were found to be induced by a reduction in serotonin 
concentrations in the brain (Lucki, 1998). The theory focused on central 
serotonergic deficiency as a prominent feature in the aetiology of depression, 
which influenced the pharmaceutical industry towards developing drugs 
targeting the serotonergic system. This resulted in a wide-spread use of the 
narrowly selective pro-serotonergic antidepressants, namely serotonin selective 
17 
 
reuptake inhibitors (SSRIs) in the 1990’s. However, since then it has been 
recognised that the aetiology of depression is more complex and efforts are now 
being placed on elucidating the contribution of other neuroregulatory systems 
that may be involved. Of particular concern is the high rate of patients who do 
not respond to currently available pro-serotonergic therapeutics (30-40%), which 
may be related to the heterogeneity of mood disorders (Kirsch et al., 2008; 
Matthews et al., 2005, Slattery and Neumann, 2010).  
Considering that up to 50% of depressed patients exhibit underlying 
dysfunction of the hypothalamic pituitary adrenal axis (HPA), the contribution 
of elevated glucocorticoids towards depression and mood related disorders is of 
importance (Anacker et al., 2011). By understanding the involvement and 
interactions of other neurotransmitter systems, it is envisaged that advanced 
diagnosis and more effective drugs can be developed to improve the clinical 
management of depressed patients. To further this area of research, the influence 
of elevated circulating glucocorticoids on neurotransmitter systems involved in 
depression (its development and maintenance, and recovery from the disease) 
needs to be investigated and the potential to use these changes in stratifying and 
improving the therapeutic outcome of  depressed patients needs to be evaluated.  
 
1.1 Aims and Hypothesis 
1.1.1 Aims 
The aim of this thesis is to understand the influence of chronically elevated 
glucocorticoids on the serotonergic, peptidergic and endocannabinoid 
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neurotransmitter systems, which are known to be involved (or putatively 
involved) in the development of depression. More specifically, I aim to assess 
receptor responses to chronic glucocorticoid exposure, as a model of chronic 
stress, and couple these changes with an analysis of endogenous ligand 
concentration. Initially serotonergic responses to chronically elevated 
glucocorticoid level are determined as a reference system. Then the relative 
contribution of the oxytocinergic, vasopressinergic and CB1 receptor systems 
will be measured as there are known interactions between these neurotransmitter 
systems and serotonergic neurotransmission (Jørgensen et al., 2003; Haj-
Dahmane and Shen, 2009; Yoshida et al., 2009). There is great interest in 
elucidating the role of oxytocin in the stress response as selective serotonin 
inhibitors (SSRIs) are known to induce the release of oxytocin (Uvnas Moberg et 
al., 1999). Oxytocin governs emotional behaviours that lead to positive social 
interactions (Kosfeld et al., 2005; Debiec 2007; Heinrichs et al., 2003) and is 
released in the hippocampus, amygdala,  septum and hypothalamus i.e. regions 
that are rich in glucocorticoid receptors and involved in the regulation of mood  
(Engelmann et al., 1996; Huber et al., 2005; Liberzon and Young 1997). 
Furthermore the 5-HT1A receptor antagonist WAY100635 inhibits 5-HT induced 
release of oxytocin and vasopressin (Jørgensen et al., 2003). Whereas, oxytocin 
has a tonic inhibitory role on the HPA axis, the vasopressinergic system is a 
potent activator of the HPA axis (Scott and Dinan, 1998). The effect of 
chronically elevated glucocorticoids on vasopressin 1a receptor binding in 
extralimbic brain regions has not previously been studied, although interactions 
between the vasopressinergic and serotonergic system are established. The V1a 
receptor is of relevance to aggression-related behaviour (McCall and Singer, 
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2012). Aggression is thought to be regulated via interactions between the 
serotonin and vasopressin systems, whereby serotonergic synapses have been 
observed on vasopressinergic neurones at the level of the hypothalamus, with 
serotonergic innervation to the hypothalamus originating from the raphé (Ferris 
and Delville, 1999). Thus, it is of interest to determine the vasopressinergic 
response to glucocorticoids in relation to those of the serotonergic and 
oxytocinergic systems. Furthermore, the study also aims to investigate CB1 
receptor responses to corticosterone. The CB1 receptor also exerts a tonic 
inhibitory action on the HPA axis (Cota et al., 2007). Activation of the CB1 
receptor in the raphé leads to inhibition of serotonin release in projection areas 
(Egashira et al., 2002) whereas pharmacological blockade of CB1 receptors 
enhances basal extracellular serotonin concentration in the prefrontal cortex 
(Haj-Dahmane, 2011). This is the first study to investigate the effect of 
corticosterone on CB1 receptor binding in extralimbic regions such as the raphé 
and attempts to relate any changes to the serotonergic and peptidergic system 
responses to glucocorticoids.   
In addition, the present study aims to understand the glucocorticoid-induced 
changes in receptor binding in regards to endogenous neurotransmitter 
concentration. The changes observed in 5-HT1A, oxytocin and vasopressin 1a 
receptor binding will be considered alongside changes in serotonin turnover, 
oxytocin and vasopressin content in brain regions involved in the stress 
response. This is the first time that this type of dual approach has been taken to 
gain a more complete understanding of the responses of these neurotransmitter 





It is hypothesised that chronic treatment with corticosterone, will lead to 5-HT1A 
receptor density changes similar to those already published in the literature. 
More specifically, there will be a reduction in binding at the 5-HT1A receptor in 
the limbic brain regions implicated in responses to stress. Also, it is hypothesised 
that these receptor changes will be linked to serotonin turnover effects in limbic 
brain regions implicated in responses to stress. 
Also, it is hypothesised that chronic exposure to glucocorticoids will 
result in changes to the oxytocin and vasopressin 1a receptors in brain regions 
that are involved in the regulation of responses to stress. The direction of 
changes in receptor binding will reflect changes in the concentration of their 
endogenous neurotransmitter. In addition, it is hypothesised that plasma 
concentrations of oxytocin and vasopressin will reflect central concentrations of 
each neuropeptide.  
With regards to the endocannabinoid system, it is hypothesised that 
chronic exposure to high concentrations of glucocorticoid for 21 days will result 
in changes to CB1 receptor binding in brain regions that are involved in the 
regulation of responses to stress. The direction of changes in receptor binding is 
expected to reflect changes in the concentration of endocannabinoids, according 
to the previously published literature. More specifically, it is hypothesised that 
chronic exposure to glucocorticoids will result in an decrease in CB1 receptor 
binding in amygdala and hippocampus amongst other brain regions associated 
with the regulation of responses to stress.  
The aims and hypothesis stated above are tested using a preclinical approach, 
whereby rats were administered corticosterone (400 µg/mL) for 21 days and 
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changes in receptor binding were assessed using autoradiography. Furthermore, 
concentrations of serotonin, oxytocin and vasopressin were measured in discrete 
brain regions using HPLC or radioimmunoassay. Exact details of methodology 
are given in chapter 4 and further discussion of the aims and hypothesis are 
given in the respective experimental chapters. As hypothesised above, chronic 
exposure to glucocorticoids will result in changes in the serotonergic, 
peptidergic and endocannabinoid systems which all regulate the stress response. 
There are interactions between these neurotransmitter systems as well as their 
involvement in the stress response. It is hypothesised that glucocorticoid 
exposure influences the serotonergic system, but this is also affected by the 
peptidergic and endocannabinoid systems which could contribute to the 
dysfunction observed in stress-related mood disorders. 
 
1.2 Outline of thesis 
This thesis is organised in the following manner: 
In chapter 2, an introduction to depression, anxiety and hence stress 
related mood disorders is given. I discuss the factors that cause these disorders 
and the current understanding of the neurobiology of depression with a focus on 
the involvement of HPA axis dysfunction. Then in chapter 3, I discuss the 
involvement of the central serotonergic, peptidergic and endocannabinoid 
systems in depression and regulation of the stress response.  
Chapter 4 focuses on methodology. I discuss the theory of techniques 
selected for use in this thesis with justification for their selection. I then provide 
detailed methods for the experiments conducted as part of this investigation. I 
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also report findings from a feasibility study which was designed to evaluate the 
most effective method for dosing rats with glucocorticoids for subsequent 
experimental chapters, i.e. administering corticosterone (CORT) by daily 
subcutaneous injections or addition of CORT to drinking water for 21 days. 
Chapters 5, 6 and 7 describe the experimental studies designed to assess 
whether elevated corticosterone concentrations induce changes in central 
receptors or their endogenous ligands. Changes are measured in discrete brain 
regions known to be involved in the regulation of mood. Chapter 5 focuses on 
the serotonergic system. I report on changes in binding to the 5-HT1A receptor 
and attempt to relate them to changes in endogenous serotonin concentration. In 
chapter 6, I describe changes in binding to the oxytocin and vasopressin 1a 
receptors in response to elevated glucocorticoid levels and also attempt to relate 
them to changes in endogenous peptide concentrations. Chapter 7 describes 
changes at the CB1 receptor after chronic exposure to corticosterone. 
Finally, chapter 8 summarises the findings from the work presented 
herein with a view to understanding the impact of glucocorticoids on 
serotonergic and non-serotonergic receptor responses and coupling these with an 
analysis of endogenous ligand concentration in both limbic and extralimbic 
regions. The interactions of these neurotransmitter systems are also discussed. I 
also outline future work that is enabled from this study and the potential of these 
receptor systems as targets for molecular imaging of glucocorticoid associated 








Depression and anxiety as stress 
related disorders 
Mental health disorders such as depression, unipolar or bipolar disorder, 
depressive illness and dysthymia are common and widespread throughout the 
world. It is estimated that 1 in 6 people will experience some form of depression 
at any given time in the UK, which is often accompanied by an anxiety –related 
disorder (The Office for National Statistics, 2000). Depression is the most costly 
mental health disorder in Europe, with an annual spend of € 118 billion in 2004 
as determined from a population of 466 million, across 28 countries (Sobocki et 
al., 2006). Furthermore, treatment resistant patients show an even higher per 
patient medical cost (Olchanski et al., 2013). In fact, The World Health 
Organisation (WHO) have reported that the incidence of depression is on the 
increase and that this disorder could come second place in the ranking of 
Disability Adjusted Life Years (DALY’s, calculated as the sum of years of 
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potential life lost due to premature mortality and the years of productive life lost 
due to disability) for all ages and both sexes worldwide by the year 2020  This 
warrants further research into the causes, treatment and prevention of depression 
in order to curb its global growth and its associated burden on the economy 
(Murray and Lopez 1997; WHO, 2012).  
 
2.1   Different types of depression 
Depression is a heterogeneous disorder with patients experiencing a 
varying degree of depression from a single episode, to one which may become 
progressively worse, or to those that follow a remitting-relapse pattern 
throughout their lives. Each form of depression is distinct from each other, 
although there may be some overlapping symptoms. Major depressive disorder 
(MDD) is characterised by a series of symptoms which significantly affect an 
individual’s ability to function normally. Daily activities such as sleeping, eating 
and working are severely disrupted. Dysthymic disorder is not as severe as 
MDD, but the symptoms will last for at least two years, although episodes of 
MDD may co-occur during this time. There are also a range of disorders which 
can be grouped and classified as minor depression; these are psychotic 
depression, postpartum depression and seasonal affective disorder. In addition, 
there is a less common type of depression called bipolar depression (BD) which 
is characterised by severe mood swings, from extreme high and lows (National 
Institute of Mental Health, 2011). Depression may also arise as a result of 
suffering a life-changing illness such as cancer (Avis et al., 2013), diabetes 
(Baumeister et al., 2012) and stroke (Bartoli et al., 2013) amongst many chronic 
illnesses which may lead to depression. 
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Depression is often comorbid with an anxiety related disorder and in fact, 
prolonged periods of anxiety can lead to depression. Anxiety disorders are also 
heterogeneous ranging from generalised anxiety disorder, phobias, panic 
disorder, post-traumatic stress disorder (PTSD), obsessive compulsive disorder 
(OCD) and separation disorder (Kessler et al., 1995). One of the major risk 
factors for developing an anxiety disorder is exposure to stress (Yehuda, 2002). 
The neurobiology of depression and stress-related depression can be found in 
section 2.1.3. 
 
2.1.1  Diagnosis of depression 
As a diagnostic test for depression does not exist, clinicians depend on 
the use of patient self-reports and clinical observations, which are scored against 
a recognised set of behavioural and clinical criteria stated in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM, American Psychiatric 
Association), the International Classification of Disease (ICD, World Health 
Organization) and guidance from the National Centre for Health and Clinical 
Excellence (NICE 2009). However, diagnosis in this way can be subjective, 
nonspecific and many clinicians struggle to confirm a diagnosis of depression 
which has led to the over prescription of antidepressants into the general 
population (Pajer et al., 2012). In addition, a further clinical unmet need is for a 
test which distinguishes between the different types of depression. This would 
enable the stratification of patients according to the type of depression, allowing 
for more effective selection of treatment regime and hopefully a better 
therapeutic outcome.  
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Interest is growing in identifying biomarkers which may improve the 
accuracy of diagnosis providing objective data to confirm the verbal information 
provided by the patient, or specificity of the diagnosis to a particular type of 
depression (Pajer et al., 2012). A biomarker is defined as a measurable feature 
that is associated with a particular disorder (Pajer et al., 2012). They can be used 
for diagnosis or stratification of patients within a heterogeneous disease and 
determining the most suitable treatment approach (Schmidt et al., 2011). Whilst 
it is accepted that no single biomarker exists for depression, investigators 
continue to study changes in depression and look for a biosignature or panel of 
biomarkers which may aid diagnosis or stratification of patients for therapy. 
These can be classified as either blood based cerebrospinal fluid (CSF) or tissue 
based biological changes that are associated with a disease and can be measured 
using a range of techniques (detailed in chapter 4). 
A range of variables have been investigated as potential biomarkers from 
inflammatory mediators, cytokines and growth factors through to hormones and 
receptors (Schmidt and Duman, 2007; Krishnan and Nestler 2008; Miller et al, 
2009; Castren and Rantamaki, 2010). For example, brain-derived neurotrophic 
factor (BDNF) has been reported to be reduced in the blood of depressed 
patients (Sen et al., 2008); and concentrations of monocyte chemoattractant 
protein-1 are increased in cerebral spinal fluid (CSF) of depressed patients. 
Moreover, the serotonin metabolite, 5-hydroxyindole acetic acid (5-HIAA) is a 
strong predictor of depression (Raison et al., 2009), and glucocorticoid levels in 
plasma have been shown to reflect central changes in glucocorticoid receptor 
expression in some, but not all depressed patients (Schmidt et al., 2011).  
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Non-invasive molecular imaging techniques such as positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) 
can be used to detect abnormalities in the brains of depressed patients, such as 
changes in receptor number or affinity. These receptor changes can be 
considered as biomarkers of the disease they are associated with and are 
discussed further in section 2.1.3. At present, PET/SPECT can be used as a 
diagnostic tool for neurological disorders, as a research tool to understand the 
neurobiology of the disorder and also as a pharmaceutical tool to measure drug 
receptor occupancy during development of novel therapeutics. GE Healthcare is 
particularly interested in the development of radiolabelled probes to potentially 
diagnose, stratify and monitor treatment responses in depressed patients. 
However, in order to do so, neurobiological changes which are commensurate 
with PET/SPECT imaging need to be identified before radiolabelled probes can 
be developed to target these. Thus, a greater understanding of the aetiology and 
neurobiological changes associated with depression is needed. 
 
2.1.2 Factors causing depression 
Although the precise aetiology of depression is not fully understood, it is 
widely accepted that environmental, genetic and neurobiological factors will 
affect the onset of the disease. Genetic studies conducted in twins have identified 
a heritable link in depression (Ørstavik et al., 2007; Kendler et al., 2009; 
Sullivan et al., 2000). It has been suggested that at least 37% of major depression 
is heritable, whereas the prevalence of BD in the general population is 1%, but 
can be up to 20% in first degree relatives of the BD subpopulation (Merikangas 
et al., 2002) and 60% in monozygotic twins (Kendler et al., 1993). Furthermore, 
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not all mood disorders share the same heritability. Early-onset, reoccurring and 
severe depression have higher heritability than other forms (Kendler et al., 
2009). Most of the research on a familial link to depression has focused on 
identifying genetic polymorphisms which occur within families, however, 
contradictory results have been reported (Arias et al., 2012; Illli et al., 2013). 
Although a single gene mutation responsible for the development of depression 
has not yet been identified, areas of chromosomes with a link to depression have 
been found. Mutations in these areas affect monoamine neurotransmission and 
cause polymorphisms of other neurochemicals such as BDNF as well as over 
activation of the hypothalamic pituitary adrenal (HPA) axis (Levinson 2006).  
Another common risk factor for development of depression is exposure 
to stress for example childhood abuse, early life neglect, a stressful life event 
(Kendler et al., 2008; Heim and Nemeroff, 2010). The majority of the general 
population will have experienced extreme stress at some point in their lives and 
considering that anxiety-related disorders and mood disorders have a combined 
lifetime prevalence of 49.6%, with an early onset (median age of 11 years and 30 
years respectively), a vast proportion of the population are at risk of developing 
one of these (Kessler et al., 2005). Many studies have correlated exposure to 
stress with development of depression (Turner et al., 1995; Turner and Lloyd, 
1999). A greater frequency of stressful life events leads to an increase in 
depressive symptoms (Gibbs and Rude, 2004) and chronic stress is more 
strongly related to depression than acute stress (McGonagle and Kessler, 1990). 
The type of stressors that may lead to the onset of a mood disorder is variable; 
from the birth of a child, the death of a loved one, physical abuse, financial 
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worries and work-related stress. The mechanism of how stress leads to 
depression is discussed later in section 2.2 
 
2.1.3  Neurobiology of depression 
Depressive disorders are known to be associated with structural and 
neurochemical changes in the brain, which may represent neuroplastic changes. 
Neural plasticity is the mechanism by which the brain circuitry is able to adapt 
and reorganise itself in response to internal and external stimuli such as life 
experiences or brain injury (Duman, 2009). Neuroplastic changes may manifest 
as changes in dendritic function, synaptic remodelling, long term potentiation, 
axonal sprouting, neurite extension, synaptogenesis and neurogenesis (Manji et 
al., 2003). In this thesis, plasticity is determined as the ligand dependant up- or 
down regulation in receptor expression as these are changes which may be 
imaged by PET/SPECT. 
The regions of the brain which regulate emotions, mood and associated 
behaviours is collectively called the limbic system. This is a group of structures 
that links autonomic responses to behavioural responses.  The main regions of 
the brain which comprise the limbic system are the cingulate, amygdala and 
hippocampus. These limbic regions are connected to the forebrain regions and 
also the hypothalamus. The hippocampus primarily functions in learning and 
memory processes receiving inputs principally from the entorhinal cortex, and 
projecting to the septal area (Nolte, The Human Brain, 5th edn). The amygdala 
functions as the emotional processing centre of the brain and receives afferents 
carrying a huge amount of sensory data from several locations and projects to 
the cerebral cortex and hypothalamus (Nolte, The Human Brain, 5th edn). In 
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addition to the limbic system, aberrant function of the prefrontal cortex is also 
evident in depression. This region functions to control cognition and working 
memory (Duman, 2009).  
 
2.1.3.1 Neuroimaging in depression 
Structural abnormalities in the limbic region of depressed patients can be 
visualised using neuroimaging and post mortem analysis. In depression, 
hippocampal volume reductions of between 10-20% have been reported in 
depressed patients measured using MRI (Bremner et al., 2000; Duman, 2009). 
However, amygdala volumes have been observed to either increase (Frodl et al., 
2003) or decrease in depression (Sheline et al., 1998; Kronenberg et al., 2009). 
In addition, in vivo MRI imaging studies have revealed a reduced volume of the 
prefrontal cortex in depressed patients (Reviewed in Duman. 2009). These 
structural abnormalities may be specific to the subtype of depression, as 
reductions in the prefrontal cortex and amygdala showed specificity to BD when 
compared with MDD (Brambilla et al., 2002; McGrath et al., 2004).  
Post mortem studies also show structural abnormalities associated with 
depression. A reduction in hippocampal volume is associated with the length of 
time the subject suffered from depression (Cobb et al., 2012). Surprisingly, 
although hippocampal volume is reduced, there is an increase in the density of 
glia, pyramidal neurons and granule cell neurons (Stockmeier et al., 2004). In 
addition, post mortem studies have revealed changes in the forebrain of 
depressed patients, with a concomitant decrease in cortical thickness, glial 
density, neuronal size and density (Rajkowska et al., 1999).  
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Further to these structural changes, functional neuroimaging (PET, 
SPECT, fMRI) of depressed patients has allowed for the indirect measurement 
of abnormalities in regional brain activity (McGrath et al., 2004). This can be 
determined by measuring changes in blood flow, glucose metabolism or receptor 
binding. In depression, there is a reduction in cerebral blood flow to the 
prefrontal cortex, frontal cortex and limbic brain regions (Bonne et al., 1996; Ito 
et al., 1996; Drevets et al., 1997). There is also a general and global reduction in 
glucose metabolism in depressed patients; however, some studies have revealed 
an increase in glucose metabolism in the prefrontal cortex and limbic system 
(Baxter et al., 1989; Ketter et al 2001). In addition, fMRI studies have also 
shown increased activation of the limbic regions in depression (reviewed in 
McGarth et al., 2004).  
There are only a small number of radioligands currently available for 
imaging depression. Most of these have focused on the serotonergic system, 
where changes in binding to the 5-HT1A, 5-HT2A, 5-HT2C receptors and also the 
serotonin transporter have been reported in depression. However results from 
these studies are inconsistent and contradictory (more details are described in 
chapter 3). Imaging studies on other neurotransmitter systems are limited; 
however PET imaging of the dopaminergic system has revealed a reduction in 
dopamine D1 receptor binding in the striata of depressed patients. Whereas, D2/3 
receptor binding is just as inconsistent as the serotonergic changes reported. 
Furthermore, a reduction in binding to the histamine 1 receptor and the 
muscarinic M2 receptor was seen in depression, but these receptor systems are 
less well studied in depression.  
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2.1.3.2 Neurochemistry of glucocorticoid related depression 
The neurochemistry of depression is complex and involves many 
different neurotransmitter systems. These are discussed further in chapter 3. 
However, up to 50% of depressed patients also show an elevation of circulating 
cortisol levels throughout the circadian rhythm. This is often regarded as a 
predisposing risk factor for developing a psychiatric disorder (Keller et al., 2006; 
Anacker et al., 2011; Pillai et al., 2012). Cortisol is a glucocorticoid and also the 
primary mediator of the stress response. It is produced in response to the 
activation of the HPA axis. More details of the stress response and the HPA axis 
are given in section 2.2. However, amongst many functions, glucocorticoids are 
involved in neurobiological processes such as neurogenesis, neuroinflammation, 
neurodegeneration, memory and learning (Garcia-Bueno et al., 2008). 
Importantly, glucocorticoids enhance mood, emotions and mental performance, 
all of which are adversely affected in depression (Lupien et al., 2007; de Kloet et 
al., 2008). 
  Preclinical studies have shown that corticosterone (the rodent equivalent 
to cortisol) is required for the formation of memories, maintenance of working 
memory and extinction of those memories no longer required (de Kloet et al., 
2008). However, exposure to chronic stress results in a deficit in learning and 
memory tasks (McEwen 1999; McLaughlin et al., 2007) and also enhances fear 
conditioning by strengthening adverse memories which arise from stress-induced 
sensitisation of the amygdala (Sandi et al., 2001). In addition, chronic exposure 
to corticosterone or repeated stress induces atrophy of apical dendrites in the 
CA3 subfield of the hippocampus characterised by decreases in branch points, 
branch length and synaptic suppression which is associated with loss of spatial 
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learning and memory (Bisagno et al., 1999; Magarinos and McEwen 1995; 
Magarinos et al., 1998; McEwen, 2005; McLaughlin et al., 2007; Sousa et al., 
2000). These appear to be reversible when glucocorticoid levels are returned to 
normal (Duman. 2009). Importantly, these glucocorticoid induced changes in 
brain are similar to the changes that have been observed in post mortem brains of 
depressed patients (Manji et al., 2003).  
Moreover, specificity of HPA axis dysfunction (and hence 
hypersecretion of glucocorticoids) to depression comes from observations that 
antidepressant treatments normalise many aspects of the HPA axis dysfunction, 
thus providing further evidence of its involvement in the development of 
depression. For these reasons, it is thought that there is a significant contribution 




Physiological stress was defined by Selye in 1936 and is the term given 
to a phenomenon which alters the normal functioning of the body (Selye 1936). 
Stress can be defined as a real or perceived threat to an individual’s wellbeing 
(McEwen 2000). Organisms have developed different physiological responses to 
stress that are essential for the maintenance of life. The theory of Hawks and 
Doves personality types described by Korte et al., 2005 states that the ‘Hawks’ 
show high aggression and are more likely to be involved in flight-or-fight 
responses, whereas ‘Doves’ show low aggression and so when faced with a 
stress will exhibit a freeze-or-hide response. The physiological response to stress 
can be protective or adaptive, for example, Sapolsky (2000) famously described 
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a scenario in which a zebra running away from a predatory lion will need to 
divert energy away from physiological functions which are not essential at that 
particular moment in time i.e. suppression of appetite, immune response, 
gastrointestinal activity, reproductive and growth systems (protective measures) 
to enable energy to be diverted for adaptive responses such as increased 
gluconeogenesis, lipolysis, proteolysis, blood pressure, breathing rate and heart 
rate. At the end of the stress response the normal physiological and biochemical 
state is restored.  Although this system is highly regulated, it can lead to disease 
if it is chronically activated especially in response to continuous psychological, 
social and cognitive stimuli.  
 
2.2.1 Homeostasis, allostasis and allostatic load 
There are certain parameters which are crucial for survival and these are 
required to be kept constant within a very narrow range e.g. pH, temperature, 
osmolarity and oxygen tension. The mechanism by which the body maintains 
this is called homeostasis (McEwen 2000). However, there are some 
physiological parameters, which are able to adapt to a changing environment. 
For example, heart rate, blood pressure, synthesis and release of some cytokines, 
neurotransmitters and hormones. The flexibility of these critical systems helps 
maintain essential-to-life parameters relatively constant, a process which is 
called allostasis (Karatsoreos and McEwen, 2011). The mediators of allostasis 
are listed in table 2.1. The physiological concentration of these mediators is 
tightly regulated, and when dysregulated, results in structural and chemical 
changes that may lead to pathological changes. This damage is termed allostatic 
load i.e. the cost (negative effects) of adaptation (McEwen 2002a and b; 2003). 
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An allostatic load may occur after exposure to repeated stress, failure to 
habituate to repeated stress, failure to turn off the stress response after a threat 
has passed or through the inability to produce an adequate response.  
 
2.2.2 Hypothalamic-Pituitary-Adrenal Axis 
The hypothalamic pituitary adrenal (HPA) axis is a neurological 
mechanism which serves to connect the nervous and endocrine systems, 
extending across the hypothalamus, pituitary gland and adrenal glands. Its 
primary function is the secretion of glucocorticoids, cortisol in humans and 
corticosterone in rodents, and also the secretion of adrenaline and noradrenaline 
(Lupien et al., 2007).   
 
Table 2.1 – Table identifying mediators of allostasis.  Adapted from McEwen 2002(b).  
 




Catecholamines (adrenaline, noradrenaline) 
Cytokines (e.g. IL-6, IL-1, TNF-α) 
Many systemic hormones (e.g. thyroid hormone, insulin, insulin-like growth factors, 
leptin) 
Many pituitary hormones (e.g. prolactin, ACTH, growth hormone) 
Tissue mediator 
Cortico-Releasing Factor  
Excitatory amino acids 
Monoamines (e.g. serotonin, noradrenaline, adrenaline, histamine) 
Neuropeptides (e.g. oxytocin, vasopressin, neuropeptide Y, cholecystokinin, enkephalin, 
dynorphin, substance P 
Other neurotransmitters (e.g. GABA, glycine endocannabinoids) 
Others 
Many cytokines (e.g. TNF-α, IL-6, IL-4, IL-10, IFN-γ) 




Glucocorticoids function to maintain homeostasis. Upon activation of the 
HPA axis, the parvocellular neurosecretory cells of the paraventricular nuclei in 
the hypothalamus release corticotroph releasing hormone (CRH) and also the 
neuropeptide arginine vasopressin (AVP) into the capillaries of the primary 
plexus. CRH and AVP travel in the hypophyseal portal veins to the anterior 
pituitary gland (Raison and Miller 2003). Here, they induce the release of 
adrenocorticotroph hormone (ACTH) into the secondary plexus and hypophyseal 
veins and eventually into the general circulation. ACTH acts on the adrenal 
glands to stimulate the production of glucocorticoids. Once released, 
glucocorticoids exert a range of effects associated with maintenance of 
homeostasis and affect a wide range of cellular and molecular networks through 
transcriptional influence over a large percentage of the human genome 
(Chrousos and Kino 2007). Glucocorticoids are highly lipophilic and readily 
cross cell membranes. The hormone binds to intracellular receptors (these are 
discussed later), upon binding the receptor complex translocates to the nucleus 
where it interacts with transcription factors or binds to DNA directly resulting in 
an up- or down-regulation of the expression of certain genes (Pariante and Miller 
2001). This is depicted in figure 2.1. 
Glucocorticoids, as mediators of allostasis, regulate a number of 
important physiological processes, such as mood, sleep, metabolism, normal 
cardiovascular tone and activity of the immune system (Chrousos and Kino 
2007). Because of this, they are also responsible for allostasis and allostatic load 
resulting in disease. Hence, chronically elevated concentrations of 
glucocorticoids are involved in many pathologies; e.g. cardiovascular disease, 
diabetes, hypertension, osteoporosis, autoimmune inflammatory disease, allergic 
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disorders and depression (Swaab, 2005; Lupien et al., 2007). There are ‘checks 
and balances’ to maintain the status quo and prevent an allostatic load e.g. 
glucocorticoids promote gluconeogenesis and then initiate an increase in 
locomotor activity and appetite to replenish the diminished energy stores. 
However, if appetite is increased without an accompanying increase in 
locomotor activity, a state of allostatic load is attained. The individual is then at 
risk of obesity, cardiovascular disease, insulin resistance or loss of bone mineral 
density and muscle protein (McEwen 2002b). Thus, it is important to regulate 
the concentration of glucocorticoids. Thus, the HPA axis is tightly controlled by 
a sensitive negative feedback mechanism which is regulated by circulating 
glucocorticoids. This is discussed in more detail in section 2.2.1.  
As glucocorticoids are lipophilic, they readily cross the blood brain 
barrier to exert their effects through interactions with two intracellular receptors, 
the high affinity mineralocorticoid receptors (MRs) (Kd = 0.5nM) and the lower 
affinity glucocorticoid receptors (GRs) (Kd = 5nM) (Rozeboom et al 2007). 
These receptors are densely located in important regions for regulating processes 
associated with learning, memory and emotions; namely, the hippocampus, 
amygdala and frontal cortex (Lupien et al 2007). When the release of 
glucocorticoids is blocked, these processes are impaired (Maheu et al., 2004; 
Lupien et al., 2007). Glucocorticoid secretion follows a circadian rhythm, which 
peaks during the morning, slowly declining to its lowest level during the 
nocturnal period (circadian trough; evening in humans but morning in rats) 





Figure 2.1. Pathways of glucocorticoid signalling.  Taken from Raison CL and Miller 
AH (2003). Reprinted with permission from the American Journal of Psychiatry, (Copyright 
©2003).  American Psychiatric Association. 
 
 
A high density of the MRs is also found in the hypothalamus, a region of 
the brain that is primarily involved in homeostatic control and a high density is 
also found in the hippocampus. In contrast, the glucocorticoid receptors are 
widespread throughout the brain, but highly expressed in hypothalamic CRH 
neurons and pituitary corticotrophs as well as the amygdala and prefrontal cortex 
(Herman et al., 2005).  They co-localise with MRs in the hippocampus but have 
a much lower affinity (6-10 times lower) for corticosterone (Han et al., 2005; 
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Lupien et al., 2007). Thus, glucocorticoids have a tonic influence over the HPA 
axis via MRs such as during the circadian trough. In this phase, approximately 
90% of MRs are occupied and only 10% of GRs (Lupien et al., 2007). Whereas 
GRs only come into play at much higher concentrations of glucocorticoids, e.g. 
those observed after a prolonged period of stress (Spencer et al., 1998), or during 
the circadian peak, where the MRs are saturated and approximately 67-74% of 
GRs are also occupied (Lupien et al., 2007). Therefore, it is the GRs which 
regulate the feedback inhibition of the HPA axis (as discussed further in section 
2.2.3). 
 The continuous control of the HPA axis employs the involvement of 
numerous neurotransmitter systems/receptors including the above mentioned 
glucocorticoid and mineralocorticoid receptors, the serotonergic system, the 
neuropeptides; oxytocin, vasopressin and the endocannabinoid system. In 
particular, interactions between the glucocorticoids and serotonergic systems 
have been determined to be pivotal in the regulation of the HPA axis. Serotonin 
activates the HPA axis by acting at the hypothalamus to impact CRH release. 
Enhanced serotonergic neurotransmission has led to increased glucocorticoid 
release into the bloodstream (Heisler et al., 2007). Furthermore, electron 
microscopy has shown interactions of 5-HT neurone axons and CRH-containing 
neurones in the paraventricular nuclei (PVN) indicating a direct influence of 
serotonin on activation of the HPA axis (Liposits et al., 1987). In addition, there 
are two important neuropeptides which regulate the HPA axis; vasopressin and 
oxytocin. Vasopressin functions synergistically with CRH to activate the HPA 
axis. Oxytocin on the other hand has an inhibitory tone on the HPA axis, 
possibly by activating HPA re-activity (Neumann et al., 2000). More recently, 
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there has been a lot of research around the involvement of endocannabinoids in 
the HPA axis. Each of these receptor systems and their respective roles in the 
stress response and depression are described in more detail in chapters 2 and 6-8.  
 
2.2.3 Regulation of the HPA axis – Negative feedback 
mechanism 
Under normal conditions, the concentration of glucocorticoids increases 
in response to a stressful stimulus. However, in order to ‘switch off’ this stress 
response, the HPA axis negative feedback mechanism must be activated, see 
figure 2.2. This is triggered by the increase in glucocorticoid concentration and 
prevents the further release of CRH, ACTH and hence glucocorticoid. In this 
way the organism is able to protect itself from an allostatic load. The negative 
feedback of the HPA axis is primarily mediated through the glucocorticoid 
receptor (Falkenberg and Rajeevan 2010). 
The glucocorticoid induced negative feedback mechanism is a 
coordinated response involving different brain regions. The bed of nucleus stria 
terminalis (BNST), amygdala and hippocampus all exert an inhibitory tone on 
the HPA axis. The BNST is an important region that integrates and processes 
both excitatory and inhibitory signals from limbic regions i.e. there are 
GABAergic projections from the amygdala to the anterior BNST and from the 
posterior BNST to the hypothalamus. Specific lesions in either the anterior or the 
posterior BNST result in increased or decreased corticosterone secretion, 
respectively (Dunn and Whitener 1986; Dunn, 1987). The amygdale receives 
excitatory inputs from cortical and thalamic regions and is connected to the 
hypothalamus, but also to other regions which also project to the hypothalamus. 
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The hippocampus is the primary mediator of the negative feedback mechanism 
and hence has a high density of glucocorticoid and mineralocorticoid receptors. 
Inhibition of the HPA axis from the hippocampus occurs via glutamatergic 
efferents from the ventral subiculum to the dorsal medial hypothalamus where 
they make contact with GABAergic neurones that inhibit the activation of the 




Figure 2.2. Schematic diagram outlining the HPA axis and negative feedback 
mechanism. The black arrows represents the normal functioning of the HPA axis and a 
common pathway where, CRH=corticotrophin releasing hormone, AVP=arginine 
vasopressin, ACTH=adrenocorticotroph hormone. The green pathways represents inputs 
that activate the HPA axis where, 5-HT=serotonin. The red lines represent the negative 
feedback mechanism which inhibits the HPA axis. 
 
 
2.2.4 Diseases associated with HPA axis dysfunction 
Irregularities of the negative feedback mechanism can lead to either 
hyperactivity or hypoactivity of the HPA axis. The glucocorticoid cascade 
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hypothesis describes a hyperactive HPA axis whereby, prolonged exposure to 
stress is associated with disruption of the normal feedback mechanism resulting 
in the overproduction of glucocorticoids or it could arise from a genetic 
predisposition to HPA axis hyperactivity (Raison and Miller, 2003). This leads 
to a feed-forward mechanism whereby the concentration of glucocorticoids 
continues to increase resulting in an allostatic load. Conversely, HPA axis 
hypoactivity results from insufficient glucocorticoid production (Raison and 
Miller, 2003). Table 2.2 below lists examples of various clinical states that have 
been associated with disrupted HPA function. Interestingly, glucocorticoid 
therapy to overcome deficiencies induces steroid psychosis, suggesting that an 
exogenously induced elevation in glucocorticoid concentration results in 
neurobiological changes that develop into psychiatric illness (Lupien et al., 
2007).  
 
Table 2.2 – Medical states associated with HPA axis dysfunction. Adapted from Juruena 
et al., 2004. 
 
 
Increased HPA axis 
activity 
Decreased HPA axis 
activity 
Disrupted HPA axis 
activity 














Chronic fatigue syndrome 
Fibromyalgia 
Adrenal suppression 











One of the most prevalent disorders of a hyperactive HPA axis is 
depression. There is extensive evidence demonstrating that depressed patients 
exhibit increased levels of circulating glucocorticoids, increased glucocorticoid 
excretion, decreased corticosteroid receptor function, decreased response to 
ACTH by the pituitary gland, an enhanced adrenal response to ACTH and 
increased levels of CRH in cerebrospinal fluid (CSF), plasma and urine 
(Holsboer, 1999; Chrousos and Kino, 2007; Swaab et al., 2005; Juruenas et al., 
2004). 
In the next chapter, I discuss the role of the serotonergic, 
neuropeptidergic (oxytocin and vasopressin) and endocannabinoid 
neurotransmitter systems in stress related depression. Then in the remainder of 
the thesis, I outline studies designed to investigate the effect of chronic exposure 
to glucocorticoids on these neurotransmitter systems with a view to identify the 







Chapter 3  
 
Neurotransmitter systems involved in 
stress related depression 
It is well established that depression is a multifactorial disease which 
involves perturbations in many neurotransmitter systems. In particular, when 
considered as a stress related disorder, irregularities in the systems that regulate 
the HPA axis are implicated. This thesis focuses on the neurotransmitter and 
receptor specific responses of the serotonergic, neuropeptidergic and 
endocannabinoid systems to elevated glucocorticoid levels with a view to 
determine whether any such changes/responses could be applicable to imaging 
stress related depression using PET. In this chapter, I first describe the current 
strategies towards PET imaging of depression, and then outline the role of each 
of the neurotransmitter systems mentioned above in the regulation of the stress 





 For many decades, irregularities in the monoamine and then later on the 
serotonergic system were considered to be responsible for the development of 
depression. Traditionally it was thought that depression is associated with 
reduced serotonergic tone in the brain, whereas anxiety is associated with 
increased serotonergic activity (reviewed in Jacobsen et al., 2012). However, this 
assumption now stands inaccurate as a serotonin deficit is not seen in all cases of 
depression and the fact that between 30-40% of patients do not respond to pro-
serotonergic antidepressant therapies (Matthews et al., 2005; Jacobsen et al., 
2012). Instead, depression is now considered to be multifactorial, and is thought 
to arise due to dysregulation of many different pathways (Jacobsen et al., 2012). 
This is especially true if the heterogeneity of depression is considered.  As 
outlined in chapter 2, there are many factors which can lead to the development 
of depression, however an underlying common pathway which is seen in up to 
50% of depressed patients is HPA axis hyperactivity (Anacker et al., 2011). The 
resultant elevation in cortisol concentration throughout the diurnal rhythm 
contributes to neurobiological changes associated with depression. Thus the 
irregularities in the mechanisms which govern the HPA axis are implicated in 
the aetiology of depression. In particular the serotonergic, peptidergic and 
endocannabinoid systems have been investigated for their role in the onset and 
development of the disorder. A detailed discussion on each of these can be found 
in sections 3.2, 3.3 and 3.4 respectively.  
 Clinically, neurobiological abnormalities in depression can be studied in 
vivo using PET. In this respect, the serotonergic system has received the most 
attention to date. However, such studies have revealed contradictory results, 
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confounding the interpretation of these and failing to find a relationship between 
serotonergic dysfunction and severity of depression. There are numerous 
radioligands available for imaging SERT, 5-HT1A and 5-HT2A receptors. Some 
PET studies have reported a reduction in 5-HT1A receptor binding potential (BP) 
in mesiotemporal cortex (MTC) by 27%, and raphé, by 42%, in unmedicated-
depressed patients (Drevets et al., 1999). Similar results have been reported for 
the insula, cingulate cortex, temporal and orbital cortex (Sargent et al., 2005). In 
addition, a 17 % decrease in 5-HT1A receptor binding was measured in drug-free, 
recovered depressed patients (Bhagwagar et al., 2004). However, in contrast, 
others have shown an increase in 5-HT1A receptor binding in drug naïve or 
recovered depressed patients (Parsey et al., 2006; Sullivan et al, 2009), and there 
is one report of a PET study that showed no difference in the binding to 5-HT1A 
receptors of depressed subjects (Mickey et al., 2008). The contradictory results 
obtained from these studies can be attributed to differences in the subpopulation 
of depressed patients selected, effects of medication and also differences in the 
analysis of the PET scan. For example, the use of the simplified reference tissue 
model (SRTM), with the cerebellum as the reference region, may result in an 
underestimation of BP due to the presence of a significant number of 5-HT1A 
receptors in the cerebellum (Parsey et al., 2006).  
Such discrepancies have also been noted in studies that attempt to image 
dysfunction in SERT and the 5-HT2 receptors. Both increases (Reivich et al., 
2004; Cannon et al., 2006a) and decreases (Parsey et al., 2006; Oquendo et al., 
2007) in the expression of the serotonin transporter in depressed patients have 
been reported. The same was observed when imaging the 5-HT2 receptors 
(Meyer et al., 1999; Sheline et al., 2004; Bhagwagar et al., 2006). Again, the 
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differences may be attributed to the different subset of depressed patients used in 
these studies. 
With regards to molecular imaging of the neuropeptidergic and 
endocannabinoid systems in depression, this is currently hampered by the lack of 







I] labelled small molecular probes to image the oxytocin receptor but these 
have failed preclinically due to a lack of specificity over the vasopressin 1a 
receptor and also due to low brain uptake (Smith et al., 2012). In addition, there 
has been a lack of studies evaluating radioligands for PET/SPECT imaging of 
the vasopressin 1a receptor reported to date. For the cannabinoid system there 
has been more interest and progress on the development of radioligands for 
imaging CB1 receptors. However, these are still to be shown to be effective for 
clinical imaging (Yasuno et al., 2008; Herance et al., 2011).  
 In this thesis, I aim to understand the influence of chronically elevated 
glucocorticoids on the serotonergic, peptidergic and endocannabinoid systems as 
regulators of the HPA axis with a view to identify potential targets within these 
systems for the development of PET/SPECT imaging probes The role of each in 
depression, and in particular stress related disorders is discussed separately 
below. 
 
3.2 The serotonergic system 
Serotonin (5-hydroxytryptamine, 5-HT) is a biogenic amine which was 
first isolated from the enteric system in 1947 (Rapport et al., 1947). In the 
periphery, serotonin is most abundantly found in the gastrointestinal system (90-
95% of total serotonin), where it regulates enteric smooth muscle contraction 
48 
 
during the process of digestion (Gersohn et al., 1989). In addition, platelets also 
contain a high amount of serotonin, where it is responsible for vasoconstriction 
of blood vessels (Opacka Juffry, 2008). Interestingly, only a small portion (1-
2%) of the total amount of serotonin present is found in the central nervous 
system (CNS). This is surprising considering the serotonin network is the most 
extensive and regulates a diverse range of physiological processes (more details 
can be found below) (Beattie and Smith, 2008). 
Serotonin is synthesised from the essential amino acid L-tryptophan 
which originates from diet (Lanfumey et al., 2008). However, peripherally 
synthesised serotonin cannot cross the blood brain barrier, so it must also be 
synthesised locally within the brain. Synthesis is carried out by the conversion of 
L-tryptophan (which does readily enter the brain) to serotonin via a two-step 
process. The first step is the hydroxylation of tryptophan to the intermediate, 5-
hydroxytryptophan. This occurs via the enzyme tryptophan hydroxylase, and is 
considered to be the rate-limiting step in serotonin synthesis. The second step 
involves decarboxylation of 5-hydroxytryptophan, to 5-hydroxytryptamine 
(serotonin or 5-HT) by the enzyme, amino acid decarboxylase. To remove 
serotonin from the synaptic cleft, it is transported back into the neurone and 
metabolised by monoamine oxidase (MAO). The major metabolite of serotonin 
is 5-hydroxyindoleacetic acid (5-HIAA), however, in the pineal gland, serotonin 
is converted to melatonin regulating circadian rhythms (Opacka-Juffry, 2008).  
Centrally, serotonin production is limited to the serotonergic neurones 
originating in the raphé region of the brain (Mössner et al., 2004).  From here, 
neurons project extensively throughout the brain i.e. to the hippocampus, frontal 
cortex and striata, making the serotonergic system the most diffuse network in 
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the brain (Descarries et al., 1990; McQuade and Sharp, 1997). This is shown in 
figure 3.1. Thus, serotonin is involved in a wide range of physiological functions 
e.g. thermoregulation, locomotion, sexual behaviour, appetite, cardiovascular 
tone and regulation of mood and emotions (Lanfumey et al., 2008). For this 
reason, serotonergic dysfunction is implicated in disease states such as 
depression, anxiety, schizophrenia, obsessive compulsive disorder, migraine and 
eating disorders (Lucki, 1998).  
Within neurones, serotonin is stored in vesicles, which are 40 nm in 
diameter and concentrated at synapses, protecting the neurotransmitter from 
degradation by MAO (Tamir et al., 1994). Upon stimulation of the neurone by 
an action potential, serotonin may be released from dendrites, axons and cell 
bodies, to propagate nerve transmission to the contacting neurone. (De-Miguel 
and Trueta, 2005). As well as serotonin, the vesicles also contain a serotonin 
binding protein (SBP) and as the name suggests, this protein binds serotonin 
upon synthesis in the cytoplasm, and transports it into the vesicles for storage 
and subsequent release (Tamir et al., 1994).  
 




Once released, serotonin exerts its effects through the serotonin receptor, 
of which there are seven families (5-HT1-7) and fourteen subtypes (Barnes and 
Sharp, 1999). In particular, the 5-HT1A receptor is implicated in depression 
(Hoyer, 2002) along with the 5-HT2C receptors (Lanfumey et al., 2008; 
Leventopoulos et al., 2009). However, in this thesis, due to its pivotal role in 
depression (as reviewed in Lanfumey et al., 2008) attention is given to the 5-
HT1A receptor and the influence of elevated glucocorticoids on 5-HT1A receptor 
binding.  
 
3.2.1 The 5-HT1A receptor 
The 5-HT1A receptor is one of many in this class (5-HT1A-F) and was 
identified by displacement of [
3
H]5-HT binding by the full agonist, 8-hydroxy-
di-propylaminotetralin (8-OHDPAT). Through such experiments, it was 
identified that a high density of 5-HT1A receptors was located in the 
hippocampus, septum, amygdala, raphé and cortical regions of the brain 
(Palacios et al., 1990). The presence of 5-HT1A receptors in these areas suggests 
a possible role for the receptor in the regulation of mood and emotion (Palacios 
et al., 1990).  
The 5-HT1A receptor exists as both presynaptic autoreceptors 
(somatodendritic receptors) and as postsynaptic receptors. The presynaptic 
autoreceptors are predominantly located on 5-HT neurone cell bodies and 
dendrites in the raphé region. Destruction of the serotonergic cell bodies in the 
raphé using the toxin 5,7-dihydroxy-tryptamine resulted in a loss of 5-HT1A 
receptor binding in the same region confirming that the receptors are present 
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presynaptically. Similarly, kainic acid induced lesions of the hippocampus 
(which degenerates pyramidal cells and interneurons) are associated with the 
loss of 5-HT1A receptor binding suggesting that 5-HT1A receptors are located 
postsynaptically in the hippocampus (Palacios et al., 1990). Considering the 
extensive serotonergic innervation throughout the CNS, activation of 5-HT1A 
autoreceptors influences activity in a large number of brain regions i.e. 
stimulation of presynaptic receptors, reduces serotonergic activity in projection 
areas. In addition, the 5-HT1A receptor is able to interact and influence other 
neurotransmitter systems i.e. inhibit dopamine and glutamate release (Murphy et 
al., 1998). 
The 5-HT1A receptor subtype has a high affinity for serotonin (<10 nM) 
(Peroutka and Snyder, 1979). The receptor is coupled to the inhibitory G-
proteins and therefore when bound by an agonist, has an overall inhibitory tone 
on neurotransmission. There are two G-proteins to which the receptor may bind; 
the Gi or the G0. When coupled to a Gi protein (as in the raphé), production of 
cyclic AMP is prohibited and when coupled to G0 (as in the hippocampus), 
potassium channels are prevented from opening. It is thought that differences in 
the G-protein coupling may explain the regional differences that exist in 
adaptive responses at both 5-HT1A receptors (Mannoury la Cour et al., 2006). 
Moreover, continual stimulation by agonists is known to desensitise and 
internalise the presynaptic receptors in the raphé, but not the postsynaptic 
receptors in the hippocampus (Riad et al., 2001).  
Several human polymorphisms of the 5-HT1A receptor gene have been 
found and are linked to psychiatric disorders. One of the most extensively 
studied is the -1019 polymorphism which exists in some cases of depression and 
52 
 
anxiety. It results in an overexpression of the 5-HT1A autoreceptor and hence a 
reduction in serotonin neurotransmission (Lemonde et al., 2003; Strobel et al., 
2003). Moreover, this polymorphism is associated with poor responses to 
therapy e.g. drug naïve schizophrenic patients with the polymorphism exhibit a 
reduction in the alleviation of negative and depressive symptoms (Reynolds et 
al., 2006).  
   
3.2.2 Serotonergic system and depression  
There is extensive evidence for the involvement of serotonergic 
dysfunction in depression and related mood disorders. Although it is no longer 
considered to be the only player, the fact is that the contribution of the serotonin 
system to depression and anxiety is significant and thus cannot be ignored. 
Especially, since all the currently available antidepressant treatments target the 
serotonergic system at various levels (Den Boer et al., 2000). These are 
discussed further at the end of this section. 
Inducing a deficit of endogenous serotonin using either reserpine or via 
tryptophan depletion leads to the onset of depressive symptoms and this formed 
the basis of the serotonin hypothesis of depression. However, both these 
treatment paradigms not only affect 5-HT concentrations, but also affect other 
neurotransmitter systems such as the dopaminergic, noradrenergic, cholinergic 
and glutamatergic systems. Therefore the effects of reserpine or tryptophan 
depletion cannot be ascribed to just the serotonin system (reviewed in Jacobsen 
et al., 2012). Post mortem analysis revealed an increase in the binding of the 
agonist [
3
H]OH-DPAT in the raphé region, which the authors attributed to a  
reduction in serotonin activity in the brains of depressed patients (Stockmeier et 
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al., 1998). Whereas, low 5-HIAA levels in CSF have been associated with 
suicide but not necessarily depression (Nordström et al., 1994; Placidi et al., 
2001). In addition, post mortem brain tissue from depressed patients and also 
those that have committed suicide express a lower concentration of 5-HT and 5-
HIAA (Owen and Nemeroff, 1994).  
However, there is some evidence to show that actually depression may be 
associated with enhanced central serotonergic activity. This is measured by an 
increased prolactin response to dexfenfluramine (the amphetamine analogue 
which causes a release of serotonin) (Strickland et al., 2002).  Also, in some 
instances, 5-HIAA levels in CSF are reported to be higher in depressed patients 
suggesting increased serotonergic function (Sullivan et al., 2006). 
  In both humans and animals, serotonin is known to activate the HPA 
axis, resulting in the secretion of CRH, ACTH and glucocorticoids. This effect 
has been shown to be potentiated by the 5-HT1A agonist, ipsapirone (Klaassen et 
al., 2002) and abolished by serotonin antagonists (Fuller, 1990), providing 
evidence for interactions between the serotonergic system and regulation of the 
HPA axis. Preclinical studies have reported that glucocorticoids influence the 
expression and function of central 5-HT1A receptors. In response to chronic 
corticosterone administration, 5-HT1A receptor mRNA density in the 
hippocampus, parietal cortex, prefrontal cortex and posterior cingulate is 
reduced, whereas, adrenalectomy resulted in an increase in 5-HT1A receptor 
density (Mendelson and McEwen, 1991, 1992; Flugge, 1995). In addition, 
glucocorticoids have also been shown to affect the function of 5-HT1A receptors. 
Low doses of corticosterone attenuated hippocampal and raphé 5-HT1A receptor 
function, whereas high doses, enhanced 5-HT1A receptor function (Joels et al., 
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1991; Karten et al., 1999; Fairchild et al., 2003). Glucocorticoids have also been 
reported to influence the concentration of serotonin in a region dependent 
manner. In general, exposure to stress increases 5-HT levels in the raphé, 
prefrontal cortex, hippocampus and amygdala (Maswood et al., 1998; Amat et 
al., 2005). However  decreases in 5-HT content of the amygdala and septal 
nuclei have also been reported after an acute stress (Kirby et al., 1995). The role 
of serotonin in the stress response is discussed further in chapter 5. 
The most commonly prescribed antidepressants, are the selective 
serotonin reuptake inhibitors (SSRIs). Although they are effective treatments for 
depression, the response is slow and it can take several weeks of treatment 
before an improvement in clinical symptoms is seen. The exact mechanism of 
action of SSRIs is still being elucidated, but it is thought that they act by 
suppressing serotonin transporter-mediated 5-HT reuptake and hence increase 
the concentration of 5-HT in the synaptic cleft (Raap et al., 1999). This, in turn, 
is thought to desensitise presynaptic 5-HT1A receptors, blocking their inhibitory 
action on the autoreceptors, and increasing serotonin release in the projection 
areas (Benmansour et al., 1999; Hjorth et al., 2000). The administration of 
pindolol, a selective 5-HT1A autoreceptor antagonist used as an adjunct to SSRI 
treatment supports the theory of autoreceptor desensitisation as a key early event 
in the mechanism of action of SSRI treatment (Ballesteros and Callado, 2004). 
Agonists of the 5-HT1A receptor have also shown to exhibit antidepressant 
effects. For example, the agonist gepirone desensitises presynaptic 5-HT1A 
neurones but not postsynaptic receptors (Blier and de Montigny, 1987).  
Enhancement of serotonin neurotransmission as a mechanism of 
antidepressant action can also be achieved by electric convulsive shock therapy 
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(ECS) and also by monoamine oxidase inhibitors (MAOIs) which sensitises 
postsynaptic 5-HT1A receptors in the hippocampus (Stockmeier et al., 1992; 
Burnet et al., 1994) and inhibits the breakdown of 5-HT (Nemeroff, 2002)  
respectively.  Figure 3.2 outlines therapeutic approaches to treating depression. 
However, irrespective of the way in which serotonin activity is enhanced, in 
order to achieve long-term benefit from antidepressant action, it is necessary to 
re-establish neurogenesis in adult brain. This is a process which is dependent on 
serotonin (and the 5-HT1A receptor) to enhance the production of new neurons 
(Gould, 1999). The SSRI, fluoxetine has been shown to stimulate neurogenesis, 
via the 5-HT1A receptors (Santarelli et al., 2003).  
 
Figure 3.2. A serotonergic synapse showing mechanisms of action for common 
antidepressant drugs (Opacka-Juffry, 2008), where SERT = serotonin transporter, MAO 
= monoamine oxidase, MAOIs = monoamine oxidase inhibitors, SSRIs = selective 
serotonin reuptake inhibitors. 
 
3.3 The neuropeptidergic system 
Neuropeptides are molecules composed of a short chain of amino acids, 
they are released from the nerve terminal to act on cell surface membranes and 
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are then degraded i.e. they are not recycled back into the neuron (Arzumanyan et 
al., 1985). There are many different peptides released by the brain which 
participate in numerous physiological functions e.g. neuropeptide Y (NPY) 
regulates feeding, body weight (Patel et al., 2006) and regulates pain processes 
(Bjersing et al., 2012);  apelin regulates drinking and fluid retention (Roberts et 
al., 2009); orexin regulates sleep/wake cycles (Blumber et al., 2007); galanin 
regulates memory (Ogren et al., 2010); kisspeptin regulates reproduction/fertility 
(Hameed et al 2011) and substance P regulates vomiting and nausea (Rojas et 
al., 2010). In addition to the neuropeptides mentioned above, there are also 
oxytocin and vasopressin, which are studied in this thesis. These two 
neuropeptides are discussed in more detail for the remainder of this section. 
Centrally, oxytocin and vasopressin are synthesised in the supraoptic 
(SON) and PVN of the hypothalamus. The peptides are released from the 
hypothalamic parvocellular and magnocellular neurones. Oxytocin released from 
axon terminals of the parvocellular neurones, exerts local effects.  Whereas 
oxytocin originating from the axon terminals and dendrites of magnocellular 
neurones will enable a more diffuse actions of oxytocin at remote distances 
within the brain (Baskerville and Douglas 2010; Onaka et al., 2012). In addition, 
there are extrahypothalamic vasopressinergic and oxytocinergic fibres which 
originate from the BNST and terminate in the limbic brain regions e.g. septum 
and hippocampus (Engelmann et al., 1996). Therefore, vasopressin and oxytocin 
are also released in limbic regions (Neumann and Landgraaf, 2012).  
From the hypothalamus, most oxytocinergic and vasopressinergic 
neurones project into the posterior pituitary gland (Baskerville and Douglas 
2010). From here, oxytocin and vasopressin are released into the general and 
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central circulation to exert their actions via the oxytocin, vasopressin 1a and 1b 
receptors (Neumann and Landgraaf 2012; Onaka et al 2012). This would imply 
that circulating peripheral concentrations of the peptide may reflect central 
concentrations in the brain. However this is not the case as certain stimuli may 
result in a rise in central neuropeptide synthesis and release without changing 
concentrations in the blood (Landgraaf and Neumann 2004; Neumann 2007). 
There are a number of regions where the vasopressin 1a receptor is 
coexpressed with the oxytocin receptor, however they are located in discrete 
areas separate of each other. For example, oxytocin receptors are located in the 
rat amygdala (lateral part of central amygdaloid nucleus (CeA)) and nucleus 
accumbens (shell), whereas the vasopressin 1a receptor is expressed in the core 
of the nucleus accumbens and the medial part of the CeA. This complimentary 
location of the two receptors may explain the opposite effects of oxytocin and 
vasopressin on fear behaviour (Huber et al., 2005). Generally, oxytocin is 
considered to be anxiolytic and to have antidepressant like effects, whereas 






Figure 3.3. Oxytocin and vasopressin synthesis and release in brain (Meyer-Lindenberg 
et al., 2011) 
 
 
3.3.1 The oxytocin neuromodulatory system 
The hormone oxytocin participates in many physiological functions, 
through actions at peripheral as well as central binding sites. Peripherally, the 
stimulation of milk ejection (Neumann et al., 1993) and the stimulation of 
uterine contraction (Barberis et al., 1998) are important functions regulated by 
oxytocin. Centrally, oxytocin is involved in regulating emotional behaviours 
such as pair bonding (Insel and Shapiro 1992; Young and Wang 2004; Lim and 
Young 2006), maternal behaviour (Bosch et al., 2005; Lim and Young 2006), 
sexual arousal (Caldwell et al., 1992; Baskerville and Douglas 2010), social 
bonding (Popik and van Ree 1998; Ferguson et al., 2001), trust (Kosfeld et al., 
2005), reducing anxiety and fear (Kirsch et al., 2005; Windle et al., 2007), 
processes of learning and memory (de Oliviera et al., 2007) and provides 
tolerance to some addictive drugs (Kovacs et al., 1998).  
Oxytocin is a nonapeptide which is synthesised and released from the 
PVN and SON regions of the brain. It is cleaved from a pre-peptide as it is 
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transported down the axon to terminals in the posterior pituitary gland. From 
here, it is released into the blood bound to a carrier protein, neurophysin I. 
Oxytocin is found in high concentrations in the pituitary gland and is present in a 
1:1 ratio with neurophysin (Gimpl and Farenholz 2001). Once in the general 
circulation, oxytocin exerts the above mentioned peripheral effects. However, 
oxytocin which has been released into the general circulation is not able to pass 
through the blood brain barrier (BBB) and enter the brain, although in some 
instances 0.001% has been shown to cross the BBB (Uvnäs-Moberg, 1998). 
Thus, oxytocin is also synthesised and released locally within the brain from 
axon terminals and dendrites.  
Within oxytocinergic neurones, the peptide is packaged into vesicles at 
the axon terminals which release their contents upon the generation of an action 
potential (which triggers influx of Ca
2+
) (Baskerville and Douglas 2010).  On the 
other hand, the dendritic release of oxytocin is electrically independent and 
occurs in response to intracellular release of Ca
2+ 
(Ludwig et al., 2002).
 
Due to 
the fact that these two distinct pathways for oxytocin release exist, the 
circulating and central oxytocin concentrations can either be independent of each 
other or can occur in synergy. For example, Engelmann et al., (1999) showed 
that oxytocin is released by the SON without an increase in peripheral oxytocin 
levels, whereas rodent studies showed that suckling led to the concomitant 
release of oxytocin into the bloodstream as well as in the SON and PVN (Moos 






3.3.1.1 The oxytocin receptor 
The encoded oxytocin receptor is a G-protein coupled receptor which is 
389 amino acid polypeptides in size and has seven transmembrane domains 
(Baskerville and Douglas 2010).  The oxytocin receptor is structurally similar to 
the vasopressin receptors displaying 25% homology (Barberis et al., 1998). 
Oxytocin acts as a full agonist at the receptor, whereas vasopressin acts as a 
partial agonist (Gimpl and Farenholz 2001). Although both oxytocin and 
vasopressin bind to the oxytocin receptor, the latter displays a 10-fold lower 
affinity for the receptor. It has been reported that a 100-fold higher concentration 
of vasopressin is required at the oxytocin receptor to elicit the same response as 
oxytocin (Gimpl and Farenholz, 2001). 
Upon activation, the receptor stimulates the activity of phospholipase C-ß 
isoforms, which leads to the generation of inositol phosphate 3 (InsP3) and 
diacylglycerol (DAG). This in turn leads to the release of Ca
2+
 from intracellular 
stores and activation of PKC (Gimpl and Farenholz, 2001). These signalling 
pathways activate a range of cellular responses such as neuronal firing, 
neurotransmitter release, smooth muscle contraction, and protein 
phosphorylation (Baskerville and Douglas 2010). After persistent activation the 
oxytocin receptor becomes desensitised and internalises. In fact, 5-10 minutes of 
stimulation resulted in a greater than 60% internalisation of the human oxytocin 
receptors expressed in HEK 293 fibroblasts (Gimpl and Farenholz, 2001). These 
are then recycled back to the cell surface (Stoop, 2012).   
Due to the involvement of the oxytocin receptor in a range of 
physiological processes, the receptor undergoes transient changes in its 
expression during development, particularly in the brain i.e. it is up- and 
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downregulated adaptively as the brain matures. For example, a high density of 
oxytocin receptors is observed in the cingulate cortex and a low density in the 
olfactory tubercles of the infant rodent brain but this is reversed as the brain 
matures to adulthood (Tribollet et al., 1992). In addition, there are marked 
species differences with respect to the central regional distribution of oxytocin 
receptors in part related to differences in function (Tribollet et al., 1992).  
 
3.3.1.2 Oxytocin and depression 
The distribution of the oxytocin receptor in brain regions associated with 
the regulation of mood and emotions, as well as a defined role for oxytocin in 
affliative behaviours suggests that this neuromodulatory system may be involved 
in neuropsychiatric disorders. Oxytocin is amongst the factors which regulates 
HPA axis activity and is in fact anxiolytic (Heinrichs and Dome, 2008). The 
neuropeptide transiently increases corticosterone release, resulting in activation 
of the glucocorticoid induced negative feedback mechanism which is then 
followed by a sustained suppression of the HPA axis (Peterssen et al., 1996).  In 
this way, oxytocin exerts an inhibitory influence on the HPA axis, leading to a 
reduction in glucocorticoid levels (Neumann et al., 2000). Moreover, recently 
oxytocin has been shown to protect against glucocorticoid induced inhibition of 
neurogenesis and to stimulate neurite growth in the hippocampus (Leuner et al., 
2012). Taken together this suggests that abnormalities in the regulation of the 
HPA axis by oxytocin may contribute to the HPA dysfunction seen in 
depression.  
Preclinically, intracerebral administration of oxytocin counteracts 
anxiety–like behaviours such as reduced immobility during the forced swim test 
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and reduced vocalisation of distress in rodent models (Insel and Winslow, 1991; 
Windle et al., 1997). In addition, a repeated daily injection of oxytocin has been 
demonstrated to reduce the time spent immobile during the forced swim test 
(Arletti and Bertolini 1987). The anxiolytic actions of oxytocin are abolished 
after administration of an oxytocin receptor antagonist indicating specificity of 
effect to the oxytocin receptor. Preclinical studies investigating the oxytocinergic 
regulation of the HPA axis are discussed in more detail in chapter 6. 
Although, preclinical studies have shown a clear relationship between 
oxytocinergic dysfunction and depression, findings from clinical studies are 
more contradictory. Low oxytocinergic activity has been associated with 
postpartum depression where first-time mothers with low infant attachment also 
exhibit reduced plasma oxytocin concentration (Strathearn et al., 2009). In 
comparison, major depression is also associated with reduced plasma oxytocin 
concentrations when compared to age-matched controls (Frasche et al., 1995; 
Scantamburlo et al., 2007). However, in contrast, other studies have shown 
increases in plasma (Parker et al., 2010) and salivary oxytocin concentrations 
(Holt-Lunstat et al., 2011) in some depressed patients. Only a small number of 
studies have looked at changes in CSF oxytocin levels in depression, but these 
findings are also inconsistent. In one study, a decrease in CSF oxytocin was 
found in depressed patients (Pitts et al., 1995), whereas, others have found no 
difference between depressed and control subjects (Demitrak and Gold 1988).  
Moreover, the anxiolytic influence of oxytocin has been evaluated in 
humans too. Intranasal administration of oxytocin caused an increase in risk-
taking behaviour (Kosfeld et al., 2005) and improved communication in both 
men and women during partner conflict (Ditzen et al., 2009). In addition, 
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performance was improved on a stress task, which involved public speaking, in 
the presence of social support (which reduces cortisol production and increases 
oxytocin release) and performance was further enhanced after oxytocin 
administration (Heinrichs et al., 2003). In fact, it is thought that oxytocin may be 
beneficial to those suffering mental illnesses that are linked to social dysfunction 
e.g. phobias, autism or those with a persistent fear and avoidance of social 
interactions (Kosfeld et al., 2005). Post mortem analysis of brains from 
depressed patients have shown a 23% increase in oxytocin-immunoreactive 
neurones in the PVN of the hypothalamus concomitant with HPA hyperactivity 
measured during life (Purba et al., 1996; Meynen et al., 2007; Wang et al., 
2008). The role of oxytocin in the stress response is discussed in more detail in 
chapter 6. 
Further evidence for a beneficial role for oxytocin in the treatment of 
depression comes from the observation that antidepressant therapies such as 
SSRIs induce the release of oxytocin; this suggests that the hormone itself may 
be useful in alleviating the symptoms of depression (Unvӓs-Moberg et al., 1999). 
More recently the novel oxytocin agonist, carbetocin, was shown to be 
comparable to imipramine in alleviating depressive behaviours in the forced 
swim test. These effects were abolished when an oxytocin receptor antagonist 
was administered suggesting carbetocin and imipramine owe their efficacy in 
part to actions at the oxytocin receptor (Chaviaras et al., 2010). In addition, a 
new drug treatment for sexual dysfunction, siladenafil, also exhibits 
antidepressant-like effects by evoking oxytocin release from the pituitary gland 




3.3.2 The vasopressin neuromodulatory system 
Vasopressin (arginine vasopressin, AVP) is a nonapeptide hormone 
which is also synthesised in the magnocellular neurones of the SON and released 
into the general circulation as well as locally within the brain in a similar way to 
that described above for oxytocin. The two peptides are structurally closely 
related, with the only difference being that oxytocin has a leucine amino acid at 
position eight, whereas vasopressin contains an arginine amino acid at that 
position. However, it is this difference which enables each peptide to interact 
with their respective receptors (Barberis et al., 1998).  
The physiological function of vasopressin is related to maintaining 
homeostatic control (Stoop, 2012). Peripherally, AVP has antidiuretic and 
vasoconstrictive effects. It is released in response to increased plasma 
osmolality, hypervolemia, hypotension and hypoglycaemia (Laszlo et al., 1991). 
AVP is transported along nerve fibres and released into the posterior pituitary 
from where it enters the general circulation (Antoni 1986).  Centrally, AVP is 
released from parvocellular neurones of the PVN, BNST, amygdala and 
suprachiasmatic nucleus (SCN) (DeVries et al., 1985). The neuropeptide is 
stored in large dense-core vesicles (LDCV) which are distributed in the soma, in 
dendrites, and in axonal varicosities (Stoop, 2012). The release of the peptide 




 In the brain, AVP mediates emotions such as aggression, fear, stress, 
anxiety, regulation of the circadian rhythm (Hofman and Swaab 1994) and is 
also implicated in memory and learning (Caldwell et al., 2008). It is released 
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with circadian rhythmicity into the CSF, and peaks during the middle of the light 
phase (Caldwell et al., 2008).  
 
3.3.2.1  The vasopressin receptors 
Vasopressin exerts its effects through plasma membrane bound receptors. 
There are two subtypes of the vasopressin receptor; the V1 and V2 receptors. 
The V1 receptors are further subdivided into vasopressin 1a (V1aR) and 
vasopressin 1b (V1bR) receptors (Barberis et al., 1992). All three subtypes are 
found in the CNS, but the density of V1 receptors is greater than V2 receptors 
(Tribollet 1992). The receptors are G-protein coupled with seven transmembrane 
domains. The V1a and V1b receptor subtypes are coupled to the Gαq/11 protein 
which activates PLC, but the V2 receptor is coupled to the Gs protein and 
activates cyclic AMP (Caldwell et al., 2008). The V2 receptor is primarily found 
in the kidney and collecting ducts (Narayen and Mandel, 2012) and will not be 
considered further here. The focus of this study is given to the vasopressin 1a 
receptor subtype and is therefore discussed in more detail below.   
The V1a receptor is predominately distributed in the brain, but can also 
be found in peripheral organs e.g. kidney, liver, spleen, platelets and smooth 
muscle. In the brain, autoradiography and in situ hybridization studies have 
revealed high densities of the V1a receptor in the septum, hippocampus, 
amygdala, BNST, hypothalamus, substantia nigra, dorsal raphé and superior 
colliculi (Johnson et al., 1993). The vasopressin 1a receptor can signal 
independently of PLCβ, PKC or intracellular calcium concentration. AVP will 
affect neuronal excitability through the opening of nonspecific cationic channels 
or by the closing of potassium channels. Similarly to the oxytocin receptor, 
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activation of the vasopressin 1a receptor leads to internalisation of the receptor 
(Innamorati et al., 1998). 
 
3.3.2.2 Vasopressin and depression 
The distribution of vasopressin receptors as well as the role of 
vasopressin in the regulation of normal memory processes and circadian rhythms 
governing sleep patterns, suggests a role for AVP in depression. Particularly, as 
both these functions are disrupted in depression (Scott and Dinan, 2002). In 
contrast to oxytocin, vasopressin is anxiogenic and aggression promoting via 
activation of the HPA axis, particularly during chronic stress (Aguilera et al., 
2007). In fact, AVP transcription is enhanced by glucocorticoids during stress 
(Kovacs et al., 2000). The neuropeptide is a weak secretagogue of ACTH, but 
acts synergistically with CRF to release ACTH when the HPA axis is activated 
(Carrasco and Van der Kar, 2003). 
Preclinical studies have shown exposure to stress induces AVP release in 
the PVN, SON, septal nuclei and amygdala (Wotjak et al., 1998). Brattleboro 
rats have a genetic disposition towards vasopressin deficiency which prevents 
activation of the HPA axis and therefore, this strain of rat is protected from 
glucocorticoid induced neurological damage providing evidence for a role of 
vasopressin in neurological disorders (Fodor et al., 2012). In fact, Brattleboro 
rats show less immobility in the forced swim test suggesting that this 
antidepressive behaviour is partly explained by the lowered vasopressin activity 
(Mlynarik et al., 2007). Conversely, a high anxiety-bred strain of rat showed 
hyper anxiety associated with overexpression of vasopressin neurones in the 
PVN, which was normalised by the antidepressant, paroxetine (Keck et al., 
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2003). Furthermore, the vasopressin V1a receptor is implicated in mediating the 
anxiogenic effects of AVP, where V1aR overexpression is associated with 
increased anxiety (Landgraaf et al., 1995) and  vasopressin 1a receptor knockout 
mice display less anxiety (Bielsky et al., 2004). The role of vasopressin in the 
stress response is discussed further in chapter 6. 
 There have been fewer clinical investigations looking at the relationship 
between vasopressin and depression than those reported for oxytocin. However, 
increased levels of circulating AVP have been found in depressed patients (van 
Londen et al., 1997; Meyen et al., 2006; Bao and Swaab, 2010). In addition, 
plasma AVP levels were further increased in patients who have attempted to 
commit suicide when compared to those depressed patients that were not 
suicidal (Inder et al., 1997; Merali et al., 2006). Centrally, vasopressinergic 
neurones in the hypothalamic PVN and SON are activated in depression, 
contributing to an increase in the release of ACTH from the pituitary gland. Not 
only are they activated, but the number of vasopressinergic neurones and also 
vasopressin 1a receptor mRNA was increased in depressed patients (Wang et al., 
2008).  In addition, a post mortem study showed increased activation of 
vasopressin neurons in the paraventricular nucleus of depressed subjects (Purba 
et al., 1996).  
Currently there are no available antidepressants which target the 
vasopressin system. However, the vasopressin 1a receptor, antagonist 
d(Ch2)5Tyr(Me)AVP, when administered into the mediolateral septum and the 





3.4  The endocannabinoid system 
Endocannabinoids are synthesised from polyunsaturated fatty acids. They 
are synthesised and released on demand in response to an increase in 
intracellular calcium (Di Marzo et al., 2005). The first endogenous cannabinoids 
to be discovered were anandamide (N-arachidonoyl ethanolamine) and 2-
arachidonoylglycerol (2-AG) and these are the most widely studied.  
Endocannabinoids have been shown to be synthesised peripherally 
(Sugiura et al., 1996) as well as in the brain (Devane and Axelrod, 1994). 
Centrally, these lipid mediators are involved in processes that regulate eating, 
anxiety, memory, learning, reproduction, metabolism, growth as well as being 
involved in neuroinflammation and neurodegeneration (Skaper and Di Marzo, 
2012).   Multiple pathways exist for the synthesis of anandamide and 2-AG. 
Anandamide is produced from the precursor N-acyletholamine phospholipid. 
The most common pathway for synthesis of 2-AG is from the hydrolysis of 
phosphotidylinositol 4,5 bisphosphate into the intermediate secondary messenger 
diacylglycerol (DAG). This is then converted to 2-AG by the enzyme 
diacylglycerol lipase (DAGL) (Skaper and Di Marzo, 2012). Endocannabinoids 
are removed from the synapse via uptake into cells and enzymatically degraded 
by several enzymes. The major metabolite formed from degradation of both 
anandamide and 2-AG is arachidonic acid, but the enzymes involved are 
different. Anandamide is hydrolysed by cyclooxygenase 1 (COX1), fatty acid 
amide hydrolase 1 and 2 (FAAH1, FAAH2) and  N-acyletholamine hydrolysing 
acid amidase (NAAA). Whereas, 2-AG is metabolised by cyclooxygenase 2 
(COX2), monoacylglycerol lipase (MAGL) or αβ-hydrolase 6 and 12 (ABHD6, 
ABHD12) (Muccioli, 2010).  
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  Endocannabinoids are retrograde messengers; when released from the 
postsynaptic neurones they act at the presynaptic neurone to terminate the signal 
(Christie and Vaughan, 2001). They are highly lipophilic allowing them to 
readily cross most cell membranes although, specific cannabinoid transporters 
also exist that aid in their transport across certain membranes (Hilliard and 
Jarrahian 2003; Alexander and Cravatt 2006). One such transporter is present at 
hippocampal neurones and glial cells. It facilitates endocannabinoid signalling 
by transporting anandamide and 2-AG from the synapse (Wilson and Nicoll, 
2001).   
 
 




(a) An action potential 
results in the influx of 
Ca2+, which causes the 
synthesis and release 
of endocannabinoids . 
  
(b) These act at CB1 
receptors on the 
presynaptic neurone to 




(c) The endocannabinoids 
are removed from the 
synapse through 
enzymatic degradation 
in glial or neurone cells 
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3.4.1 The endocannabinoid receptors 
Endocannabinoids exert their effects through the CB1 and CB2 receptors 
which differ in their distribution and signalling mechanism, and therefore 
regulate different physiological functions. The greatest density of the CB1 
receptor is found in the brain, and much lower concentrations of the receptor are 
found in neurones within the heart, vas deferens and small intestine (Mackie 
2005; Howlett 2000). On the other hand, the CB2 receptor forms part of the 
immune system and is primarily found in peripheral tissues e.g. spleen and 
tonsils. Until recently, it was thought that the CB2 receptor was only found in 
peripheral tissues, where it is responsible for mediating the immune response 
through modulating cytokine release. However CB2 receptors are also located in 
the CNS, albeit at lower densities than the CB1 receptor (Roche and Finn 2010). 
Centrally, CB2 receptors are expressed on neurones and glial cells in the 
cerebral cortex, hippocampus, striatum, amygdala, thalamic nuclei, 
periaqueductal grey, cerebellum (Ashton et al., 2006; Gong et al., 2006; Onaivi 
et al., 2006; Brusco et al., 2008). These receptors are involved in 
neuroinflammatory and neurodegenerative disorders e.g. multiple sclerosis, 
Alzheimer’s disease, Huntingdon’s disease, Parkinson’s disease and traumatic 
brain injury (Pazos et al., 2004; Molina-Holgado et al., 2005; Benito et al., 
2008). CB2 receptors are also present in the spine and modulate nociception 
processes (Sang et al., 2006). However, this thesis investigates the influence of 
chronic exposure to corticosterone on the CB1 receptor and therefore the CB1 
receptor will be the focus for the remainder of this section. 
In the brain, the CB1 receptor is regionally distributed with a high 
density of CB1 receptors found in basal ganglia and cerebellum, where they are 
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responsible for movement. A high density is also found in the hippocampus and 
cerebral cortex, where the CB1 receptor participates in processes associated with 
short term and long term plasticity i.e. memory processing, cognition and reward 
processes (Skaper and Di Marzo, 2012). In addition, the CB1 receptor also 
contributes to pain modulation and therefore is densely localised in the spinal 
cord and periaqueductal gray (Pertwee, 2005). The receptor is primarily located 
at the presynaptic terminal and its activation by retrograde endocannabinoids 
inhibits the release of GABA and glutamate (Rea et al., 2007). 
 Signalling is thought to be mediated through Gi/o proteins, negatively 
coupling the CB1 receptor to adenylyl cyclase and positively coupling then to 
mitogen-activated protein kinase (Howlett et al., 2002). In addition, the CB1 
receptor is also positively coupled to potassium ion channels and negatively to 
calcium channels (Howlett 2000). It has been demonstrated that the CB1 
receptor can activate adenylyl cyclase through coupling to Gs proteins, a 
mechanism that may allow for cross-talk between CB1 receptors and other non-
CB1 receptor G-protein receptors such as the serotonergic receptors (Glass and 
Felder 1997; Calandra et al., 1999; Breivogel and Childers 2000; Jarrahian et al., 
2004).  The CB1 receptor is particularly important during brain development, 
maturation and connectivity via regulation of neural progenitor cell proliferation, 
pyramidal specification and axonal growth (Skaper and Di Marzo, 2012). It is 
well known that the CB1 receptor is involved in the regulation of food intake 
and energy expenditure, and CB1 receptor antagonists/inverse agonists have 
been developed as potential anti-obesity agents. However, repeated 
administration of these agents has been shown to be associated with anxiety and 
depression (Bermudez-Silva et al., 2010).  
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3.4.2 Endocannabinoids and depression  
The CB1 receptor is found in the brain regions responsible for anxiety, 
aversive and defensive behaviours such as the prefrontal cortex, hippocampus, 
hypothalamus, amygdala and periaqueductal gray (Herkenham et al., 1991; Tsou 
et al., 1998). Although, the role of the endocannabinoid system in neurological 
disorders is still emerging, endocannabinoids are known activators of the HPA 
axis and thus increase secretion of glucocorticoid (Weidenfeld et al., 1994; 
Wenger et al., 1997). Preclinically, exposure to various stressors consistently 
results in secretion of endocannabinoids e.g., food deprivation increases 
endocannabinoid levels in the hypothalamus and limbic forebrain regions 
(Kirkham et al., 2002), retrieval of aversive memories increases 
endocannabinoid levels in the amygdala (Mariscano et al., 2002), pain increases 
endocannabinoid synthesis in the periaqueductal gray (Walker et al., 1999) and 
repeated restraint stress elevates endocannabinoid secretion in the amygdala 
(Patel et al., 2009). However, in contrast, chronic unpredictable stress decreases 
secretion of 2-AG in the hippocampus (Hill et al., 2005) suggesting stressor 
specific changes in endocannabinoid concentration. Furthermore, exposure to 
stress downregulates the CB1 receptor in the hypothalamus (Wamsteeker et al., 
2010) and the hippocampus (Hill et al., 2005; Reich et al., 2009; Hill et al., 
2009).  
Interestingly, animal studies have shown that endocannabinoids can exert 
anxiogenic as well as anxiolytic effects; where low doses are anxiolytic 
(Berrendero and Maldonado 2002) and high doses are shown to be anxiogenic 
(Arevalo et al., 2001; Genn et al., 2004). These effects are also reflected with 
cannabis use in humans, where recreational use of cannabis is anxiolytic but 
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chronic use can lead to anxiety and panic attacks (Thomas, 1996; Tournier et al., 
2003). Moreover, inhibition of FAAH has been shown to cause an elevation of 
anandamide in the brain suppressing anxiety–like behaviour in rats and mice 
(Kathuria et al., 2003; Fegley et al., 2005; Bortolato et al., 2007; Moreira et al., 
2008). This effect is abolished in the presence of the CB1 receptor specific 
antagonist, rimonabant, suggesting specificity of the anxiolytic function of 
anandamide to the CB1 receptor (Moise et al., 2008). Similarly, CB1 receptor 
knockout mice also exhibit increased anxiety and depressive-like behaviours 
(Haller et al., 2002; Maccarone et al., 2002). In addition, CB1 receptor gene 
variants showed increased susceptibility to stress-related disorders and 
depression (Juhasz et al., 2009).   
Clinically, an increase in CB1 receptor density has been reported in the 
prefrontal cortex of depressed and suicide victims (Hungard et al., 2004; Vinod 
and Hungund 2006). Serum levels of anandamide and 2-AG are reduced in 
depressed patients, and correlates with the duration of depressive episode (Hill et 
al., 2009).  
There still remains much to be understood regarding the potential 
therapeutic value of targeting the endocannabinoid system for treatment of 
depression and/or stress related disorders.  At present only 3 drugs that activate 
the CB1 and CB2 receptors have been approved and these are for symptomatic 
management of cancer i.e. amelioration of chemotherapy induced nausea and 
vomiting and stimulation of appetite. However, an analysis of the pharma 
pipeline has revealed candidates in development for anxiety and depression too 
(Thomson Reuters, Integrity ™, 2012). Endocannabinoid ligands, FAAH 
inhibitors and anandamide reuptake inhibitors are all being investigated as 
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potential treatment targets for depression. Preclinical studies evaluating these 
novel drug candidates have reported antidepressive behaviour during the forced 
swim test, mediated primarily through the CB1 receptor (reviewed in Roche and 
Finn, 2010). More details on the endocannabinoid in stress related depression 
can be found in chapter 7. 
 In the next chapter, I describe the techniques and outline detailed 
protocols that are used in this thesis to investigate each of the above mentioned 










Many different experimental approaches are used to induce a state of 
depression or anxiety in laboratory animals. These allow the function of the 
HPA axis and its involvement in the aetiology of stress-induced depression to be 
studied. Such methods have included exogenous administration of 
glucocorticoids or exposure to a psychological or physical stressor that activates 
the endogenous stress mechanism. The effects of such approaches can then be 
assessed using either behavioural tests or through measuring changes in 
physiological and biochemical markers. In this chapter, I outline the techniques 
which have been used as part of this thesis. I also give details of the materials 
and methods used for studies conducted as part of this investigation. In addition, 
I outline a feasibility study to determine the optimum method for corticosterone 




In order to assess the effects of glucocorticoids in depression, various 
techniques can be used to increase the level of the stress hormone, 
corticosterone, in a rat. These can be grouped into physical stressors such as 
chronic social (Mckittrick et al., 1995, 2000; Bodnoff et al., 1995; chronic 
restraint (McLaughlin et al., 2007, Magarinos and McEwen 1995, Watanabe et 
al., 1992, Gregus et al.,  2005) and chronic unpredictable stress (Lopez et al., 
1998) or experimental stressors involving the direct administration of 
corticosterone via subcutaneous pellet implantation (Akana et al., 1992; 
Chalmers et al., 1993; Meijer et al., 1997; Karten et al., 1999; Bodnoff et al., 
1995; Bisagno et al., 2000; Bush et al., 2003), subcutaneous injections 
(Watanabe et al., 1992; Karten et al., 1999; Czyrak et al., 2002; Gregus et al., 
2005; Jacobsen and Mork 2006; Zahorodna et al., 2006) or via drinking water 
(Magarinos et al., 1998; Fairchild et al., 2003; Donner et al., 2012).  
The addition of corticosterone to drinking water is a relatively new and 
non-invasive method for the administration of corticosterone throughout the 
diurnal rhythm (Magarinos et al., 1998). Both cases of stressor (physical and 
experimental) have been shown to cause neurochemical and behavioural changes 
in the rat which correlate to stress-induced depression as seen in humans. These 
include changes in physiological parameters such as an increase in plasma 
corticosterone levels and attenuated weight gain (referenced as above). In this 
thesis, exogenous corticosterone is administered to rats. The different methods 





4.2 Study design used in this thesis 
This thesis outlines experimental studies which investigate the effects of 
chronic exposure to exogenous corticosterone on receptor binding at central 5-
HT1A, oxytocin, vasopressin 1a and CB1 receptors in adult rats. In addition, I 
attempt to relate changes in receptor binding to changes in the concentration of 
endogenous ligand. The study was designed as an experiment with between 
group comparisons. Age-matched male Wistar rats were randomly assigned to 
one of two groups, either a group which was exposed to high doses of the stress 
hormone, corticosterone or to a control group which received vehicle (0.8% 
ethanol).  The independent variable was the treatment (corticosterone or vehicle) 
whilst the dependent variables were central receptor binding and concentration 
of neurotransmitter. 
 
4.2.1 Ethical considerations 
The experiments were conducted across both the GE Healthcare 
(Hammersmith Imanet, Hammersmith Hospital, London) site and Roehampton 
University. All animal treatments and in vivo studies were approved under The 
Animal (Scientific Procedures) Act, 1986. The study was approved by both the 
Imperial College, Ethical Review Process (ERP) and Roehampton University 
Ethics Boards (Appendix A). The work was carried out under the Home Office 
project licence (PPL 70/6744) in the Imperial College London designated 
facilities at Hammersmith Hospital.  
The number of animals used in this thesis was justified by previous work 
carried out at GE Healthcare and Roehampton University, which established the 
minimum group size required to observe statistically significant changes in the 
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variables of interest assuming biological effects of 15% and above. Guidance 
was also sought from The Home Office with regard to the principle of ‘3Rs’ 
(Reduction, Refinement and Replacement). This ensured that the study design 
and methodology utilised a minimal number of animals and that alternatives to 
the use of animals had been considered.  
The post mortem brain tissues were harvested and frozen at GE 
Healthcare and transported to the University of Roehampton, Department of Life 
Sciences for processing. 
In the next section, I outline a feasibility study to determine the optimum 
dosing regime to be used for further studies presented in this thesis (i.e. those 
presented in chapters 5, 6 and 7). Then after that I outline the theory, materials 
and methods used for experiments as part of this study. 
 
4.3 Feasibility study 
 In order to study the influence of chronic exposure to glucocorticoids on 
receptor binding, it was decided to administer exogenous corticosterone at a dose 
that would result in a flattening of the diurnal rhythm of corticosterone release, 
and also in an attempt to minimise inter-individual differences associated with 
psychosocial stressors. In this section, I describe a feasibility study which was 







4.3.1 Feasibility study - Introduction 
 As described above, a feasibility study was designed to identify the 
optimum corticosterone treatment paradigm. The endpoints i.e.  A success 
criterion was set as suppression of the HPA axis (assessed by thymus and 
adrenal gland atrophy) without breaching the weight loss severity limits imposed 
by the Home Office project licence. A reduction in body weight was expected 
after corticosterone treatment; however a loss greater than 20% would 
necessitate termination of the animal and exclusion from the study. Animals 
were administered CORT via daily subcutaneous injections (40 mg/kg, Gregus 
et al., 2005) or via addition to their drinking water (400 µg/mL, Magarinos et al., 
1998) for 21 days. Body weight measurements were taken throughout the 
treatment period and at sacrifice adrenal glands and thymus glands were 
dissected and weighed.   
 
4.3.1.1 Exposure to corticosterone by subcutaneous injections  
An effective method for increasing corticosterone concentration in 
animals is through subcutaneous injections. Corticosterone is virtually water-
insoluble but suspensions in oil, tween and saline have shown to elevate plasma 
CORT levels. A 10 mg/kg suspension dose of CORT resulted in an occupancy of 
the glucocorticoid receptor for most of the day (Karten et al., 1999; Watanabe et 
al., 1992). In addition, a positive correlation was found to exist between CORT 
dose and depression like behaviour, with a 40 mg/kg dose producing the most 
significant increase in depression like behaviour during the social interaction 




4.3.1.2 Exposure to corticosterone in drinking water  
Addition of corticosterone to drinking water is a relatively new and non-
invasive method for the administration of corticosterone, with the advantage that 
the hormone is accessible throughout the diurnal rhythm (Magarinos et al., 
1998). Corticosterone, initially dissolved in a small amount of ethanol (0.8 % of 
total volume) whilst stirring over gentle heat, is simply diluted with tap water 
and made available to the animals (Rees et al., 2004). The amount of 
corticosterone ingested can be calculated based on an assumption that each rat 
consumed an equal volume of water (Fairchild et al., 2003). This approach has 
been used by Magarinos et al., 1998, who report a decrease in adrenal, spleen, 
and thymus gland weights, as well as an attenuation in weight gain after 
treatment with 400 µg/mL of CORT for 21 days. They also report atrophy of the 
hippocampal brain region. It is thought that such changes may contribute to the 
loss of hippocampal volume, which is typically observed in depressed patients 
and provides an explanation for the reduction in learning and memory 
behaviours associated with depression (Manji et al., 2003). 
 
4.3.2 Feasibility study – Methodology 
Young adult (2 months old) male Wistar rats (Harlan Olac, U.K.) were 
randomly assigned to either a corticosterone (CORT) or vehicle treated group 
(mean initial body weight = 220.7g ± 6.5g (mean ± SD); n=12 in each group). 
The CORT treated group was further divided so that half were administered 
daily subcutaneous injections of CORT, whereas the other half were 
administered CORT via addition to drinking water. Each CORT group had a 
parallel control group that received vehicle. The groups of animals were not 
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counter balanced for weight, but were randomly assigned to each treatment.  The 
segregation of animals is schematically described in figure 5.1. For identification 
purposes each rat was assigned a code as this is also described in figure 5.1. 
Animals were kept on a 12 hour light:dark cycle (lights on at 7.30am and off at 
7.30pm) and at ambient temperature (19-21
0
C). They were housed in cages of 
three with access to food (Charles River, UK) and water ad libitum. Animals 
were acclimatised for 7 days before the study commenced, during which time 
the animals were regularly handled.  
For administration by subcutaneous injections, corticosterone (Sigma, 
Poole, Dorset, UK) was given at a dose of 40 mg/kg suspended in physiological 
saline. Approximately 0.5 mL of Tween (Sigma, Poole, Dorset, UK) was added 
to stabilise the suspension. Each day, animals were weighed prior to receiving 
either corticosterone or vehicle in a volume of 1 mL/kg into the subcutaneous 
tissue surrounding the neck. All animals were treated for 21 days with dosing 
carried out before 11am each day. A similar treatment paradigm has been used 
previously by Gregus et al., 2005 who demonstrated that corticosterone treated 
rats showed depression like behaviour in the forced swim test. 
For administration via drinking water, corticosterone (Sigma, Poole, 
Dorset, UK) was dissolved in ethanol (Rees et al., 2004) and then diluted with 
tap water to give a final concentration of 400 µg/mL. A parallel group of rats 
had an equivalent amount of ethanol added to their drinking water (0.8% of total 
volume). Animals were weighed every day for the duration of the treatment 
period.  Water bottles were also weighed to measure the volume of water 
consumed. Corticosterone and vehicle drink solutions were replaced every 
second day with a freshly prepared solution. Water bottles were wrapped in 
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aluminium foil to protect from light as the stability of corticosterone in light was 
not known. This treatment was based on that described in Magarinos et al. 
(1998) and more recently Donner et al. (2012).  
Formal behavioural testing was beyond the scope of the studies presented 
in this thesis, however, each day an informal observation was made on the 
general appearance of the animals and for any signs of distress.  
At the end of the treatment period, animals were sacrificed after a 24 hour 
hormone free period (van Gemert et al., 2006). This was included to negate any 
effects of an acute dose of corticosterone on the variables measured. The animals 
decapitated whilst very lightly anaesthetised i.e. an anaesthetic box was filled 
with isoflurane and nitrous oxide/oxygen gaseous anaesthetic for 3 mins, the rat 
was placed inside the chamber for 1 min before removal and decapitation. 
Animals were sacrificed in a random manner across treatment groups and during 
the first part of the light phase i.e. before 11am. Brain tissue generated from the 
feasibility study was used for training purposes (cryosectioning or regional brain 
microdissection). Whole brains were either immediately frozen at -40
0
C in 
isopentane or hand-dissected into the following regions: prefrontal cortex; 
striatum; hypothalamus; frontal cortex; amygdala; dorsal hippocampus; ventral 
hippocampus; and  periaqueductal gray and snap frozen in isopentane (-40
0
C) on 







Figure 4.1 Experimental design and animal identification. Rats were randomly assigned 
to either a vehicle (V) or CORT (C) treated group (n=12 in each treatment group) 
divided between 4 cages. Animals were further divided into a subgroup that received 
CORT via subcutaneous injection and another that received CORT via addition to their 
drinking water (n=6 per subgroup and per treatment group). Each rat within the cage 
was identified by the following code ‘cage number, treatment group, animal number’ 
i.e. 1VR1 or 1CR1.  Animals in cages 1 and 2 were assigned to the subcutaneous 




4.3.1.3 Feasibility study – Results 
All data presented here is expressed as mean ± SD in the text and table, 
whereas graphically, they are expresses as mean ± SEM.  In addition, data were 
tested for and passed the Kolmogorov-Smirnov test for normality.  
At sacrifice, the thymus and adrenal glands (left and right side combined) 
were dissected and weighed. Organ weights are expressed as mg/100 g body 
weight and are shown in table 4.1. Student’s two-tailed t-test (unpaired) was 
used to test for effects of CORT treatment on organ weights. Statistical analysis 
is shown in appendix B. Each treatment paradigm was tested separately i.e. 
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vehicle vs CORT in subcutaneous injection treated group and vehicle vs CORT 
in drinking water group. Both glands were significantly reduced in weight after 
CORT treatment when compared to vehicle treated animals irrespective of the 
method for CORT administration. Daily subcutaneous injection of CORT for 21 
days resulted in a decrease in adrenal gland weight from 10.38 ± 1.5 mg/100g 
body weight in the vehicle treated group to 3.68 ± 1.6 mg/100g body weight in 
CORT-treated animals representing a 64.4% reduction (P<0.0001). Thymus 
gland weights were also reduced from 172.90 ± 15.8 mg/100g body weight in 
the vehicle treated group to 85.71 ± 22.3 mg/100g body weight in CORT-treated 
animals representing a 50.4% reduction in weight (P<0.0001). When CORT was 
administered via drinking water for 21 days, adrenal glands were reduced in 
weight from 19.27 ± 3.4 mg/100g body weight to 6.86 ± 0.8 mg/100g body 
weight, representing a 64.2% reduction (P<0.0001). Thymus gland weights in 
this group were also reduced from 178.70 ± 18.8 mg/100g body weight to 91.29 
± 40.1 mg/100g body weight, representing a 48.9% reduction (P=0.0007). 
 
Table 4.1. Effect of chronic exposure to CORT on thymus and adrenal gland weights. 




























10.38 ± 1.5 3.68 ± 1.6 *** 64.4 19.27 ± 3.4 6.86 ± 0.8*** 64.4 
Thymus 172.90 ± 15.8 85.71 ± 22.3 *** 50.4 178.70 ± 18.8 91.29 ± 40.1 *** 48.9 
 
Table 4.1 At sacrifice, adrenal and thymus glands were dissected and weighed. Tissue 
weight (mg) was normalised to the individual body weight of animal (g) (n=6 per 
treatment group). Data are expressed as mean ± SD. Statistical analysis was via 




Weight gain was measured throughout the treatment period to ascertain 
the tolerability of the CORT treatment. Vehicle treated animals in both the 
subcutaneous injection and drinking water groups gained weight in the expected 
manner. When CORT was administered by subcutaneous injection, significant 
effects of treatment (F(1,210) = 1223, P = <0.0001) and duration of treatment 
(F(20, 210) = 20.84, P = <0.0001) on weight gain were observed. The interaction 
was also significant (F(20,210)  = 24.64, P = <0.0001). When CORT was 
administered via drinking water, weight gain was also attenuated with significant 
treatment effects (F(1,210) = 1059, P = <0.0001) and duration of treatment 
effects (F(20,210) = 26.06, P = <0.0001). The interaction was also significant 
(F(20,210) = 17.80, P = <0.0001). Data are shown in figure4.2 (A) and (B). 
Statistical analysis is shown in appendix B. Further analysis between treatment 
groups at individual time points using two-tailed Student’s t-test (unpaired) with 
Bonferroni correction with a significance level set at P = 0.05,  revealed that 
weight gain was attenuated in CORT treated animals for both administration 
paradigms. In the subcutaneous injection group, vehicle treated rats steadily 
gained weight with an increase from 211g ± 7g to 291g ± 19g, representing a 
38% increase in body weight over the duration of the study. However, the mean 
weight of CORT-treated animals changed from 213g ± 6g to 214g ± 17g 
representing only a 0.5 % increase in body weight over the same period. In the 
drinking water group, vehicle treated rats also steadily gained weight with an 
increase from 232g ± 9g to 324g ± 16g, representing a 40 % increase in body 
weight over the duration of the study. However, the mean weight gain of CORT-
treated animals increased from 226g ± 10g to 236g ± 20g representing only a 4% 
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increase in body weight over the same period. Thus, treatment with CORT for 
21 days via daily subcutaneous injections or via addition to drinking water 
significantly attenuated weight gain in male Wistar rats.  
Furthermore, a two way ANOVA with bonferroni correction was used to 
test for statistical differences between the two different treatment paradigms. 
There was no effect of administration method on the rate of weight gain in the 
treated groups.   
Analysis of water consumption in the group treated with corticosterone 
via addition to drinking water showed that CORT treated animals ingested an 
average of 52.2 mg/kg of CORT per day. This was based on an average water 
consumption of 30 mLs of water per animal per day (assuming that each animal 
consumed an equal amount of water). 
It is worth noting that the animals receiving daily CORT injections 
displayed a greater degree of distress, assessed by their general appearance i.e. 
hunched posture, lack of grooming and rearing behaviour in the home cage, than 
those administered CORT in drinking water. 
 
4.3.1.4  Feasibility study – Discussion 
The feasibility study was designed to determine a suitable dosing 
regimen for subsequent studies. Both CORT treatment methods resulted in 
atrophy of the adrenal and thymus glands indicative of suppression of the 
endogenous HPA axis, and this was consistent with previous studies looking at 
the effects of exogenous corticosterone administration (Magarinos et al 1998; 
Karten et al., 1999; Gregus et al., 2005; Donner et al., 2012). In addition, both 
CORT treatment paradigms resulted in a reduction of weight gain similar to that 
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previously reported (Magarinos et al., 1998; Gregus et al., 2005; Donner et al., 
2012). Although there was no significant statistical difference in the rate of 
weight gain between the group receiving CORT via subcutaneous injection and 
that receiving CORT via drinking water, the administration of CORT via daily 
subcutaneous injection was considered to be a more severe treatment due to the 
more pronounced attenuation in weight gain. In addition, these animals 
displayed a general appearance which was indicative of distress i.e. hunched 
posture, lack of grooming, discolouration of fur and resistance to handling. 
When CORT was administered in drinking water, weight gain was also 
attenuated in the CORT treated group however, these animals did not show the 
above mentioned signs of distress and were easier to handle. In addition, the 
vehicle treated rats showed a normal pattern of weight gain during the treatment 
period.  
In conclusion, it was decided to proceed with the drinking water route of 
CORT administration for further experimental studies. This was decided based 
on the above findings that CORT administered via drinking water resulted in 






Figure 4.2. Weight gain of vehicle and CORT treated animals. Each animal was 
weighed every day and weight gain in grams from day 0 is plotted. Figure 4.2 (A) 
represents the subcutaneous injection group and (B) the drinking water group.  Data are 
expressed as mean ± SEM of n=6 per treatment group. Statistical analysis was carried 
out using 2-way ANOVA for effects of treatment and the duration of treatment with a 
Bonferroni post hoc test for multiple comparisons at a significance level of 0.05. A 










4.4 Techniques used in the present thesis 
The theoretical background for each of the techniques utilised in this 
thesis are given followed by detailed materials and methods used for each 
experiment.  
Wistar rats were used for all experimental studies described in this thesis. 
They are an outbred strain commonly used in stress biology research due to their 
susceptibility to glucocorticoid induced pathology (Karten et al., 1999; 
Leventopoulos et al., 2009). Stress resistant and more stress susceptible strains 
also exist as well as strains specifically bred for high or low anxiety states (Keck 
et al., 2005). Rats are social animals and prefer to be group housed with a 12 
hour light period. Being nocturnal animals, they will primarily feed during the 
dark phase. On average, rats eat 5g of feed per 100g bodyweight daily and drink 
10mls of water per 100g body weight daily. They have a naturally exploratory 
nature and will take interest in their environment. Failure to do so indicates poor 
health. Other indicators of distress and/or pain are increased vocalisations, 
aggressive behaviour and resistance to handling or struggling (Wolfensohn and 
Lloyd 2
nd
 Edn).      
 
4.4.1    In vivo corticosterone administration for subsequent studies 
This section describes the corticosterone administration protocol 
which was used for the studies outlined in experimental chapters 5, 6 and 
7.  
Animals were purchased from Harlan Olac, U.K., and group-housed in 
batches of four. They were kept on a 12 hour light:dark cycle (lights on at 7.30 
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am and off at 7.30 pm) and at an ambient temperature (19-21
0
C) with access to 
standard rat feed and water ad libitum . All animal procedures were carried out 
in agreement with UK Home Office (Scientific Procedures (Animals Act) 1986) 
guidelines on animal experimentation and conducted by authorised personnel. 
The study design and dosing regime was similar to that described above in 
section 4.3. Thirty two young adult (2 months old) male Wistar rats (Harlan 
Olac, UK) were randomly assigned to either a corticosterone or vehicle treated 
group (mean initial body weight ± SD= 217g ± 10.7g; range 190-234g; n=16 per 
treatment group). Treatment began after a 7 day acclimatisation period, during 
which time the animals were regularly handled. Corticosterone was dissolved in 
ethanol as previously described (Rees et al., 2004) and added to drinking water 
(400 µg/mL) for 21 days according to Magarinos et al. (1998). A parallel group 
of rats received an equivalent amount of ethanol added to their drinking water 
(0.8%). Animals were as described in figure 4.1. Except that here, animals were 
housed in cages of four animals. Corticosterone and vehicle drinking solutions 
were replaced every second day with freshly prepared solutions. All water 
bottles were wrapped in aluminium foil to protect against any degradation of 
CORT as the stability of the hormone under light was not known. Water 
consumption was monitored as well as individual rat weight every second day. 
The drinking water was also replaced with fresh solutions at this time. Animals 
were sacrificed after a 24 hour hormone free period during the first part of the 
light phase, i.e. before 11am, as described in section 4.3. During the in vivo 
dosing period, animals were informally observed for general appearance and 
also for signs of distress in the same way as that carried out in the feasibility 
study. At sacrifice, tissues were collected and used for 5-HT1A, oxytocin, 
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vasopressin 1a and CB1 receptor autoradiography. These tissues were also used 
for HPLC determination of 5-HT and 5-HIAA. Whole brains were either frozen 
in isopentane on dry ice (-40
0
C) for autoradiography or dissected into the 
following 8 regions: hypothalamus, prefrontal cortex, frontal cortex, striatum, 
amygdala, dorsal hippocampus, ventral hippocampus, and raphé. Each region 
was placed into a microcentrifuge vial and snap frozen in isopentane on dry ice 
(-40
0
C). Whole brains were cryosectioned into 20 µm sections as described later 
in section 4.4.2.3. Brain tissue sections and dissected regions were kept frozen at 
-80
0
C until analysis. 
Additionally, for radioimmunoassay of peptide concentration (presented 
in chapter 6), an additional and separate group batch of animals was included.  
This additional group (n=8 for vehicle treatment and n=10 for corticosterone 
treatment) underwent the same dosing regime as described before, but the 
animals were sacrificed by decapitation without anaesthesia (this was removed 
from the protocol in case it had an impact on the peptide concentration) and also 
without a 24 hour hormone free period. The rationale for sacrifice without a 24 
hour hormone free period was to account for the short half-life of the 
neuropeptides; 1-6 minutes for oxytocin (Grewen et al., 2010) and ~10-35 
minutes for vasopressin (Delmas et al., 2005), and the fact that there was no 
evidence suggesting that oxytocinergic and vasopressinergic effects are still 
evident after a 24 hour CORT washout period. Therefore, in this study, there 
were two timepoints considered for RIA experiments; a 0hr group that was 
sacrificed immediately after withdrawal of corticosterone and a 24hr group that 
was sacrificed after a 24 hour hormone free period. Sacrifice of animals began 
during the first part of the light phase and was completed by 11am (as described 
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in section 4.3). A statistical analysis of the water consumed, weight gained, 
adrenal and thymus gland weights was carried out to test for consistency 
between this group of animals and the previous group. This can be found in 
appendix B. 
Whole trunk blood was collected into pre-heparinised chilled vials 
containing a protease inhibitor (500 KIU/mL blood of Aprotinin) to protect the 
peptides from degradation (Delmas et al., 2005; Grewen et al., 2010). Blood was 
immediately spun to obtain plasma (3 min x 13,000g) and frozen. Whole brains 
were dissected into the following 8 regions: pituitary gland, hypothalamus, 
prefrontal cortex, septal nuclei, amygdala, dorsal hippocampus, ventral 
hippocampus and raphé and snap frozen as previously described. Brain tissue as 
well as plasma samples were kept frozen at -80
0
C until analysis.  
 
4.4.2 Autoradiography 
Autoradiography is a radiological technique that is used for the 
identification and localisation of a protein of interest. It is commonly used to 
visualise receptors in tissue samples, however it is dependent on the availability 
of a radiolabelled ligand. In this thesis, autoradiography is used to identify the 5-
HT1A, oxytocin, vasopressin 1a and CB1 receptors after chronic exposure to 
corticosterone. The protocols used for each experiment and analysis of data 






4.4.2.1 Principles of autoradiography 
The principles of autoradiography are based on receptor-ligand 
interactions using a radiolabelled ligand for the system under investigation 
(Knoche, 1991). The advantage of autoradiography, over other histological 
techniques such as immunohistochemistry, is the fact that amount of radioligand 
bound can be quantified. This can be done by deducing the specific binding of a 
radioligand and is based on the following formulae:- 
 
Specific binding = Total binding – non specific binding 
 
Where: Specific binding = amount of the radioligand bound to the target of   interest. 
Non-specific binding = non displaceable binding to other sites (receptors, lipids or   cell 
membranes). 
Total binding = encompasses both specific and non-specific binding. 
 
Radioligand binding data must be normalised for the amount of non-
specific binding as failure to do so, may result in an overestimation of specific 
binding. For autoradiographical procedures, this can be achieved by the addition 
of saturating concentrations of unlabelled ligand to the incubation buffer. The 
unlabelled material competes with the radiolabelled compound, to provide a 
measure of background (non-specific binding) for the radioligand (Knoche, 
1991).  
A wide range of radionuclides (unstable isotopes which emit energy as 
















I. There are 
several steps to an autoradiography experiment and these are outlined below, 




a) Tissue Preparation:- Typically, frozen tissue is cryosectioned into thin 
slices and mounted onto glass polysine or gelatine coated slides. The 
thickness of the slices cut depends on the sensitivity and resolution 
required. For tritium compounds, the standard section thickness is 
between 10-20 µM, this is due the low penetrability of the [
3
H] 





I] labelled ligands and film-based 
visualisation techniques.  
 
b) Incubation:- The radioligand is added to physiological buffer such as 
Tris(hydroxymethyl)aminomethane (TRIS). This forms the basis of an 
incubation buffer. In some instances, it may be necessary to add salts 
such as magnesium chloride or sodium chloride etc. to allow optimal 
conditions for binding. The sections are incubated in this solution. The 
incubation time varies for each target and is related to the time taken for 
the radioligand to obtain a state of pseudo equilibrium i.e. when the 
formation of the radioligand complex is equal to its dissociation.  
 
c) Washing:- The incubation stage is terminated by rinsing the sections in 
ice-cold washing buffer. The purpose of this step is to remove any 
unbound/free radioligand.  
 
d) Exposure to film:-  The slides are dried before exposure to x-ray film 
which is essentially a plastic sheet that has an emulsion coating on one 
side. This emulsion comprises of a gelatin matrix that has either small 
silver halide or silver bromide crystals embedded into it. Gelatin is an 
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important component of the emulsion, as it ensures that each crystal is 
spatially segregated from adjacent crystals and that these are uniformly 
distributed across the emulsion. It also protects the crystals during the 
developing and fixing stages. Factors such as the crystal number and size 
are physical characteristics associated with the x-ray film, and determine 
what application the film may be used for (Knoche, 1991). Films such as 
Hyperfilm 
3
H and Hyperfilm ßmax have a high silver content and fine 
grain size, making them ideal for autoradiography. As the radioisotope 
from the specimen underlying the film decays, it emits energy. This is 
absorbed by the crystals and they become activated i.e. silver ions (Ag
+
) 
are converted into silver atoms (Ag
0
). Several silver ions are converted to 
silver atoms in response to a single emission. For this reason, areas of the 
specimen which contain high amounts of radioactivity result in a greater 
degree of activation on the film. This results in the formation of a latent 
image, which cannot be seen until the film is developed. 
 
e) Film development:- This is the process by which the remaining Ag+ ions 
within a crystal are converted to metallic silver. It is an important step as 
the latent image formed during exposure cannot be seen unless it is 
amplified in this way. The film is immersed into a developing fluid, 
which usually consists of a mixture of reducing agents in an alkaline 
solution. This results in the reduction of silver ions to metallic silver of 
the crystals which already contain Ag
0
 atoms and in the formation of a 
‘negative visual image’, where the blackening of the film is directly 
proportional to the amount of radiation reaching it.  The developing 
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process is time-dependent and must be stopped in time, as eventually all 
of the crystals present in the film will convert to metallic silver. Usually, 
a diluted solution of acetic acid can be used to stop the development 
process and also neutralise the film.  
 
f) Film fixation:- During this step, the film is immersed into a fixing 
solution. The purpose of which is to remove any remaining silver 
bromide/halide. This step is less time-sensitive and suitable results are 
obtained as long as the film is in contact with the fixing solution for a 
long enough period of time to remove all silver ions. 
  
 Once developed and fixed, the images on the films can be analysed to 
provide quantitative data. 
 
4.4.2.2 Materials used for autoradiography 
All incubation reagents, developing solutions (Kodak D19 developer), 
fixing solutions (Kodak rapid fixer) and Radioactive film (Kodak Biomax) were 
purchased from Sigma Aldrich (Poole, Dorset, UK). Brains were sectioned on a 
Bright cryostat (Bright Instruments), sections were mounted onto polysine 
coated slides (Thermo Scientific). [
3
H]microscale standards were purchased 
from Amersham (Buckinghamshire, UK). [
125
I] microscale standards were 
purchased from American Radiolabeled Chemicals (USA). 
The 5-HT1A receptor radioligand used was [0-methyl-
3
H]WAY 100635, 
specific activity: 2.81 TBq/mmol, 76Ci/mmol; radioactive concentration:  
1 MBq/mL (NEN Perkin Elmer). 
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I]OVTA), specific activity: 81.4 
TBq/mmol, 2200 Ci/mmol,  radioactive concentration: 50 μCi/mL (American 
Radiolabeled Chemicals, USA).  
The iodinated vasopressin V1a receptor radioligand was [phenylacetyl 




I]AVP), specific activity: 81.4 
TBq/mmol, 2200 Ci/mmol; radioactive concentration: 0.05 MBq/mL (American 
Radiolabeled Chemicals, USA). 
The CB1 receptor radioligand used was [
3
H]CP 55,940 specific activity: 
5.328 TBq/mmol, 144.0 Ci/mmol; radioactive concentration: 1MBq/mL (NEN 
Perkin Elmer). 
 
4.4.2.3 Methodology for brain sectioning 
Frozen brains collected from the in vivo studies described above were 
coronally cut into 20 µM sections in an anterior-posterior direction using a 
cryostat (Bright, U.K.) and collected onto polysine-coated slides. Sections were 
collected at the following coordinates relative to bregma according to Paxinos 
and Watson (5
th
 Edn; 2005): prefrontal cortex 3.72 to 2.76  mm, dorsal 
hippocampus -2.92 to -3.6 mm, hypothalamus (ventral medial hypothalamic 
nuclei) -1.80 to -3.12 mm, paraventricular hypothalamic nuclei -1.80 to -1.92 
mm, amygdala -1.92 to -3.36 mm, ventral hippocampus -5.16 to -5.88 mm, 





4.4.2.4     Methodology for 5-HT1A receptor autoradiography 
On the day of analysis, slides were removed from the -80
o
C freezer and 
allowed to thaw for 4 hours. Slides were placed onto two trays; one designated 
for determination of total binding and the other (adjacent sections) designated 
for determination of non-specific binding. The autoradiography protocol as 
described in Leventopoulos et al. (2009) was followed.  
1) Sections were preincubated with Tris-HCl, pH 7.4 for 30 minutes to 
remove endogenous neurotransmitter and rehydrate the tissue. This was 
carried out by addition of 1 mL of buffer onto each slide ensuring that all 
tissue was covered with the solution.  
2) Sections were then incubated with 2 nM of [3H]WAY 100635 in Tris-
HCl, pH 7.4 for 2 hours. Again, 1 mL of incubation buffer was added to 
each slide, ensuring that all tissue was covered.  
3) Non-specific binding was determined in adjacent sections incubated in 
the same way but in the presence of 10 µM serotonin.  
4) At the end of the incubation period, solutions were removed by pouring 
to waste.  
5) Sections were washed by placing the slides into container filled with ice-
cold Tris-HCl, pH 7.4 for 3 mins. Sections were washed in this way 
twice i.e. 2 x3 min washes, followed by three dips in ice-cold distilled 
water 
6) Sections were allowed to dry overnight.  
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7) The following day, the slides and tritium standards were exposed to 
Kodak Biomax film for 6 weeks (in cassettes at-4
0
C), and then manually 
developed using Kodak D-19 developer and rapid fixer.  
 
4.4.2.5 Oxytocin receptor autoradiography 
On the day of analysis, slides were removed from the -80
o
C freezer and 
allowed to thaw for 4 hours. Slides were placed onto two trays; one designated 
for determination of total binding and the other (adjacent sections) designated 
for determination of non-specific binding. The oxytocin receptor 
autoradiography procedure was based on Liberzon and Young (1997) and 
Champagne et al. (2001).  
 
1) Brain sections were incubated with 0.1 nM of [125I]OVTA in 0.05M Tris-
HCl, 0.1% BSA, 10mM MgCl2, 0.05% bacitracin pH 7.4 for 1 hour at 
room temperature . This was carried out by addition of 1 mL of buffer 
onto each slide ensuring that all tissue was covered with the solution.  
2) At the end of the incubation period, solutions were removed by pouring 
to waste. 
3)  Sections were washed for 8 min by placing the slides into container 
filled with ice-cold Tris-HCl (0.05M, pH 7.4) with 0.1% BSA, 0.01% 
triton-X and 100mM choline chloride. Sections were washed in this way 
three times i.e. 3 x8 min washes, followed by three quick dips in ice-cold 
distilled water.  
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4) Non-specific binding was determined in adjacent sections by addition of 
1 mL of buffer to each slide as described but in the presence of 100 mM 
of oxytocin.  
5) Air-dried slides and iodine-125 standards were exposed to Kodak 
Biomax film (in cassettes at -4
0
C) for 48 hours and then manually 
developed using Kodak D-19 developer and rapid fixer.  
 
4.4.2.6 Vasopressin 1a receptor autoradiography 
On the day of analysis, slides were removed from the -80
o
C freezer and 
allowed to thaw for 4 hours. Slides were placed onto two trays; one designated 
for determination of total binding and the other (adjacent sections) designated 
for determination of non-specific binding. The procedure was based on 
Campbell et al. (2009).  
1) Sections were incubated with 65 pM [125I]AVP in 0.05M Tris-HCl, 
0.1% bovine serum albumin (BSA), 10 mM MgCl2, 0.05% bacitracin 
pH 7.4 for 1 hour at room temperature.  Incubation was conducted by 
addition of 1 mL of incubating buffer to the slides ensuring that all 
tissue sections were covered. 
2)  At the end of the incubation period, solutions were removed by 
pouring to waste.  
3) Sections were rinsed for 8 minutes by placing the slides into 
container filled with ice-cold Tris-HCl (0.05M, pH 7.4) with 0.1% 
BSA, 0.01% triton-X and 100 mM choline chloride, Sections were 
washed in this way three times i.e. 3 x 8 min washes.  
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4) An additional 30 minute rinse in 0.05M Tris-HCl, pH 7.4 was carried 
out, followed by three quick dips in ice-cold distilled water.  
5) Non-specific binding was determined in adjacent sections by 
incubating with1 mL of buffer in the same way as described above 
but in the presence of 50 µM of vasopressin .  
6) Air-dried slides and iodine-125 standards were exposed to Kodak 
Biomax film for 48 hours (in cassettes at -4
0
C and then manually 
developed using Kodak D-19 developer and rapid fixer. 
 
4.4.2.7 CB1 receptor autoradiography 
On the day of analysis, slides were removed from the -80
o
C freezer and 
allowed to thaw for 4 hours. Slides were placed onto two trays; one designated 
for determination of total binding and the other (adjacent sections) designated 
for Dalton and Zavitsanou (2010) was followed.  
 
1) Sections were incubated with 5nM [3H]CP 55,940 in 0.05M Tris-HCl 
with 5% BSA, pH 7.4, for 2 hours at room temperature by placing 1 
mL of incubation buffer onto each slide ensuring that all tissue was 
covered,  
2) Non-specific binding was determined by incubating sections with 1 
mL of buffer in the same way as described above but in the presence 
of 10 μM Rimonabant,  
3) At the end of the incubation period, solutions were removed by 
pouring to waste. Sections were rinsed for 3min by placing the slides 
into container filled with ice-cold Tris-HCl with 5% BSA, pH 7.4, 
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Section were washed in this way three time i.e. 3 x 3min washes, 
followed by three quick dips in ice-cold water and allowed to dry 
overnight.  
4) The following day, sections and tritiated microscales were apposed to 
Kodak Biomax film for 10 weeks (in cassettes at -4
0
C) and then 
manually developed using Kodak D-19 developer and rapid fixer. 
 
4.4.2.8 Film development 
 On the day of development, the cassettes were transported to the dark 
room. The developing solution was prepared by diluting the D19 developer with 
distilled water (1:1 v/v) and was placed into a tray. In separate trays, fixing 
solutions and a stop solution was placed (1L of distilled water with a drop of 
glacial acetic acid). Then film development took place as follows: 
 
1) Take tape off cassette, carefully lift the film and place shiny side down 
into the developing tray. Agitate tray until film is covered. Leave for 1 
min. 
2) Remove delicately and place into stop for 1 min, making sure the film is 
covered. 
3) Remove and place in fixer solution for 3 min 
4) Once fixed, turn lights on and transfer film into bowl of distilled water. 
5) Run under distilled water for at least 30 min 






4.4.2.9 Image analysis 
Images were analysed using densitometry by means of the image analysis 
software MCID
TM
 (version 7.0, Imaging Research Inc., Interfocus Ltd, UK). 
Individual regions of interest (ROIs) were identified and specific binding of the 
radioligand to respective receptor was measured by subtracting the non-specific 
binding (as determined from adjacent sections). For 5-HT1A and CB1 receptor 
binding, where tritiated radioligands were used images were calibrated for 
density against commercially available microscales with decay correction to 
estimate radioactivity content in nCi/mg tissue. [
3
H]radioligand binding was then 
converted to pmol/mg tissue. In the case of oxytocin and vasopressin 1a receptor 
binding, an attempt was made to calibrate images against [
125
I]microscales, 
however this was not possible due to the poor quality of the commercially 
available standards. A non linear relationship was found to exist between 
concentrations of standard and relative optical density (ROD), deeming these 
unsuitable for quantification of images. For this reason, iodinated images were 
analysed using the relative optical density measure of the MCID system. 
The exact locations of the ROIs sampled for 5-HT1A receptor 
autoradiography are shown in figure 4.3 (A-E). For oxytocin receptor and 
vasopressin a1a receptor sampling, the ROIs sampled are shown in figure 4.4 
(A-E). For CB1 receptor autoradiography, the ROIs sampled are shown in figure 
4.5 (A-F). The ROI sampled has been identified by highlighting it with an 
orange shape on the left hemisphere. Where applicable, both left and right sides 
were sampled separately and data combined to give a single value. ROIs were 
selected as a combination of known receptor distribution, areas of dense binding 
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and resolution of images obtained. For example, further subregional analysis of 







H]CP 55,940 due to the resolution of autoradiography images 
allowing identification of subregions. However, it should be noted that 
subregional analysis of tissue dissected for HPLC/RIA was not possible, 
although the same regions were selected. For example, with autoradiography, 
dorsal hippocampus subregions CA1 rad, CA2 rad, CA2 pyr, CA3 rad and 
MODG were sampled, whereas for determination of neurotransmitter 
concentration, it was only possible to dissect whole dorsal hippocampus. 
To enable consistency between sampling, the size of the ROIs were kept 
constant. Dimensions of each ROI are listed appendix C as the ROIs in figure 
4.3 (A-E), figure 4.4 (A-E), figure 4.5 (A-F) are not drawn to scale. 
Interassay coefficient of variation was calculated for each 
autoradiography experiment. A total 6 films were used for [
3
H]WAY100635 and 
the interassay coefficient of variation in sampling between films was determined 
to be <7%.  A total of 4 films each were used for [125I]OVTA and [125I]AVP, 
with an inter-assay coefficient of variation determined to be <7% for sampling 
between [
125
I]OVTA films and <11% for sampling between [
125
I]AVP films. A 
total 5 films were used for [
3
H]CP 55,940 and the interassay coefficient of 
variation between films was determined to be <7%.  
 
4.4.3 Determination of neurotransmitters in the brain  
 The present study measures concentrations of 5-HT, 5-HIAA (major 
metabolite of 5-HT), oxytocin and vasopressin in discrete brain regions after 
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chronic exposure to corticosterone. This was conducted using either high 
performance liquid chromatography (HPLC) or radioimmunoassay (RIA).  
Here, first the theoretical background of each technique is described i.e. HPLC 
in section 4.4.3.1 and RIA in section 4.4.3.2 This is followed by detailed 
materials and methods for experiments which are presented later in chapters 5 
and 6.  
 
4.4.3.1 High performance liquid chromatography 
High performance liquid chromatography (HPLC) is an established 
analytical technique which is popular for the separation and quantification of 
analytes from a range of matrices. The technique has evolved considerably and 
currently there are many different forms of chromatography. In general, 
however, the components of an HPLC system are the same. A highly polished 
narrow stainless steel tube which has been packed with small sized porous silica 
particles (3-10µm) termed the stationary phase; a buffer solution –mobile phase 
which carries the mixture of analytes through the system; a pump which enables 
the movement of the mobile phase through the system at a constant flow rate and 
a detector that enables identification of the analytes. Essentially, separation of a 
mixture occurs as a result of interactions between the analyte of interest and the 







Figure 4.3 (A-E) –Location of ROI’s sampled for 5-HT1A receptor autoradiography. 
Representative images taken from the Paxinos and Watson Rat Brain Atlas 5
th
 Edn 
showing regions sampled for [
3
H]WAY 1000635 autoradiography, where 1= PRL 
(prelimbic cortex), 2= (CGL) cingulate cortex, 3= M2 (motor cortex), 4= M1 (motor 
cortex), 5= CA1-rad (radial layer of field CA1 of dorsal hippocampus), 6= CA2-rad 
(radial layer of field CA2 of dorsal hippocampus), 7= CA2 pyr ( pyramidal layer of field 
CA2 of dorsal hippocampus), 8= CA3-rad (radial layer of field CA3 of dorsal 
hippocampus), 9= MODG (dentate gyrus of dorsal hippocampus), 10= hypothalamus, 
11= amygdala, 12=  pir 3 (third layer of piriform cortex), 13= PVN (paraventricular 
hypothalamic nuclei), 14= subiculum, 15= CA1-rad (radial layer of field CA1 of ventral 





















Figure 4.4 (A-E). Location of the ROIs sampled for oxytocin and vasopressin 1a 
receptor autoradiography. Representative images taken from the Paxinos and Watson 
Rat Brain Atlas 5
th
 Edn showing the regions sampled for oxytocin and/or vasopressin 1a 
receptor autoradiography, where, 1= LSD (lateral septal nuclei), 2= MS (Medial septal 
nuclei), 3= Nucleus accumbens (shell), 4 = GI (granular insular cortex), 5 = PODG 
(polymorph layer of the dentate gyrus), 6= MODG (molecular layer of the dentate 
gyrus), 7= PO (posterior thalamic nuclear group), 8= LDDM (lateral dorsal nuclei), 9= 
VM (ventromedial thalamic nuclei), 10= PEFLH (perifornical lateral hypothalamus), 
11= VMDH (dorsal part of ventromedial hypothalamic nucleus), 12= CeA (central 
amygdala nucleus), 13= PVN (paraventricular hypothalamic nuclei), 14= GrDG 







Figure 4.5 (A-F) –Location of ROIs sampled for CB1 receptor autoradiography. 
Representative images taken from the Paxinos and Watson Rat Brain Atlas 5
th
 Edn 
showing regions sampled for [
3
H]CP 55,940 autoradiography, where 1= PRL (prelimbic 
cortex), 2= (CGL) cingulate cortex, 3=M2 (motor cortex), 4= M1 (motor cortex), 5= 
AcbC (nucleus accumbens core), 6= AcbSh (nucleus accumbens shell), 7=striata, 8= 
PVN (paraventricular hypothalamic nuclei), 9= CA1-rad (radial layer of field CA1 of 
dorsal hippocampus), 10 = CA2-rad (radial layer of field CA2 of dorsal hippocampus), 
11= CA3-rad (radial layer of field CA3 of dorsal hippocampus), 12=PODG (polymorph 
layer of dentate gyrus dorsal hippocampus), 13= amygdala, 14= VMDH (ventromedial 
hypothalamic nuclei), 15= Substantia nigra, 16=CA1-rad (radial layer of field CA1 of 








 One adaptation of the original technique is reversed-phase HPLC and 
this has proved particularly useful for isolating neurotransmitters. Others types 
include absorption, ion exchange, size exclusion and gel permeation, each 
differing in the stationary phase used (Holman, 1993). In reversed-phase HPLC 
the silica stationary phase has been modified by addition of a covalently bonded 
hydrophobic moiety usually an n-alkyl chain C8 or C18. The mobile phase is 
more polar than the stationary phase and hence polar (hydrophilic) compounds 
are eluted faster than non-polar (hydrophobic) compounds (Holman, 1993).  
The sample to be analysed is introduced to the top of the column. As the 
sample moves through the column, the individual components are differentially 
retained on the stationary phase (a process that is dependent on the strength of 
interaction between the analyte and the hydrophobic moieties of the stationary 
phase). In this way, components of the sample are eluted from the column at 
different times. These are referred to as the retention times and are defined by 
the time elapsed between injection onto the column and being detected. There 
are many factors that will influence the retention time of a compound such as 
type of stationary phase, mobile phase composition, pH and temperature which 
may affect the separation of analytes (Isimer et al., 1991). In addition, organic 
modifiers and anion pairing agents can be added to the mobile phase that alter 
the retention times of compounds allowing more control over the separation. For 
example, in the context of indole analysis, the separation of 5-HT from its more 
acidic metabolite, 5-HIAA can take a long time. However, through addition of 
methanol (organic modifier of the mobile phase), it is possible to speed up the 
overall runtime. Furthermore, octane sulphonic acid (anion pairing agent) 
strengthens the interaction of amines with the stationary phase and so increases 
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their retention time (Isimer et al., 1991). HPLC is a highly sensitive technique 
and the parameters mentioned above must be kept constant as even small 
changes in any of these can be detrimental to the analyses (Isimer et al., 1991). 
 As the analytes are eluted from the column, they pass through a detector 
which has been programmed to identify the analyte of interest based on one of 
several properties, for example ultraviolet (UV), fluorescent or electrical signals 
(Stein, 1982).  Electrical chemical detection (ECD) is one of the most sensitive 
detection methods for HPLC and is often used in studies measuring 
neurotransmitter concentrations. ECD relies on the generation of a potential 
difference between the working electrode and the mobile phase. The detectors 
can be set in an oxidation or reduction mode. In the oxidation mode, any 
component of the mobile phase (including analyte of interest) which can be 
oxidised will pass electrons (and hence current) from the mobile phase to the 
working electrode. The flow of current is directly proportional to the 
concentration of the analyte and so quantification of each analyte can be attained 
(Stein, 1982).  
 
4.4.3.2  Materials used for HPLC experiment 
All mobile phase reagents, extraction solvents (perchloric acid and 
EDTA) and indoleamine standards were purchased from Sigma Aldrich (Poole, 
Dorset, UK). The HPLC hardware system used was the ESA, model 582 solvent 
delivery system, with an ESA Coulochem II electrochemical detector coupled to 
the EZChrom Data Capture and Analysis software. Extracts were filtered 
through a syringe filter (Millipore) and placed into light protective chromacol 
vials and inserts (Chromacol) before separation of components on an analytical 
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HPLC column (5µM Spherisorb ODS, 4.6 x 100mm analytical column (Waters 
Analytical)).  
 
4.4.3.3 Methodology for Indole determination by HPLC 
Prior to tissue analysis, the HPLC method was optimised. Standards were 
generated from 5mM stock solutions, ranging between (0.03-5.00 µmol/L). Rat 
brain tissue collected during the feasibility study was used here for method 
development and optimisation. Indoleamines extracted from striatal and frontal 
cortex tissue were analysed at 2 µA with a standard curve in the range of 0.1-5 
µmol/L, whereas a higher sensitivity (0.5 µA; standard curve range 0.025-1.25 
µmol/L) was required for hypothalamus, prefrontal cortex, amygdala, dorsal 
hippocampus, ventral hippocampus and raphé, due to a combination of lower 
indoleamine content and smaller tissue mass of these regions.  A typical standard 
curve from the validation of striatal and prefrontal cortex tissue analysis is 
shown in figure 4.6. The higher sensitivity range standard curve used for the 






Figure 4,6 Calibration curves from the lower sensitivity range of standards for 5-HIAA 
and 5-HT (0.10-5.00 µmol/L). This range of standards was used to quantify 5-HIAA 






Figure 4.7 Calibration curves from the higher sensitivity range of standards for 5-HIAA 
and 5-HT (0.03-0.62 µmol/L). This range of standards was used to quantify 5-HIAA 
and 5-HT content in hypothalamus, prefrontal cortex, amygdala, dorsal hippocampus, 
ventral hippocampus and raphé tissue obtained from both vehicle and CORT treated 
rats. 
 
Once the methodology was optimised, the following protocol was followed for 
extraction and sample preparation: 
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1) Frozen tissue from the current study was weighed and immediately 
homogenised (sonicated for 20 seconds) in ice-cold 0.1M perchloric 
acid/0.5mM EDTA (Zaczek and Coyle 1982).  
2) Tissues were kept on ice for 20 minutes before centrifugation (3,000 
rpm, 4
o
C for 20min).   
3) The resulting supernatant was filtered through 0.4 µm filters 
(Millipore, U.K.) and 200 µL of the supernatant was placed into 
chromacol vials. 
4) A 50 µL aliquot was analysed on a 5 µm Spherisorb 4.6 x 100 mm 
column (Waters Ltd, UK.). 
 
The mobile phase consisted of 0.05M NaH2PO4, 1 mM OSA, 0.1 mM 
EDTA, 10% MeOH, pH 3.2 at a flow rate of 1mL/min. The electrochemical 
detector settings were as follows: screening electrode 0mV, analytical electrode 
+300 mV and guard cell -600 mV. The sensitivities of the analytical electrode 
ranged from 0.5 µA to 2 µA, depending on the brain region analysed. Tissue 
concentrations of 5-HT and its metabolites 5-HIAA were quantified by external 
standard curve calibration as explained above, using peak areas for 
quantification. Fresh standard solutions were prepared daily. Data were 
converted and expressed as pmol/mg tissue. 
 
4.4.4  Radioimmunoassay 
Radioimmunoassay (RIA) is a technique which is used to measure 
concentrations of hormones in a sample. It is a highly sensitive and specific 
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technique allowing detection of analytes in the picogram range (Skelley et al., 
1973). It is based on the principle of ligand-antibody binding, where the antigen 
(e.g. hormone of interest) binds to the antibody to form a complex as described 
by the equation below: 
 
 
Where: Ag = antigen 
Ab = antibody 
AgAb = antigen-antibody complex 
k= rate constant for association 
ki=rate constant for dissociation 
 
 
At equilibrium, the concentration of AgAb is the same as the concentration of 
Ag and Ab individually, 
 
Where: K = equilibrium constant (k/ki) 
 
At equilibrium, the ratio of bound fraction and free fraction can be described as: 
 
Where: B= bound fraction 
                           F= free fraction 
 
 
In order to measure B or F, a small (and constant) amount of 
radiolabelled antigen is introduced to set up a competition between the labelled 
and unlabelled antigen for the limited antibody. Then B is measured by 
precipitating the radiolabelled AgAb complex from the solution by the addition 
of a secondary antibody. After a centrifugation stage, the B fraction is 
represented by the pellet, whereas F remains in the supernatant. Both fractions 
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are counted in a gamma counter and the concentration of antigen [Ag] of interest 
in the sample determined. A standard curve is generated by running ‘known’ 
concentrations in parallel to ‘unknowns’ from which unlabelled [Ag] can be 
extrapolated. 
 
4.4.4.1 Materials used for radioimmunoassay experiment 
Commercially available kits were purchased for the analysis of 
neuropeptide concentration in plasma and tissue extracts. Separate kits were 
purchased for oxytocin and vasopressin (Phoenix Pharmaceuticals Inc.; product 
code RK-051-01, RK-065-07 respectively). The oxytocin kit had a detection 
limit of 30 pg/mL (range 10-1280 pg/mL).  The inter-assay and intra-assay 
variation was not measured  in this study, however, based on published literature 
the oxytocin kit had an inter-assay and intra-assay variation of 9% and 11% 
respectively (Marrazziti et al., 2006). The vasopressin kit had a detection limit of 
31.1 pg/mL (range 10-1280 pg/mL). Again, the inter-assay and intra-assay 
variation was not measured in this study, however, based on published literature 
the vasopressin kit had an inter-assay and intra-assay variation of <9% and 
<12% respectively (Oritz et al., 2002). The cross reactivity of the oxytocin kit 
was 100% with oxytocin and 0% with Lys-vasopressin, Arg-vasopressin, growth 
hormone, alpha-ANP, Met-Enkephalin, gonadotropin releasing factor, 
somatostatin, thryotropin releasing hormone, vasoactive intestinal peptide, Pacap 
27-NH2.  Whereas, the cross reactivity of the vasopressin kit was 100% 
with [Arg8]-Vasopressin, [Arg8]-Vasotocin and vasopressin metabolite 
neuropeptide, 38% with [Lys8]-Vasopressin, 0.8% with  Deamino-[D-Arg8]-
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Vasopressin and 0% with -ANP (1-28), Oxytocin,  ACTH, LH-RH,  Met-
Enkephalin, PACAP-38, PACAP-27 Amide and Pressionic Acid.  
 Plasma samples were measured after solid phase extraction using Sep 
pak cartridges Strata-X, C18; 3 x 300 mg/mL (Phenomenex).  
A commercially available kit was also used for the determination of 
corticosterone in plasma (MP Biomedicals; product code 07120102). Plasma 
corticosterone concentration was measured directly without prior extraction as 
instructed by the kit protocol. The minimum detectable amount of corticosterone 
using this kit was 7.7 ng/mL. The intra-assay variation and inter-assay variation 
was quoted to be <10% and <7% respectively (MP Biomedicals). The cross 
reactivity of the kit was 100% with corticosterone, 0.34% with 
deoxycorticosterone, 0.1% with testosterone, 0.05% with cortisol, 0.03% with 
aldosterone, 0.02% with progesterone, 0.01% with androstenedione, 0.01% with 
5-α dihydrotestosterone, <0.01% with cholesterol, dihydrotestosterone, 
dehydroepiandrosterone sulphate, 11-desoxycortisol, dexamethasone, 20α-
dihydroprogesterone, estrone, estradiol-17α, estradiol -17β, estriol, 
pregnenolone, 17α-hydroxypregnenolone and 17α-hydroxyprogesterone.  
 
4.4.4.2 Methodology for determination of peptide concentration 
by radioimmunoassay  
 
Oxytocin and vasopressin concentrations were measured in dissected 
brain regions using radioimmunoassay with prior extraction of peptides as 




1) On the day of extraction, samples were removed from the -80oC freezer but 
kept packed on dry ice.  
2) Each brain region was individually weighed before addition of 0.1M acetic 
acid (200 µL for each region except prefrontal cortex, where 800 µL was 
added due to the greater tissue mass).  
3) The sample vials were then immediately placed into a bath of boiling water 
for 20 minutes.  
4) After 20 mins, sample vials were removed and allowed to cool to room 
temperature.  
5) The vials were then frozen at -20oC (tissue debris and acetic acid extract 
together) until analysis. 
Plasma quantification of oxytocin and vasopressin was carried out after 
solid phase extraction (SPE) of the peptides from acidified plasma samples using 
Strata X, SPE cartridges (C18; 3 x 300 mg/mL; Phoenix Pharmaceuticals Inc.). 
This was achieved using the reagents and protocol supplied in the RIA kit and is 
outlined below: 
 
1) Dilute the plasma samples by addition of 500 µL of buffer A to 500 µL of 
plasma.  
2) The SPE cartridges were equilibrated by addition of 1 mL buffer B and then 
3 x 3 mL of buffer A.  
3) The acidified plasma sample (1 mL) was then loaded onto the column. 
4) The column was then washed with 2 x 3 mL of buffer A.  
5) The peptides were then eluted by addition of 3 mL of buffer B.  
6) The eluent was collected and evaporated to dryness in a centrifugal 




Tissue extracts were analysed as outlined in the RIA kit and is described below: 
1)  100 µL of extract was added to 100 µL of primary antibody (rabbit anti 
peptide serum),  
2) The samples were vortexed and incubated at 40C for 24 hours.  




4) The following day, 100 µL of goat anti rabbit IgG serum and normal rabbit 
serum was added to each tube. 
5)  Samples were vortexed and incubated for a further 90 minutes at room 
temperature  
6) 500 µL of RIA buffer was added to each tube and centrifuged (3,000 rpm 
for 20 minutes at 4
0
C) to separate bound and unbound radiolabelled 
fractions.  
7) The supernatant was immediately aspirated and both supernatant and pellet 
were counted in a gamma counter.  
 
4.4.4.3 Corticosterone Radioimmunoassay 
The concentration of corticosterone in plasma samples was measured 
using a commercially available kit from MP Biomedical. The samples were 
analysed directly without extraction as instructed by the kit protocol to give a 
corticosterone concentration in ng/mL. Plasma samples were measured in 
duplicate, the intraassay variation in this study was <11%.    This is outlined 
below: 
 
1) Plasma samples were diluted 1:200 with steroid diluent,  
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2) [125I]corticosterone was added before introduction of antiserum (anti 
corticosterone).  
3) The samples were vortexed and incubated at room temperature for 2 hours, 
before addition of the precipitant.  
4) The samples were vortexed again and centrifuged at 2,300 rpm for 15 
minutes. 
5)  Both pellet and supernatant fractions were counted in a gamma counter.  
 
4.5     Statistical analysis 
Data were analysed using GraphPad Prizm 4.0 (Sigma Aldrich, Dorset 
UK).  All data presented in this thesis passed the Kolmogorov-Smirnov test for 
normality.  
For effects of corticosterone treatment on consumption of drinking water 
and body weight, data were analysed by means of two-way ANOVA for effects 
of treatment and duration of treatment. If the ANOVA result showed 
significance, individual data from each time point was analysed separately using 
Student’s two-tailed t-test (unpaired) with Bonferroni post hoc test applied to 
correct for multiple comparisons. The significance level was set at P = 0.05. 
Autoradiography, HPLC and RIA (peptide content) data was also analysed using 
a two-way ANOVA for effects of treatment and region. Plasma corticosterone 
data were also analysed using a two-way ANOVA for effects of treatment and 
timepoint of sacrifice (i.e. immediately after withdrawal of CORT or after a 24 
hour period). 
Where the ANOVA showed significant effects, data were analysed 
separately with Student’s two-tailed t-test (unpaired) with Bonferroni post hoc 
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test applied to correct for multiple comparisons. The significance level was set at 
P = 0.05. Post mortem adrenal and thymus gland weights were analysed by 
Student’s two-tailed t-test (unpaired) with a significance level set at P = 0.05. 
All data presented in this thesis are expressed as mean ± SD in the text 
and tables, and are shown as mean ± SEM in graphs. Statistical differences 
assessed as described above are denoted by asterisks *.A record of the statistical 












Serotonergic responses to chronic 
glucocorticoid exposure  
   Glucocorticoids serve to maintain homeostatic control via a negative 
feedback mechanism, however, when this is dysfunctional an allostatic load 
occurs. Approximately 50% of depressed patients also show hyperactivity of the 
HPA axis in addition to serotonergic dysfunction (Holsboer, 2000; Pariante and 
Miller, 2001; Pariante, 2003; Anacker et al., 2011).  In this chapter, I investigate 
the effect that chronically elevated glucocorticoids have on central 5-HT1A 
receptor binding and serotonin turnover and discuss how these changes may be 





5.1     Introduction 
It is well known that stressful life experiences will contribute to the 
aetiology of depression and anxiety related disorders, and this relationship has 
been studied extensively (Kendler et al., 2008; reviewed in Lanfumey et al., 
2008). Overactivity of the HPA axis arising from the loss of negative feedback is 
an important hallmark of these disorders (Anacker et al., 2011). In addition, 
aberrant serotonergic signalling has also been described in depressed patients 
with an underlying HPA axis dysfunction (Mikkelsen, 2004; Anacker et al., 
2011). Thus, the involvement of serotonin in the regulation of the stress response 
has been the subject of intense interest (Baganz et al., 2010; Goel et al., 2011; 
Curran and Chalsani, 2012). In particular, it is thought that an individual’s 
response to antidepressants may be dependent on differences in their HPA axis 
responsiveness and also to the degree of abnormalities in the serotonergic system 
(Anacker et al., 2011). This would provide one explanation for the high 
proportion of depressed patients which are treatment-resistant, although it is 
likely to be a combination of many other factors too such as involvement of the 
GR and other neurotransmitter systems (Anacker et al., 2011). 
 At a molecular level, interactions between the serotonergic and 
glucocorticoid systems have been elucidated (Falkenberg and Rajeevan, 2010). 
Serotonergic influence on the HPA axis is implicated at the level of the 
hippocampus, hypothalamus, pituitary and adrenal glands (Chaouloff, 1993; 
Falkenberg and Rajeevan, 2010). Whilst serotonin activates the HPA axis 
resulting in glucocorticoid secretion, the activation of the 5-HT1A receptor can be 
considered to be anxiolytic under normal conditions, playing a role in the 
negative feedback mechanism alongside the glucocorticoid receptor (Chaouloff, 
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1993). However, in depression, serotonergic signalling at the 5-HT1A receptor is 
impaired, and in conjunction with GR dysfunction, this contributes to HPA axis 
hyperactivity by inhibiting the glucocorticoid-mediated negative feedback 
mechanism (Mikkelsen et al., 2004; Anacker et al., 2011). In addition, in the 
hypothalamus the 5-HT1A receptors are expressed by CRH neurones. The release 
of CRH from the hypothalamus is independent of hypothalamic GR receptors; 
therefore a role for the 5-HT1A receptors in regulating the HPA axis is postulated 
(Falkenberg and Rajeevan, 2010).  
 Experimentally, exogenous corticosterone can be administered to achieve 
long-term increases in peripheral concentrations in order to study their 
neurobiological effects. In this way, chronic administration of corticosterone has 
been shown to induce anxiety and depression-like behaviour in rodents 
(Ardayfio and Kim, 2006). Chronic exposure to an elevated concentration of 
glucocorticoid results in changes in central serotonergic regulation, namely a 
reduction in 5-HT1A receptor binding in the hippocampus, cortex and raphé and 
increased serotonin release (Meijer et al., 1997; Lopez et al., 1998; Bush et al., 
2003).  
 In this study, the response to chronic corticosterone was investigated at 
both the presynaptic and postsynaptic 5-HT1A receptor and related to serotonin 
turnover in the same regions. The presynaptic receptor is predominately located 
on 5-HT neurone cell bodies and dendrites in the raphé region (Palacios et al., 
1990) and due to the extensive innervation of the serotonergic system throughout 
the brain, activation of these presynaptic receptors can influence serotonergic 
activity in projection areas i.e. cortex, hippocampus, amygdala, which are all 
regions where the 5-HT1A receptor is expressed postsynaptically (Palacios et al., 
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1990). To our knowledge, this is the first attempt to simultaneously study the 
effects of chronic exposure to glucocorticoids at both the pre-and postsynaptic 5-
HT1A receptor and investigating receptor activity to serotonin turnover in the 
same region. In addition, this is the first time that the 5-HT1A receptor in limbic 
and extralimbic regions has been investigated in the same study.  
 
5.1.1     5-HT1A receptor and the stress response 
The measurement of changes in 5-HT1A receptor density after chronic 
stress or exogenous GC administration is well documented. Chronic treatment 
with corticosterone reduced 5-HT1A receptor binding in the cortex and 
hippocampus of rats (Meijer et al., 1997; Bush et al., 2003). Also, chronic 
immobilisation stress decreased 5-HT1A receptor binding in the hippocampus as 
a result of increased circulating corticosterone concentration (Mendelson and 
McEwen, 1991; 1992). In addition, repeated stress in rats and tree shrews led to 
an 11%-34% reduction in 5-HT1A receptor density in parietal cortex, prefrontal 
cortex, posterior cingulate and hippocampus (Flugge, 1995). As well as 
influencing the number of 5-HT1A receptors, glucocorticoids affect the 
functionality of these receptors. Prolonged treatment of rats with corticosterone 
(10mg/kg s.c. given twice daily for 7 days) induced attenuated population spikes 
and hyperpolarisation in the hippocampus in response to the selective 5-HT1A 
receptor agonist, 8-OH-DPAT (Czyrak et al., 2002). These corticosterone-
induced changes were reversed after treatment with imipramine, a tricyclic 
antidepressant, which acts to increase central serotonin levels (Zahorodna et al., 
2006). In addition, desensitisation of raphé autoreceptors is known to occur in 
response to glucocorticoids (Fairchild et al., 2003). 
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Interestingly, post mortem studies in depressed patients with 
hypersecretion of cortisol indicated dysfunction in the expression of the 5-HT1A 
receptor. A reduction in hippocampal 5-HT1A receptor mRNA was observed, 
which was attributed to cortisol-dependent inhibition of 5-HT1A receptor mRNA 
expression (Lopez et al., 1998). 
 
5.1.2     Serotonergic activity during the stress response 
Changes in serotonergic activity can indicate abnormalities in the 
regulation of the HPA axis. These can be measured as changes in the synthesis 
and release of 5-HT, its major metabolite 5-HIAA, or serotonin turnover, defined 
as the ratio of 5- 5-HIAA:5-HT (Fuller and Wong, 1990). Stress-induced 
increases in 5-HT release in the raphé, prefrontal cortex, hippocampus and 
amygdala have all been previously demonstrated (Maswood et al., 1998; Amat et 
al., 2005). However, regional variations in the serotonergic response to stress 
exist. Thus, a period of forced swim increased 5-HT in the striatum of rats 
whereas; 5-HT concentration in the amygdala and septal nuclei was decreased or 
remained unchanged in the hippocampus and frontal cortex (Kirby et al., 1995). 
In the same way, regional specificity exists for 5-HIAA concentration measured 
in response to stress. Immobilisation and exposure to cold stress has been shown 
to cause an increase in 5-HIAA release in the frontal cortex and raphé of rats, but 
forced exercise stress caused an increase in 5-HIAA levels in the frontal cortex 
only (Clement et al., 1993).  In another study, forced swimming reduced 5-
HIAA concentration in all regions sampled (Kirby et al., 1995).  
With this in mind, is not surprising that regional variations in the effect 
of stress on serotonin turnover are also seen. Tail pinch induced stress caused an 
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increase in serotonin turnover in the frontal cortex and hippocampus of rats, but 
not in the striata, olfactory tubercles or hypothalamus (Pei et al., 1990). 
Interestingly, the intensity of a stressor can be an important determinant of the 
serotonergic response. A high intensity electric foot shock produced increases in 
5-HT turnover in the prefrontal cortex, nucleus accumbens and hypothalamus, 
whereas no changes were measured after a low intensity electric shock in the 
same regions (Inoue et al., 1994). Furthermore, it has been demonstrated that the 
increased serotonergic neuronal activity in the raphé that results after exposure 
to stress can be attributed to an increase in 5-HT turnover and release rather than 
to an increase in neuronal firing rate (Takase et al., 2004), which is an effect that 
may arise from the stimulation of tryptophan hydroxylase by corticosterone 
(Lanfumey et al., 2008). 
 In this chapter, I describe experiments that were designed to evaluate 
changes in 5-HT1A receptor binding after chronic exposure to exogenous 
corticosterone in male Wistar rats. In addition, I quantified the concentration of 
5-HT, 5-HIAA and calculated serotonin turnover in discrete brain regions of 
CORT treated rats.  Autoradiography was used to determine binding of 
[
3
H]WAY 100635 to 5-HT1A receptors in rat brain. The highly selective 
antagonist radioligand (Ki = 0.85 nM) has been extensively used to study the 5-
HT1A receptor (Forster et al., 1995; Khawaja et al., 1995). Changes in serotonin 
turnover were measured by quantifying 5-HT and 5-HIAA in tissue 
homogenates representing total (intracellular and extracellular) tissue 





5.2   Aims and Hypothesis 
5.2.1 Aims 
The main objective of the programme of work is to establish the effect of 
chronic exposure to corticosterone, as a model of chronic stress, on the 
serotonergic system in the brain. It has been reported that high corticosterone 
levels reduce 5-HT mediated inhibition and excitatory response to 
phenylephrine, an α-adrenergic receptor agonist (Judge et al., 2004). Czyrak et 
al., 2002 observed that prolonged treatment with corticosterone (10mg/kg s.c. 
given twice daily for 7 days) induced attenuated population spikes and 
hyperpolarisation in hippocampus in response to 8-OH-DPAT, a selective 
agonist at the 5-HT1A receptor. These corticosterone-induced changes were 
reversed after treatment with imipramine, a tricyclic antidepressant, which acts 
to increase central serotonin levels (Zahorodna et al., 2006).  
 With regards to the 5-HT1A receptor, reduced binding was observed in 
the cortex and hippocampus after chronic treatment of rats with corticosterone 
(Meijer et al., 1997 and Bush et al., 2003). Further support of the fact that 
glucocorticoids influence 5-HT1A binding is a study by Chalmers et al., 1993 
which showed that adrenalectomised rats show an increase in 5-HT1A binding in 
hippocampus relative to sham operated rats. It has also been reported that 
elevated circulating corticosterone levels cause 5-HT1A receptors to become 
desensitized and receptor expression decreases. It has not been studied how the 
glucocorticoid-dependent receptor changes correlate with serotonin 
neurotransmitter activity, nor has the effect of glucocorticoids on the 
serotonergic system been assessed in extralimbic as well as limbic regions. In 
order to address this gap in knowledge, serotonin turnover and 5-HT1A receptor 
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binding will be studied in discrete brain areas post mortem. 
This thesis tests and reports, for the first time, receptor and neurotransmitter 
level changes simultaneously from the same study. Such a study, using a dual approach 
has not previously been done and will determine whether the receptors altered by 





It is hypothesised that chronic treatment with corticosterone, will lead to 
5-HT1A receptor density changes similar to those already published in the 
literature. More specifically, there will be a reduction in binding at the 5-HT1A 
receptor in the limbic brain regions implicated in responses to stress. Also, it is 
hypothesised that these receptor changes will be linked to serotonin turnover 
effects in limbic brain regions implicated in responses to stress.  
 
5.3     Materials and Methods 
All materials used for this study are given in chapter 4. Also, in chapter 
4, are methodological details on in-vivo husbandry, dosing on animals, 
collection of post mortem samples and tissue sectioning, HPLC and 
autoradiography. 
It should be noted that in this study, animals were sacrificed with the 





5.4     Results 
5.4.1     Water consumption 
Water consumption per cage was measured every second day. This was 
converted to volume of water consumed per rat (mL/rat) and is shown in figure 
5.1 (A).   
A two way analysis of variance was used to test for effects of CORT 
treatment on the volume of water consumed and also any effects associated with 
treatment duration on the volume of water consumed. Significant differences 
were found for duration (F(9,60) = 5.08, P < 0.0001) and treatment (F(1,60) = 
12.02, P = 0.001). Further analysis between treatment groups at individual time 
points using two-tailed Student’s t-test (unpaired) with Bonferroni correction 
with a significance level set at P = 0.05  revealed that CORT treated animals 
consumed less water than vehicle treated animals at day 17 of treatment. When 
normalised to body weight (figure 6.5 (B)), significant differences in volume of 
water consumed were found to be affected by duration (F(9,300) = 17.51, P < 
0.0001) and treatment (F(1,300) = 113.4, P<0.0001). The interaction was also 
significant (F(9,300) = 5.24, P <0.0001). Further analysis between treatment 
groups at individual time points using two-tailed Student’s t-test (unpaired) with 
Bonferroni correction with a significance level set at P = 0.05 revealed that 
CORT treated animals drank a greater volume of water at day 7 and then from 
day 13 until day 21 (end of the treatment period).  The amount of CORT 
ingested by the treated group was calculated. Using the average volume of water 
consumed by the CORT treated animals (mL/rat) at the beginning and end of the 
treatment (day 3, 64 mL; day 21, 70.5 mL) and the weight of the animals at the 
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beginning and end of treatment (day 3, 213.8g; day 21, 223.0g), the range of 
CORT ingested was 59.9 mg/kg/day to 63.2 mg/kg/day. The average CORT 
dose was calculated to be 55.7 mg/kg/day (based on an average of 60.7 mL of 
water consumed and an average body weight of 218.0g).  
 
5.4.2     Body weight 
Animals were weighed every second day throughout the treatment period 
and changes in body weight are shown in figure 5.2. A two way analysis of 
variance was used to test for effects of treatment on weight gain and also for 
effects of treatment duration. Significant differences were found for both 
duration (F(10,330) = 32.71, P = <0.0001) and treatment (F(1,330) = 885.4, P = 
<0.0001). The interaction was also significant (F(10,330) = 18.77, P = <0.0001). 
Further analysis between treatment groups at individual time points using two-
tailed Student’s t-test (unpaired) with Bonferroni correction with a significance 
level set at P = 0.05  revealed that CORT treated animals showed attenuated 
weight gain throughout the treatment period. Vehicle treated rats steadily gained 
weight with an increase from 220g ± 4g to 308g ± 24g, representing a 40% 
increase in body weight over the duration of the study. However, CORT-treated 
animal’s mean weight gain increased from 214g ± 14g to 223g ± 14g 
representing only a 4% increase in body weight over the same period. Thus, 
treatment with CORT for 21 days significantly attenuated weight gain in male 
Wistar rats. In addition, the effect of CORT on body weight was immediate, 








Figure 5.1. Water consumption of vehicle and CORT treated animals. Animals were 
treated with either 400µg/mL CORT or vehicle for 21 days. Based on the assumption 
that each rat consumed an equal volume of water, mean volume of water consumed per 
rat was calculated (A). This was then normalised to individual rat weight to give water 
consumption as  mL /kg (B). Data are expressed as mean ± SEM of n=16 per treatment 
group. Statistical analysis was carried out using 2-way ANOVA for treatment and 
duration of treatment. A Bonferroni post hoc test for multiple comparisons was applied 
with at a significance level of 0.05. A statistically significant effect after Bonferroni 





 5.4.3 Ex vivo readouts - adrenal and thymus gland weights 
At sacrifice, adrenal and thymus glands were dissected and weighed. 
Absolute adrenal gland weights (left and right side combined) and thymus gland 




Figure 5.2. Body weight measurements of both vehicle and CORT treated animals. 
Animals were treated as described in figure 5.1. Each animal was weighed every second 
day.  Data are expressed as mean ± SEM of n=16 per treatment group. Statistical 
analysis was carried out using 2-way ANOVA for effects of treatment duration and 
treatment itself. A Bonferroni post hoc test for multiple comparisons was applied with at 
a significance level of 0.05. A statistically significant effect after Bonferroni correction 
is denoted by *. 
 
 
Student’s two-tailed t-test (unpaired) was used to test for effects of 
CORT treatment on organ weights. Absolute organ weights were significantly 
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reduced in CORT treated animals (P<0.0001). When normalised to body weight, 
both glands were significantly reduced in weight after CORT treatment when 
compared to vehicle treated animals (P=0.0017 for adrenal glands and P<0.0001 
for thymus; CORT versus control). Chronic exposure to CORT for 21 days 
resulted in a decrease in adrenal gland weight from 22.22 ± 3.30 mg/100g body 
weight in the vehicle treated group to 15.98 ± 6.54 mg/100g body weight in 
CORT-treated animals. This represented a 28.1% reduction in adrenal gland 
weight after chronic CORT treatment. Thymus weights were reduced from 
162.60 ± 29.65 mg/100g body weight in the vehicle treated group to 110.80 ± 
34.35  mg/100g body weight in CORT-treated animals. This represented a 
31.9% reduction in thymus gland weight after chronic CORT treatment. 
 
Table 5.1. Effect of chronic exposure to CORT on thymus and adrenal gland weights. 






(organ weight (mg) 










22.22 ± 3.30 15.98 ± 6.54 ** 67.16 ± 10.47 34.69 ± 13.27 *** 
Thymus 
glands 
162.60 ± 29.65 110.80 ± 34.35 *** 493.20 ± 102.41 242.12 ± 69.28 *** 
 
Table 5.1. Animals were treated in the same way as described in figure 5.1. At sacrifice, 
adrenal glands and thymus was dissected and weighed. Tissue weights (mg) were 
normalised to body weight of the animal (g) (n=16 per treatment group). Data are 
expressed as mean ± SD. Statistical analysis was via Student’s two tailed t-test 







5.4.4     5-HT1A autoradiography  
Changes in binding to the 5-HT1A receptor were quantified after chronic 
exposure to CORT. The quantitative data showing [
3
H]WAY 100635 specific 
binding to 5-HT1A receptors expressed as pmol/mg tissue are shown in table 5.2. 
A two way analysis of variance was used to test for effects of treatment and also 
for region. Significant differences were found for both treatment (F(1,214) = 
49.49, P <0.0001) and region (F(15,214) = 26.11, P<0.0001). The interaction 
was also significant (F(15,214) = 2.74, P = 0.0007). Further analysis between 
treatment groups in each region revealed significant differences in the majority 
of regions sampled (two-tailed Student’s t-test with Bonferroni at a significance 
level set at P = 0.05). These are shown in figure 5.3. There was a significant 
increase in [
3
H]WAY 100635 binding in the prefrontal cortex, however after 
Bonferroni correction only the prelimbic (PRL) and primary motor cortex (M1) 
subregions of the prefrontal cortex, remained significantly increased by 74.8% 
and 67.3% respectively. There was also a significant increase in the piriform 
cortex, which did not remain significant after application of the post hoc test. A 
significant 81.1% increase in binding to the amygdala was seen after CORT 
treatment. In addition, the CA1 rad, CA2 rad, CA2 pyr, CA3 rad subregions of 
the dorsal hippocampus sampled showed an increase in 5-HT1A receptor binding 
after CORT treatment. But after application of Bonferroni post hoc test, only the 
CA1 rad and CA2 pyr subregions were found to be significantly increased by 
34.8% and 80.0%, respectively. Figure 5.4 shows representative autoradiograms 
of brain sections from vehicle and CORT treated rats labelled with [
3
H]WAY 
100635. Alongside, are images from brain sections showing non-specific 
binding i.e. those which were incubated in the presence of 10 µM serotonin. 
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Unfortunately, it was not possible to obtain sufficient data from the PVN 




Figure 5.3. Effects of chronic corticosterone on [
3
H]WAY  100635 binding in rat brain. 
Animals were treated with corticosterone in the same way as that outlined in figure 5.1. 
Data from regions showing a differences after corticosterone treatment are shown and 
expressed as mean ± SEM (n=8 per treatment group). Abbreviations for regions are the 
same as in figure 4.3 (chapter 4). Statistical analysis was carried out using 2-way 
ANOVA for treatment effects and regional effects followed by Bonferroni post hoc test 
for multiple comparisons, was applied with a significance level of 0.05. A statistically 









Table 5.2 Regional [
3
H]WAY 100635 binding in rat brain after chronic exposure to 
corticosterone. 
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  93.94 ± 33.39 
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  96.25 ± 39.52 









Raphé 112.64 ± 19.49 
 
103.75 ± 24.98 -7.8 0.441 
 
Entorhinal cortex   61.31 ± 14.80 
 
  71.68 ± 16.13 +16.9 0.201 
 
Table 5.2 Animals were treated in the same way as described in figure 6.5. Data are 
expressed as mean ± SD (n=8 per treatment group, except hypothalamus and subiculum 
where n=5 in vehicle group and n=6 in CORT group). Abbreviations used for regions 
are the same as in figure 4.3 (chapter 4). Statistical analysis was carried out using 2-way 
ANOVA for treatment effects and regional effects followed by Bonferroni post hoc test 
for multiple comparisons, with a significance level of 0.05. A statistically significant 










        




Figure 5.4 Representative [
3
H]WAY 100635 autoradiography images from rat brain. 
Measured after chronic exposure to corticosterone as described in figure 6.5. Images are 
from individual rats representing A = prefrontal cortex (PrL, CgL, M1, M2), B = dorsal 
hippocampus (CA1 rad, CA2 rad, CA2 pyr, CA3 rad, MODG, amygdala, pir3, C = CA1 
rad of ventral hippocampus, subiculum, D =  raphé. Further details of ROI location and 
sampling can be found in chapter 4. 
 
5.4.5     Indole determination by HPLC 
Concentrations of 5-HT, 5-HIAA and serotonin turnover (5HIAA:5-HT) 
were measured in discrete brain regions after chronic exposure to CORT. Data 
are shown in figures 5.5 (5-HT), 5.6 (5-HIAA) and 5.7 (serotonin turnover).   A 
two way analysis of variance was used to test for effects of CORT treatment on 
concentration of 5-HT, 5-HIAA and serotonin turnover measured (analysis was 
VEHICLE CORT NON SPECIFIC 
Raphé 






carried out separately for each). No significant treatment effects were observed 
in any of the regions. Therefore, further analysis between treatment groups for 
each region was not carried out. 
 
 
Figure 5.5.  Regional serotonin content in rat brain after chronic exposure to 
corticosterone. Brain tissue was dissected and concentrations of 5-HT were measured 
using HPLC-ECD after extraction.  Data are expressed as mean ± SEM (n=8 per 
treatment group except raphé, where n=6 per treatment group). Statistical analysis was 
carried out using 2-way ANOVA for treatment effects and regional effects. No 
statistical differences associated with corticosterone treatment were observed and 
therefore further statistical analysis by Student’s t-test with Bonferroni correction was 





Figure 5.6. Regional 5-HIAA content in rat brain after chronic exposure to 
corticosterone. Brain tissue was dissected and concentrations of 5-HIAA were measured 
using HPLC-ECD after extraction.  Data are expressed as mean ± SEM (n=8 per 
treatment group except raphé, where n=6 per treatment group). Statistical analysis was 
carried out using 2-way ANOVA for treatment effects and regional effects. No 
statistical differences associated with corticosterone treatment were observed and 
therefore further statistical analysis by Student’s t-test with Bonferroni correction was 
not carried out. 
 
 
 5.5     Discussion  
The present study demonstrates that long-term exposure to exogenous 
corticosterone attenuated body weight gain and also resulted in atrophy of the 
thymus and adrenal glands in male Wistar rats, consistent with suppression of 
the HPA axis (Magarinos et al., 1998). These are also associated with changes in 
the central serotonergic system. To my knowledge, this is the first report that 
quantifies the effects of exogenous corticosterone on 5-HT1A receptor binding 





Figure 5.7 Regional serotonin turnover in rat brain after chronic exposure to 
corticosterone. Brain tissue concentrations of 5-HT and 5-HIAA were measured using 
HPLC-ECD after extraction.  Serotonin turnover was calculated as the ratio of 5-
HIAA:5-HT concentration. Data are expressed as mean ± SEM (n=8 per treatment 
group, except raphé where n=6 per treatment). Statistical analysis was carried out using 
2-way ANOVA for treatment effects and regional effects. No statistical differences 
associated with corticosterone treatment were observed and therefore further statistical 
analysis by Student’s t-test with Bonferroni correction was not carried out. 
 
Corticosterone treatment affected 5-HT1A receptors in brain regions 
implicated in responses to stress. There were no changes in the concentration of 
serotonin, 5-HIAA or serotonin turnover in any brain region sampled. In this 
section, first I discuss the effect of CORT on in vivo parameters such as body 
weight and organ weights. Then changes in 5-HT1A receptor binding, indole 




5.5.1     Animal study design 
Male Wistar rats were selected as a stress-responsive strain, and have 
been extensively used in stress-related studies (Karten et al., 1999; 
Leventopoulos et al., 2009). The same non-invasive administration of 
corticosterone via drinking water (400 µg/mL for 21 days) has previously been 
shown to produce a flattening of the diurnal corticosterone rhythm and like the 
present study caused marked atrophy of the adrenal and thymus glands 
indicative of a suppressed HPA axis. Here I report a 48% reduction in the 
absolute adrenal gland weight which is comparable to the 50% reported by 
Donner et al. (2012). I also report a 51% reduction in thymus gland weight 
which is consistent with the ~54% reduction reported by Magarinos et al. (1998). 
In addition, and also consistent with previous work, the present CORT treatment 
attenuated body weight gain when compared to vehicle treated rats (Magarinos 
et al., 1998; Donner et al., 2012).  
Although a behavioural assessment of depressive or anxiety-like 
behaviour was not carried out in the present study, a noticeable change in 
behaviour, which included reduced grooming, and increased agitation in the 
CORT treated animals upon handling was observed. In addition, the calculated 
ingested CORT dose of 55.9 mg/kg/day is comparable to previously reported 
behavioural studies, where daily subcutaneous injections of 40 mg/kg to rats for 
21 days resulted in increased depression-like behaviour in the forced swim test 
with suppression of the endogenous HPA axis (Gregus et al., 2005; Johnson et 
al., 2006). Rats treated with exogenous CORT administration via addition to 
drinking water at the same dose as used here (400 µg/mL) also demonstrated 
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increased despair and anxiety-like behaviours in a dose dependent manner, as 
tested in the elevated plus maze and forced swim tests (Donner et al., 2012). 
Therefore, it can be assumed that the dose of CORT selected in the present study 
is sufficient to cause glucocorticoid related depression-like behaviour, although 
these were not formally investigated here.  
In the present study, the volume of water normalised for body weight, 
revealed that CORT treated animals consumed more water than vehicle treated 
rats towards the end of the treatment period. This is consistent with Donner et al. 
(2012) where a similar trend was observed during the last week of treatment at 
the same dose. 
 
5.5.2 5-HT1A receptor binding 
Receptor autoradiography demonstrated heterogeneous regional binding 
of [
3
H]WAY 100635 consistent with the known distribution of 5-HT1A receptors 
in rat brain (Khawaja, 1995). In the present study, exogenous CORT 
administration resulted in a significant and marked increase in [
3
H]WAY 100635 
binding in several brain regions involved in the regulation of mood and 
emotions. Specifically, 5-HT1A receptor binding was significantly increased in 
regions such as the prelimbic (PRL) and M2 (motor cortex) subregions of the 
prefrontal cortex, where postsynaptic 5-HT1A receptors are present. Also, CORT 
treatment resulted in an increase in postsynaptic receptor binding in the 
amygdala, as well as CA1 rad and CA2 pyr subregions of the dorsal 
hippocampus. However, presynaptic 5-HT1A receptor binding in the raphé was 
unaffected by the CORT treatment. Taken together, these 5-HT1A receptor 
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changes suggest that glucocorticoids are able to modulate 5-HT1A receptors, with 
differential effects on pre- and postsynaptic receptors.  
  The presynaptic raphé 5-HT1A receptors regulate serotonin release in 
serotonergic projection areas such as the prefrontal cortex and dorsal 
hippocampus and in this way, influence behavioural responses to stress by direct 
control over neurotransmitter release in cortical and limbic areas (Savitz et al., 
2009). The present findings did not show a change in 5-HT1A receptor binding in 
the raphé, suggesting that there was no change in the density of 5-HT1A receptors 
in the region. However, glucocorticoids have previously been shown to affect 
the functionality of 5-HT1A receptors in the raphé, rather than the number of 5-
HT1A receptors. A number of preclinical studies have indicated a desensitisation 
of the 5-HT1A presynaptic receptors in response to chronic glucocorticoid 
exposure (Savitz et al., 2009). Corticosterone treatment attenuated 5-HT1A 
receptor-mediated autoinhibitory responses to 5-HT in the raphé (Fairchild et al., 
2003) and electrophysiological measurements have shown a reduction in the 
inhibitory action of presynaptic 5-HT1A receptors in the dorsal raphé during 
stress (Rozeske et al., 2011). In the latter study, complementary autoradiography 
and Western blot studies confirmed a reduction in the function but not the 
expression of the 5-HT1A receptor in the raphé of the same stressed animals 
(Rozeske et al., 2011).  In addition, chronic exposure to stress did not change the 
number of 5-HT1A receptors in the DRN, but decreased their sensitivity, an 
effect which was abolished by a glucocorticoid receptor antagonist, suggesting 
specificity to the stress response (Laaris et al., 1995; 1997). 
In the present study, an increase in [
3
H]WAY 100635 binding to the post 
synaptic 5-HT1A receptors was observed. Significant increases were found in the 
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prelimbic (PRL) and motor cortex 2 (M2) subregions of the prefrontal cortex. 
These are important regions involved in the regulation of emotions and mood 
and are able to influence activity in other brain regions, coordinating the 
response to a stimulus (Miller and Cohen 2001). In this way, the prefrontal 
cortex regulates activity of raphé 5-HT neurones and hence serotonergic activity 
in projection regions, via a feedback mechanism between the forebrain and 
midbrain regions (Hajos et al., 1999, 2003; Martin –Ruiz et al., 2001). 
Moreover, this pathway has shown to be activated by addition of a 5-HT1A 
receptor agonist (8-OH-DPAT) to the prefrontal cortex and can be blocked by 
addition of the 5-HT1A receptor antagonist (WAY 100635) (Celada et al., 2001). 
Importantly, the reported increase in 5-HT1A receptor binding in this study is 
consistent with the previously reported increase in [
3
H]8-OHDPAT binding in 
the prefrontal cortex of tree shrews after 21 days of exposure to a psychosocial 
stressor, although, this was significantly reduced after 28 days (Flugge et al., 
1997) suggesting time dependent effects of corticosterone on the expression of 
prefrontal cortex 5-HT1A receptors. Taken together, it is feasible that the 
increased cortical 5-HT1A receptor binding measured in the present study after 
chronic exposure to exogenous corticosterone, could represent forebrain control 
over serotonergic neurones in the raphé and that this increase in 5-HT1A receptor 
binding in the prefrontal cortex may represent a transient response to elevated 
corticosterone levels where a possible down regulation may be seen at a later 
time point.  
 In addition, I also report an increase in [
3
H]WAY 100635 binding in the 
amygdala. This region forms part of the limbic system and is involved in 
processing emotions such as fear and anxiety. The amygdala also modulates 
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memory retrieval and consolidation processes via interactions with the 
hippocampus and prefrontal cortex (Roozendaal et al., 2009), which are known 
to be impaired by high circulating levels of glucocorticoids (Roozendaal, 2002). 
Social stress for 20 days, which is sufficient to produce a depressed state, also 
resulted in an increase in amygdala 5-HT1A receptor density albeit in mice 
(Avgustinovich et al., 2004).  
The present study showed a CORT induced increase in 5-HT1A receptor 
binding in the CA1 rad and CA2 pyr subregions. The hippocampus is the 
primary site for synaptic plasticity within the brain, which is mediated via the 
glutamate receptors (Kemp and Managhan-Vaughan 2008) and also the 5-HT1A 
receptor (Berumen et al., 2012). More specifically, the 5-HT1A receptor is 
involved in memory formation through long term potentiation (LTP) and 
associated neurogenesis via the NMDA and AMPA receptors (Berumen et al., 
2012).  Elevated levels of corticosterone have shown to induce changes at the 
AMPA and NMDA receptors which are associated with detrimental effects of 
stress on memory and learning (Tse et al., 2011). However, activation of the 5-
HT1A receptor has shown to be neuroprotective by inhibiting transport of the 
NMDA receptor to the dendritic surface, thereby inhibiting glutamate induced 
cell death (Yuen et al., 2005). Thus, the increased [
3
H]WAY 100635 binding 
reported in the present study could suggest some neuroprotective effects 
resulting from the 5-HT1A receptor upregulation although this remains 
speculative.  
Interestingly, although I measured an increase in 5-HT1A receptor binding 
in a number of postsynaptic regions, the majority of published studies report a 
decrease in 5-HT1A receptor binding after exposure to glucocorticoids (Karten et 
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al., 1999; Czyrak et al., 2002) and an increase after adrenalectomy which is 
attributed to de novo protein synthesis (Zhong and Ciaranello, 1995). It is 
possible that a reduction of adrenal hormones during the 24 hour hormone free 
period prior to sacrifice may have resulted in an upregulation of 5-HT1A 
receptors, similar to that seen after adrenalectomy. Although immediate effects 
of glucocorticoids on 5-HT1A receptor mRNA have been reported (Meijer and de 
Kloet, 1995), it is expected that changes in receptor expression would take 
longer i.e. between 16-48 hours after exposure to glucocorticoids (Mendelson 
and McEwen 1992). Whilst the possibility that 5-HT1A receptor expression in the 
present study may have been affected in this way cannot be completely 
excluded, the use of a 24 hour corticosterone free period was considered here 
based on previous findings that showed serotonergic responses were stable and 
unaffected by a 24 hour hormone period (van Gemert et al., 2006). Thus a drug 
free period was included in the present study in an attempt to negate any effects 
from an acute corticosterone exposure that would have occurred if the animals 
had been sacrificed immediately after the withdrawal of CORT (van Gemert et 
al., 2006).  
Glucocorticoids are able to regulate 5-HT1A receptor transcription, which 
occurs via both the MR and GR receptors. Low doses of glucocorticoid result in 
high MR occupancy and causes a reduction in 5-HT1A receptor number 
(Chalmers et al., 1993). At high doses both MR and GR are occupied (i.e. after 
exposure to high doses of glucocorticoids or exposure to stress) and 5-HT1A 
receptor binding was increased in the dorsal hippocampus (Chalmers et al., 
1993).  The prefrontal cortex, amygdala and dorsal hippocampus are all 
populated by MR and GR receptors, thereby transcriptional regulation of 5-HT1A 
147 
 
receptors is feasible in these regions (Han et al., 2005; Roozendaal et al., 2009). 
This would imply that the increase in receptor binding seen here may represent 
an upregulation of the receptors which may be part of the GR mediated feedback 
mechanism on the HPA axis (Chaouloff, 1993; Flugge et al., 2004).  
One final point which should also be considered is the fact that the 
majority of studies reported have quantified changes in 5-HT1A receptor binding 
using the agonist radioligand [
3
H]8-OHDPAT. This will preferentially bind to 
the high affinity form of the 5-HT1A receptor (i.e. those receptors which are G-
protein coupled) whereas in the present study an antagonist radioligand was used 
which binds to both high and low affinity receptor states (i.e. those receptors 
which are G-protein coupled and uncoupled) with equal affinity. Therefore, 
although the majority of preclinical studies on the effects glucocorticoids on 5-
HT1A receptor binding have reported a decrease in binding, the use of an agonist 
radioligand may not have detected the upregulation reported here if this is 
predominately made up of low affinity state receptors i.e. the increase in 5-HT1A 
receptor number here could represent an attempt to ‘prime’ the system by 
increasing the receptors available for easy conversion to the high affinity site 
when needed.    
 
5.5.3     5-HT and 5-HIAA content and 5-HT turnover 
In order to assess whether changes in 5-HT1A receptor binding were 
related to changes in the endogenous concentrations of 5-HT or its metabolite 5-
HIAA, dissected brain tissue was analysed for indoleamine content. Many 
studies have shown stress related changes in 5-HT, 5-HIAA or 5-HT turnover 
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throughout the brain (Rueter and Jacobs 1996; Rueter et al., 1997; Maswood et 
al., 1998; reviewed in Flugge 2004; Amat et al., 2005) albeit with stressor and 
regional dependent differences having been reported (Kirby et al., 1995; Rueter 
and Jacobs 1996). For example, increased concentration of 5-HIAA has been 
reported in frontal cortex and hippocampus after forced exercise (Clement et al., 
1993), whereas chronic unpredictable stress and restraint stress resulted in a 
decrease in 5-HIAA concentration in frontal cortex and striatum, but caused no 
change in hippocampus (Torres et al., 2002; Ahmad et al., 2010). In addition, 
exposure to stress also increased serotonin turnover in raphé, prefrontal cortex, 
amygdala and hippocampus (Maswood et al., 1998; Chaouloff et al., 1999; Amat 
et al., 2005). Interestingly, a study looking at the effects of 20 days of social 
stress reported no changes in 5-HT or 5-HIAA levels (Avgustinovich et al., 
2004). Moreover studies looking at the effects of exogenous corticosterone on 
serotonergic responses are just as contradictory. A study by Inoue et al. (1996) 
found a decrease in 5-HT concentration and no change in 5-HIAA after an acute 
dose of 50 mg/kg CORT whereas after chronic exposure at the same dose there 
was no change in 5-HT levels, but increased 5-HIAA concentration in prefrontal 
cortex. The present study also showed no change in the concentration of 5-HT, 
5-HIAA or serotonin turnover after chronic corticosterone administration. 
There are a few possible explanations for the discrepancies in the results 
obtained in this study and those reported in the literature and these should be 
considered. The number of samples per treatment group used in the present 
study is small, although not much smaller than most other studies. However, it is 
possible that a change in either direction would have been more apparent with a 
larger number of animals per treatment group. In addition, here, indole levels 
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have been quantified in tissue homogenates, and therefore both extracellular and 
intracellular neurotransmitter concentration has been measured rather than that 
which is released in response to glucocorticoids. This may provide an 
explanation for the lack effect in 5-HT concentration, however serotonin 
turnover is considered to be sensitive enough for total tissue assessment. Also, it 
should be noted that as the dissection included excision of the entire region, a 
subregional analysis of neurotransmitter levels was not possible. Therefore the 
lack of effect could be due to contamination of sample from non-affected 
subregions. There are also major experimental differences between this study 
and those previously published which may impact the results. Such differences 
include the time of day that the study and measurements were conducted, 
differences in strain of animal used, animal housing and most importantly, the 
analytical technique i.e. microdialysis where consecutive 20 min dialysate 
samples representing the extracellular compartment are analysed  (Chaouloff et 
al., 1999). Most importantly, however, it should be remembered that the brain 
tissue used here was obtained from animals sacrificed 24 hours after the 
withdrawal of CORT administered for 21 days. Thus, the measurements made 
here were to investigate the lasting effects of elevated glucocorticoid 
concentration on serotonin concentration in discrete brain regions. Typically 
glucocorticoids stimulate 5-HT neurones within 20-60 minutes and have 
reported both long lasting and rapid serotonergic effects (Luine et al., 1993; 
Inoue et al., 1996; Summers et al., 2000). Increases in serotonergic activity and 
5-HT release have been reported during the first week of exposure to chronic 
stress, which returned to basal levels by the 4th week (Summers et al., 1998, 
Avgustinovich et al., 2004). Thus, although speculative, it is possible that any 
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increase in serotonin induced by the CORT treatment may have been reversed by 
the time of measurement at 22 days post initiation of CORT treatment. 
Interestingly, Karten et al. (1999) measured small changes in 5-HT neurone 
responses after 3 weeks of high dose CORT treatment (10 mg/rat/day; sufficient 
to saturate the GR for most of the day) and postulated that a resistance to the GR 
mediated enhancement of 5-HT develops at high doses. In the present study, the 
animals were ingesting 55.9 mg/kg/day, a dose that is considerably higher 
suggesting that it is possible that resistance of GR mediated 5-HT release may 
explain the lack of changes in 5-HT seen here. 
Taken together, the present study showed that, CORT treatment for 21 
days resulted in a significant increase in [
3
H]WAY 100635 in the prefrontal 
cortex, amygdala and dorsal hippocampus without a concomitant change in 
serotonin concentration. This suggests that there are adaptive responses to 
elevated glucocorticoids, which lead to an upregulation of the 5-HT1A receptor in 
cortical and limbic regions, which will maintain serotonergic activity. Such 
adaptive responses are known to occur. For example, exposure to forced swim 
for 15 minutes resulted in an increase in 5-HT release in the striatum but a 
decrease in septal nuclei of rats (Kirby and Lucki, 1997). However, the response 
was reversed when the same animal was exposed to a subsequent 5 min forced 
swim session 24 hours later, suggesting desensitisation after the initial exposure 
to further insult. In addition, adaptive responses in 5-HT1A receptor binding have 
also been reported which include an upregulation or hypersensitivity of the 5-
HT1A receptor (Kennett et al., 1986; Flugge et al., 1997).  Failure to adapt as 
well as HPA axis hyperactivity is thought to contribute to the aetiology of 
depression. Thus, the present study indicates that responses mediated via the 5-
151 
 
HT1A receptor in response to chronically elevated glucocorticoid concentration 
may be involved in such adaptive responses (McEwen, 2001).  
With regards to in vivo clinical PET imaging studies of the 5-HT1A 
receptor in depression, there have been conflicting results published. Both 
increases and decreases in binding using the PET radioligand [
11
C]WAY 100635 
have been reported (reviewed in Savitz et al., 2009). Several PET imaging 
studies lean towards a negative association with 5-HT1A binding potential, thus 
reduced binding to the 5-HT1A receptor has been shown in raphé (up to 42%) 
and hippocampus (between 23-32%) in patients with depression (Drevets et al., 
1999, 2000 and 2007; Savitz et al., 2009). However, others have reported 
increased 5-HT1A receptor binding in depression using the same radioligand. 
Parsey et al. (2006) reported a global increase in 5-HT1A receptor binding 
potential in drug naïve depressed patients.  However, these studies have not 
considered glucocorticoid dysfunction in the subjects. There is only one report of 
PET imaging of the 5-HT1A receptor after exposure to corticosteroids 
(Montgomery et al., 2001). No changes in binding of [
11
C]WAY 100635 was 
observed in normal patients administered an acute dose of hydrocortisone, nor 
was there any change after chronic exposure to prednisolone. However, it should 
be noted that the subjects in that study were not considered to be depressed 
according to the Beck Depression Inventory nor the Hamilton Depression Rating 
Scale. Interestingly, post-mortem studies on brains of human suicide victims 
have shown an increase in 5-HT1A receptor density in the prefrontal cortex 
(Arango et al., 1995).  
The data presented in this chapter suggest that chronic exposure to 
glucocorticoids leads to an upregulation of 5-HT1A receptors and this may be 
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independent of endogenous serotonin concentration. Such receptor changes are 
amenable to PET imaging of depressed patients without the need to consider 







Chapter 6  
 
Neuropeptidergic responses to 
chronic glucocorticoid exposure  
 Oxytocin and vasopressin are both neuropeptides which regulate the 
activity of the HPA axis and are implicated in the aetiology of disorders 
associated with HPA axis dysregulation such as depression and anxiety. 
Preclinical studies have revealed abnormalities in both the oxytocinergic and 
vasopressinergic systems in response to glucocorticoid overload, effects which 
are mediated via the oxytocin and vasopressin 1a receptor (Ring et al., 2006; 
Landgraf et al., 1995).  In this chapter the influence of chronically elevated 
glucocorticoid concentration on oxytocin and vasopressin 1a receptor binding 
and on the concentration of their endogenous ligands are investigated. I discuss 
how these changes may be related to the glucocorticoid induced dysfunction 




6.1  Introduction 
The contribution of neuropeptides to the regulation of mood is now well 
established. Of particular interest are the oxytocinergic and vasopressinergic 
systems (Gimpl and Farenholz, 2001; Scott and Dinan, 2002). Both these 
peptides regulate the HPA axis, an underlying dysfunction of which has been 
reported in up to 50% of depressed patients (Anacker et al., 2011). Under normal 
conditions, oxytocin dampens HPA axis activity, having an anxiolytic effect 
(Heinrichs and Dome, 2008). In contrast, vasopressin acts synergistically with 
CRH to activate the HPA axis, resulting in an increase in glucocorticoid 
secretion and is therefore anxiogenic (Aguilera et al., 2007). It is thought that in 
depression, abnormalities in either or both the oxytocinergic and 
vasopressinergic regulation of the HPA axis occur, resulting in glucocorticoid 
dysfunction (Purba et al., 1996; van Londen et al., 1997; Scantamburlo et al., 
2007). However, the exact role of the oxytocin and vasopressin receptors in the 
disease process is still to be elucidated. Currently there is limited information on 
the regulation of these receptors by glucocorticoids.  
Often, in clinical studies, circulating peripheral neuropeptide 
concentration is measured as an indication of central oxytocinergic and 
vasopressinergic activity. However, the relationship between circulating levels 
of peptide and its release in the brain has been a matter of long-standing debate 
(Ebstein et al., 2012). It has been shown that both central and posterior pituitary 
projections originate from magnocellular hypothalamic neurones in prairie voles 
and rats (Young et al., 2009), which supports the idea of coupling between 
central and posterior pituitary release of oxytocin and vasopressin. Thus, there is 
an emerging tendency to accept the view that peripheral neuropeptide 
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concentrations are indicative of brain peptidergic activity (Shavlev et al., 2011; 
Ebstein et al., 2012) and could serve as a biomarker of depression. Therefore in 
this study, the plasma concentration of oxytocin and vasopressin was also 
measured after chronic exposure to corticosterone.  
As already mentioned in chapter 5, administration of exogenous 
glucocorticoids results in neurobiological changes that are characteristic of the 
changes seen in depression i.e. atrophy of the hippocampus has been observed in 
rats receiving corticosterone in drinking water (Magarinos et al., 1998) and 
reduced hippocampal volume has also been reported in clinical depression 
(Amico et al., 2011). An enhanced understanding of the nature of the 
relationship between elevated glucocorticoid concentration and oxytocin and 
vasopressin 1a receptor binding is important. It is plausible to expect that such a 
relationship, if one exists, could potentially be visualised by in vivo molecular 
imaging in depression with the objective to stratify and improve the clinical 
management of depressed patients. 
Autoradiography has previously been used to determine changes in the 
binding of the oxytocin receptor (Insel and Shapiro 1992; Liberzon et al., 1997) 
and vasopressin 1a receptor (Landgraf et al., 1995) in response to 





I-Tyr-NH2(9)]vasotocin), which is a selective 
oxytocin receptor antagonist with low cross reactivity to the vasopressin 
receptors has been used successfully to investigate binding to the oxytocin 
receptor. It has an affinity of 0.1 nM for the oxytocin receptor (Liberzon and 
Young, 1997). A high density of binding was observed in the neocortex, limbic 





I]AVP ([phenylacetyl 1,0-ME-D-tyr 2 ARG 6,8,TYR 9] 
125
I), 
which is a selective antagonist at the vasopressin 1a receptor with an affinity of 
1.6 nM has previously been reported to label the receptors (Thibonnier et al., 
2000). [
125
I]AVP demonstrates a high level of binding in the lateral septum, 
BNST, nucleus accumbens, central nucleus of amygdala, hippocampus, 
thalamus, and superior colliculus of rat brain (Phillips et al., 1988).  
In this chapter, I describe the experimental studies undertaken to 
determine changes in oxytocin receptor and V1aR binding after exposure to 
exogenous glucocorticoids. In addition, the regional brain content of each 
neuropeptide was measured using RIA. Peripheral (plasma) oxytocin and 
vasopressin concentrations were also measured to compare them with those of 
brain tissue neuropeptides. This is of interest given the opposing roles of 
oxytocin and vasopressin on regulation of the HPA axis; the latter being 
anxiogenic and the former anxiolytic. Oxytocin governs emotional behaviours 
that lead to positive social interactions (Heinrichs et al., 2003; Kosfeld et al., 
2005; Debiec 2007) and is released in the hippocampus, amygdala,  septum and 
hypothalamus i.e. regions that are rich in glucocorticoid receptors and involved 
in the regulation of mood  (Engelmann et al., 1996; Liberzon and Young 1997 
Huber et al., 2005). The effect of chronically elevated glucocorticoids on 
vasopressin 1a receptor binding in extralimbic brain regions has not previously 
been studied, although interactions between the vasopressinergic and 
serotonergic system are established. It has been shown that the 5-HT1A receptor 
antagonist WAY100635 inhibits 5-HT induced release of oxytocin and 
vasopressin (Jørgensen et al., 2003). Whereas, selective serotonin inhibitors 
(SSRIs) are known to induce the release of oxytocin (Uvnas Moberg et al., 
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1999). The V1a receptor is of relevance to aggression-related behaviour (McCall 
and Singer, 2012). Aggression is thought to be regulated via interactions 
between the serotonin and vasopressin systems, whereby serotonergic synapses 
have been observed on vasopressinergic neurones at the level of the 
hypothalamus, with serotonergic innervation to the hypothalamus originating 
from the raphé (Ferris and Delville, 1999). Thus, it is of interest to determine the 
vasopressinergic response to glucocorticoids in relation to those of the 
serotonergic and oxytocinergic systems. 
There are several aspects of novelty to this study, to my knowledge this 
is the first report in which changes at both oxytocin receptor and vasopressin 1a 
receptor have been measured in both limbic and extralimbic regions of the same 
tissue in response to chronic exposure to exogenous glucocorticoids. In addition, 
this is the first time that changes in oxytocin and vasopressin 1a receptor binding 
have been related to concentrations of their endogenous ligands. 
 
6.1.1 Oxytocin and the stress response 
Oxytocin is synthesised in the hypothalamic paraventricular (PVN) and 
supraoptic nuclei (SON) and released to blood in the posterior pituitary. 
Oxytocin is also released somatodendritically within the hypothalamic nuclei; 
from where it can diffuse to other brain regions (Leng and Ludwig, 2008). Thus 
oxytocin is present in the hippocampus, amygdala, septum and hypothalamus. 
These brain regions also express oxytocin receptors (Leng and Ludwig, 2008) 
and glucocorticoid receptors; (Engelmann et al., 1996; Liberzon and Young 
1997; Huber et al., 2005). Therefore a role for interactions between 
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glucocorticoids and oxytocin in the regulation of the responses to stress is 
postulated. 
 Chronic administration of oxytocin to rats transiently activates the HPA 
axis and results in an increase of corticosterone release, followed by suppression 
of the HPA axis (Petersson et al., 1999). More specifically, evidence shows that 
oxytocin is anxiolytic via inhibition of the HPA axis, which leads to the lowering 
of glucocorticoid concentration (Neumann et al., 2000; Heinrichs and Dome, 
2008). Intracerebral administration of the neuropeptide has been shown to also 
counteract anxiety–like behaviours measured as reduced immobility during the 
forced swim test and reduced vocalisation of distress in rodent models (Arletti 
and Bertolini, 1987; Insel and Winslow, 1991; Windle et al., 1997).  
The central effects of oxytocin are mediated through the oxytocin 
receptor and this is responsible for the anxiolytic effects of the peptide. 
Pharmacological doses (10µg i.c.v. or 30mg/kg i.p.) of oxytocin induce 
anxiolytic effects in preclinical models of anxiety (elevated maze test). These 
effects can be blocked by the addition of an oxytocin receptor antagonist 
suggesting the anxiolytic effects of oxytocin are mediated by direct action at the 
oxytocin receptor (Ring et al., 2006; Yoshida et al., 2009). Furthermore, 
administration of an oxytocin receptor antagonist increased stress-induced 
corticosterone release in rats suggesting that the oxytocin receptor is directly 
involved in mediating the responses to stress (Neumann et al., 2000). In addition, 
oxytocin receptor knockout mice show deficits in social behaviour and an 
increase in aggression-like behaviour suggesting that disruptions at the oxytocin 
receptor could potentially result in altered social behaviours, as seen in mood 
disorders (Takayanagi et al., 2005). Moreover, behaviours which are associated 
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with reduced anxiety, such as lactation, cause a release of oxytocin in the brain 
which is positively correlated with oxytocin receptor binding in the lateral 
septum of rats (Curly et al., 2012). Whereas, anxiety behaviours, measured as 
activity in the open field test of normal animals are negatively correlated with 
oxytocin receptor binding. Thus, it has been suggested that the oxytocin receptor 
is involved in mediating the anxiolytic effects of oxytocin (Curly et al., 2012). 
In humans, intranasal administered oxytocin initiates prosocial 
behaviours such as approach, social interaction, trust and risk-taking, all of 
which are associated with reduced cortisol production (Heinrich et al., 2003; 
Kosfeld et al., 2005). In addition, depressed patients tend to have reduced plasma 
oxytocin concentrations when compared to age-matched controls (Frasche et al., 
1995 and Scantamburlo et al., 2007),  although elevated oxytocin activity has 
also been reported in depression (Parker et al., 2010; Holt-Lunstad et al., 2011). 
These discrepancies may reflect the complexity of depression as a multi-factorial 
condition and an uncertain link between peripheral and central oxytocin. 
Analysis of post mortem brains from depressed patients has shown a 23% 
increase in the number of oxytocinergic immunoreactive neurones in the PVN. 
However, a more detailed attempt in the same study to use this to distinguish 
major depression from bipolar depression in this group failed to find any 
differences between these subtypes of depression (Purba et al., 1996). 
 
6.1.2 Vasopressin and the stress response 
Vasopressin is also released from the SON in a similar way to oxytocin 
into both the general circulation and centrally. Parvocellular neurones of the 
PVN, amygdala and BNST also release AVP (DeVries et al., 1985).  In contrast 
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to oxytocin, vasopressin is anxiogenic and aggression promoting via activation 
of the HPA axis, particularly during chronic stress (Aguilera et al., 2007). 
Chronic stress increases the expression of vasopressin in the PVN and its 
secretion into the pituitary portal circulation, stimulating the HPA axis (Van de 
Kar and Blair, 1999). This effect was consistent and irrespective of the type of 
stressor. For example forced swimming in rodents produces an increase in AVP 
in the PVN and SON (Wotjak et al., 1998) and also in the septal nuclei and 
amygdala, but this was prevented when the V1aR antagonist 
d(Ch2)5Tyr(Me)AVP was administered in the lateral and medial septal nuclei  
(Ebner et al., 1999; 2002). Also, training in the Morris water maze for three days 
also caused a release of AVP in these regions (Engelmann et al., 2006). In 
addition, anxiety-like behaviour as measured by the resident-intruder test is 
associated with AVP release into the septal nuclei (Veenema and Neumann, 
2008).  
The vasopressin V1a receptor is implicated in mediating the anxiogenic 
effects of AVP as shown by the studies of Ebner et al. (1999; 2002) mentioned 
above. V1aR overexpression is associated with increased anxiety as measured by 
the time spent in the open arm of the elevated plus maze test and is reversed by a 
V1aR antagonist (Landgraf et al., 1995).  
In humans, AVP is associated with depression where patients show 
significantly elevated plasma AVP concentration (van Londen et al., 1997). 
Those depressed patients who progressed to attempt or commit suicide showed 
even higher concentration of plasma AVP and vasopressin immunoreactivity in 
the PVN, suggesting that vasopressin may be linked with severity of the disorder 
(Inder et al., 1997; Merali et al., 2006). Furthermore, vasopressin is involved in 
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the onset and maintenance of a high anxiety state and its concentration in plasma 
has been shown to correlate both with anxiety and anxiety-related retardation in 
depression, activation of the HPA axis and in a rise in salivary cortisol, which is 
further increased during a social evaluative threat (Shalev et al., 2011).  In 
addition, a post mortem study showed increased activation of oxytocin and 
vasopressin neurones in the paraventricular nucleus of depressed subjects, as 
measured by an increase in vasopressin immunoreactivity (Purba et al., 1996).  
 
7.2 Aims and Hypotheses 
7.2.1 Aims 
This thesis investigates if long-term exposure to exogenous 
glucocorticoids (corticosterone) affects oxytocin and V1a vasopressin receptor 
binding in rat brain post-mortem and whether the changes are associated with 
regional oxytocin and vasopressin content. This is the first study to investigate 
the role of both of these peptide receptors in responses to glucocorticoids. It can 
be of translational value in the development of future pharmacological tools to 
manipulate the receptor activity and/or visualise it in vivo. 
 As outlined above, oxytocin is a contributor to the stress response as this 
is released into the bloodstream in response to a stressful stimulus (Neumann et 
al., 2000). Furthermore, the oxytocin and 5-HT system are interconnected 
through oxytocin fibres which project into the raphé, where serotonin and 
oxytocin may influence each other. Therefore, it is conceivable that increased 
corticosterone levels may also impact on oxytocin.  
In order to ensure homeostatic control, a negative feedback mechanism 
(HPA re-activity) is initiated. It has been found that oxytocin released at the 
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same time as CRH will potentiate HPA re-activity and enforce the negative 
feedback mechanism. However, a study by Neumann et al., 2000 found that in 
the presence of an oxytocin receptor antagonist, the negative feedback 
mechanism prevails. It is suggested that oxytocin may activate CRH neurones 
directly producing an even greater increase in CRH which would induce HPA 
re-activity, thus in this way oxytocin serves to protect the damage associated 
with excess corticosterone production. In the present study, brain regional 
oxytocin receptor binding as well as oxytocin content is quantitatively analysed 
in order to establish the role of the central oxytocin system in response to 
glucocorticoids.  
On the other hand and as mentioned above, vasopressin activates the HPA 
axis; in particular vasopressin is released during stress and is the main activator 
of the HPA axis (Scott and Dinan, 1998). The effect of glucocorticoids on 
vasopressin 1a receptor binding in extralimbic brain regions has not previously 
been studied, nor have changes in receptor binding after glucocorticoid exposure 
been associated with vasopressin concentration, therefore this study aims to 
establish this relationship.  
 
7.2.2 Hypothesis 
It is hypothesised that chronic exposure to glucocorticoids will result in 
changes to the oxytocin and vasopressin 1a receptors in brain regions that are 
involved in the regulation of responses to stress. The direction of changes in 
receptor binding will reflect changes in the concentration of their endogenous 
neurotransmitter. In addition, it is hypothesised that plasma concentrations of 
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oxytocin and vasopressin will reflect central concentrations of each 
neuropeptide.  
 
6.3 Materials and Methods 
All materials used for this study are given in chapter 4. Also, in chapter 4, are 
methodological details on in vivo husbandry, dosing on animals, collection of 
post mortem samples and tissue sectioning, autoradiography and RIA 
methodology.  
It should be noted that the autoradiography study was carried out in 
animals that were given a 24 hour hormone free period before sacrifice (under 
light anaesthesia), whereas oxytocin and vasopressin content was determined in 
animals that were sacrificed without this hormone free period and without the 
use of anaesthetic. In addition, plasma corticosterone was also determined from 
this subset and is shown alongside the plasma corticosterone content of animals 
with the 24 hour drug free period (as two timepoints 0hrs and 24hrs).  
 
6.4 Results 
The autoradiography part of this study used tissue generated in the study 
presented in chapter 5. Changes in body weight, water consumption, adrenal and 
thymus gland weights as well as the calculated CORT dose received by these 
animals is therefore as presented in chapter 5. For the additional in vivo dosing 
experiments conducted in this study i.e. those for neuropeptide RIA experiments 
a two-way analysis of variance was used to test for differences in weight gain, 
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water consumption and also adrenal and thymus gland weights. No significant 
differences were observed in any parameter measured. Therefore, in this chapter, 
the two batches of animals have been considered as a single group with two 
timepoints; 0hr (n=8 for vehicle group and n=10 for CORT group) and 24hr 
(n=8 per treatment group), representing animals sacrificed immediately after 
withdrawal of CORT and those sacrificed after a 24 hour hormone free period 
respectively. The statistical comparison can be found in appendix B. 
 
6.4.1 Plasma corticosterone concentration 
Concentration of plasma corticosterone in vehicle and CORT treated 
groups was measured using RIA at both 0hr and 24hr timepoints. Data are 
shown in figure 6.1. A two way analysis of variance was used to test for effects 
of treatment on the plasma concentration of corticosterone and also any effects 
associated with timepoint of sample. Significant differences were found for 
treatment (F(1,41) = 8.78, P = 0.0051) and  timepoint (F(1,41) = 28.22, P = 
<0.0001). The interaction was also significant (F(1,41) = 28.04, P = <0.0001). 
Further analysis between treatment groups at individual time points (vehicle vs 
CORT at 0hr and 24hr) was carried out using the two-tailed Student’s t-test 
(unpaired) with Bonferroni correction at a significance level of P = 0.05. This 
revealed that there was a significant 282.4% increase in plasma corticosterone 
concentration of the CORT treated group when compared to the vehicle treated 
group at t=0hrs (from 109.6 ± 100.1 ng/mL to 419.1 ± 249.6 ng/mL). Whereas in 
the 24hr group, plasma corticosterone concentration was significantly reduced 
by 80.2% in the CORT treated group (from 109.0 ± 43.9 ng/mL to 21.5 ± 15.0 
ng/mL) indicative of HPA axis suppression. In addition, two-tailed Student’s t-
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test (unpaired) with Bonferroni correction was used to test for differences within 
each treatment group at individual time points (vehicle treated at 0hr and 24hr; 
and CORT treated at 0hr and 24hr) with a significance level set at P = 0.05. This 
showed that there was no significant difference in plasma corticosterone at 0hr 
and 24hr in the vehicle treated animals (109.6 ± 100.05 ng/mL and 109.0 ± 
43.93 ng/mL respectively). However, there was a significant 94.8% decrease in 
plasma corticosterone concentration in the CORT treated group at 24hrs when 
compared to 0hrs (from 419.1 ± 249.6 ng/mL at 0hrs to 21.54 ± 14.99 ng/mL at 
24hrs) (Figure 6.1).     
 
6.4.2  Autoradiography   
6.4.2.1  Oxytocin receptor binding 
Changes in binding to the oxytocin receptor were quantified after chronic 
exposure to CORT. The quantitative data showing [
125
I]OVTA specific binding 
to oxytocin receptors are shown in table 6.1. A two way analysis of variance was 
used to test for effects of treatment and also for region. Significant differences 
were found for both treatment (F(1,114) = 20.74, P = <0.0001) and region. 
(F(8,114) = 71.35, P = <0.0001). The interaction was also significant (F(8,114) = 
6.07, P = <0.0001). Further analysis between treatment groups (veh vs CORT) in 
each region using two-tailed Student’s t-test (unpaired) with Bonferroni 
correction with a significance level of P = 0.05  revealed significant differences 






Figure 6.1. Plasma corticosterone level determined by RIA. Animals were treated with 
either 400 µg/mL CORT or vehicle for 21 days. Data are expressed as mean ± SEM. 
Statistical analysis was carried out using two-way ANOVA for effect of treatment and 
timepoint. Note: A total of 5 data points were removed from the final analysis due to 
technical errors during the pipetting of samples which meant that results obtained were 
inaccurate and outside the range of calibration standards 
 
 
These are shown in figure 6.2. Specifically, there was a significant 60.0% 
decrease in [
125
I]OVTA binding in the hypothalamus. However, binding was 
significantly increased in the LSD subregion of the septal nuclei by 87.5% and 
also in the raphé by 100%. In addition, there was a tendency towards an increase 
in [
125
I]OVTA binding in the CeA and subiculum (P<0.1). There was no change 
in oxytocin receptor binding in the whole dorsal hippocampus or insular cortex. 
It should be noted that data from the ventral hippocampus is from a total of 5 
vehicle treated animals and 4 CORT treated animals rather than 8 as for the other 
regions. The variation in the sample size is due to a tearing of the tissue in the 
subiculum region, which meant that accurate sampling was not possible. 
Unfortunately, it was not possible to obtain sufficient data from the PVN 
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subregion of the hypothalamus and prefrontal cortex subregions due to the high 
non specific binding of the radioligand. Figure 6.3 shows representative 
autoradiograms of brain sections from vehicle and CORT treated rats labelled 
with [
125
I]OVTA. Alongside, are images from brain sections showing non-





Figure 6.2. Effects of chronic corticosterone on [
125
I]OVTA binding in rat brain. 
Animals were treated with corticosterone in the same way as that outlined in figure 6.1. 
Data from regions showing a differences or tendency towards change after 
corticosterone treatment are shown and expressed as mean ± SEM (n=8 per treatment 
group, except ventral hippocampus where n=6 for vehicle group and n=5 for CORT 
treated group). Abbreviations are the same as in figure 4.4, chapter 4. Statistical analysis 
was carried out using 2-way ANOVA for treatment effects and regional effects followed 
by a Bonferroni post hoc test for multiple comparisons, with a significance level of 







 Table 6.1. Regional [
125
I]OVTA binding to oxytocin receptors in rat brain after 
chronic exposure to corticosterone. 
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0.0002 
Not detected due to high non specific binding of 
radioligand 
Prefrontal cortex 
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Dorsal hippocampus 0.03 ± 0.01 
 





0.03 ± 0.02 
 





Raphé 0.04 ± 0.01 
 
0.08 ± 0.02 * +100 <0.0001 
Insular Cortex 
 
0.03 ± 0.01  0.03 ± 0.01 0.0 0.9729 
 
Table 6.1 Animals were treated in the same way as described in figure 6.1. Data are 
expressed as mean ± SD (n=8 per treatment group, except ventral hippocampus where 
n=5 for vehicle group and n=4 for CORT treated group). Abbreviations used for regions 
are the same as in figure 4.4, chapter 4. Statistical analysis was carried out using 2-way 
ANOVA for treatment effects and regional effects followed by a Bonferroni post hoc 
test for multiple comparisons, with a significance level of 0.05. A statistically 

















Figure 6.3 Representative [
125
I]OVTA autoradiography images from rat brain. Measured 
after chronic exposure to corticosterone as described in figure 6.1. Images are from 
individual rats representing A = prefrontal cortex, B = septal nuclei (LSD, MSD), 
insular cortex, C = dorsal hippocampus, amygdala, hypothalamus, D = ventral 













6.4.2.2  Vasopressin receptor binding 
Changes in binding to the vasopressin 1a receptor were quantified after 
chronic exposure to CORT. The data representing [
125
I]AVP specific binding to 
vasopressin 1a receptors are shown in table 6.2. A two way analysis of variance 
was used to test for effects of treatment and also for region. Significant 
differences were found for both treatment (F(1,168) = 14.05, P = 0.0002) and 
region (F(11,168) = 14.46, P = <0.0001). The interaction was also significant 
(F(11,168) = 3.19, P = 0.0006). Further analysis between treatment groups in 
each region using two-tailed Student’s t-test (unpaired) with a Bonferroni post 
hoc test at a significance level of P = 0.05  revealed significant differences in 
some regions. These are shown in figure 6.4. There was a significant 42.1% 
decrease in [
125
I]AVP binding in the VMDH. Binding was increased in all other 
brain regions sampled, reaching significance in the LSD subregion of the septal 
nuclei and PODG subregion of the dorsal hippocampus where [
125
I]AVP binding 
was increased by 30.0% and 78.6% respectively. In addition, a significant 
increase in binding to the vasopressin 1a receptor was measured in the raphé, but 
significance was lost after correction for multiple comparisons with the 
Bonferroni post hoc test. Unfortunately, it was not possible to obtain sufficient 
data from the PVN subregion of the hypothalamus, prefrontal cortex subregions 
and subiculum due to the high non specific binding of the radioligand. Figure 6.5 
shows representative autoradiograms of brain sections from vehicle and CORT 
treated rats labelled with [
125
I]AVP. Alongside, are images from brain sections 
showing non-specific binding i.e. those which were incubated in the presence of 






Figure 6.4. Effects of chronic corticosterone on [
125
I]AVP binding in rat brain. Animals 
were treated with corticosterone in the same way as that outlined in figure 6.1. Data 
from regions showing a differences after corticosterone treatment are shown and 
expressed as mean ± SEM (n=8 per treatment group). Abbreviations for regions are the 
same as in figure 4.4, chapter 4. Statistical analysis was carried out using 2-way 
ANOVA for treatment effects and regional effects followed by a Bonferroni post hoc 
test for multiple comparisons, applied with a significance level of 0.05. A statistically 












Table 6.2. Regional [
125
I]AVP binding to vasopressin 1a receptors in rat brain 
after chronic exposure to corticosterone. 
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0.21 ± 0.09 
 
0.22 ± 0.07* 







Not detected due to high non specific binding of 
radioligand 
Prefrontal cortex 
     PrL 
     CgL 
     M2 
     M1 
 
 
Not detected due to high non specific binding of 
radioligand 
Septal Nuclei 
     LSD 
 
0.33 ± 0.06 
 






    CeA 
 
0.21 ± 0.09 
 






    PODG 
    MODG 
 
0.14 ± 0.05 
 0.16 ± 0.06 
 
0.25 ± 0.06* 
0.19 ± 0.04 
 






   GRDG 
   Subiculum 
 
0.25 ± 0.10 
 





Not detected due to high non specific binding of 
radioligand 
Raphé 0.25 ± 0.06 0.34 ± 0.06 +36.0 0.0140 
Nucleus Accumbens 
   Shell 
 
0.39 ± 0.09 
 






    PO 
    LDDM 
   VM 
 
0.19 ± 0.07 
0.29 ± 0.10 
0.21 ± 0.07 
 
0.25 ± 0.09 
0.31 ± 0.11 
0.22 ± 0.04 
 








Table 6.2 Animals were treated in the same way as described in figure 6.1. Data are 
expressed as mean ± SD (n=8 per treatment group). Abbreviations used for regions are 
the same as in figure 4.4, chapter 4. Statistical analysis was carried out using 2-way 
ANOVA for treatment and regional effects followed by a Bonferroni post hoc test for 
multiple comparisons, at a significance level of 0.05. A statistically significant effect 







Figure 6.5 Representative [
125
I]AVP autoradiography images from rat brain. Measured 
after chronic exposure to corticosterone as described in figure 6.1.Images are from 
individual rats representing A = dorsal hippocampus, (PODG, MODG), thalamus (PO, 
LDDM, VM), amygdala, hypothalamus (VMDH, PEFLH) B = ventral hippocampus 
(subiculum), C = raphé. Further details of ROI location and sampling can be found in 
chapter 4. 
 
6.4.3 Neuropeptide concentration 
The concentrations of oxytocin and vasopressin were measured in 
discrete brain regions and plasma (0hr) after chronic exposure to CORT. Data 
describing oxytocin concentration is shown in table 6.3 and vasopressin 
concentration in table 6.4. A two way analysis of variance was used to test for 
effects of CORT treatment on the concentration of each neuropeptide and also 
for any regional effects. Separate analyses were conducted for oxytocin and 
vasopressin.  











With regards to oxytocin concentration, significant differences were 
found for both treatment (F(1,94) = 16.99, P = <0.0001) and region (F(7,94) = 
52.94, P = <0.0001). The interaction was also significant (F(7,94) = 16.43. P = 
<0.0001).  Further analysis between treatment groups in each region was carried 
out using two-tailed Student’s t-test (unpaired) with Bonferroni correction at a 
significance level set of P = 0.05 which revealed that there was a significant 
230.8% increase in oxytocin concentration in the hypothalamus. This was the 
only brain region where oxytocin concentration was significantly affected by 
CORT treatment. In addition, although a 40.5% decrease in plasma oxytocin 
concentration was seen, but this did not reach significance. 
Analysis of brain vasopressin content did not reveal any significant effect 
of CORT treatment on vasopressin concentration in any region sampled. For this 
reason, further analysis between treatment groups for each region was not 
carried out. In the plasma, vasopressin concentration was only increased by 9.3% 
(again not significant). 
An accurate analysis of vasopressin in hypothalamus and oxytocin in 
pituitary gland could not be determined as the levels were above the calibration 
range of the assay (1280 pg/mL). An attempt was made to further dilute the 
extracts (1:100) and re-run the test, however these remained above the range of 
the calibration curve. Unfortunately, there was a large variation in the number of 
data points in each group ranging between 5-10, out of a possible n=8 in the 
vehicle treated group and n=10 in the CORT treated group. These were data 
points that fell outside of the calibration curve due to experimental errors and 
were removed from the analysis. In addition, outliers were removed from the 
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data, defined as those with a value greater than 2 standard deviations from the 
mean. The n numbers for each are given alongside the data in tables 6.3 and 6.4 
 
Table 6.3 Oxytocin content in discrete brain regions and plasma 











Above 1280 pg/mL 
 
Above 1280 pg/mL - - 
Hypothalamu
s 
57.83 ± 42.37 
(n=6) 





0.63 ± 0.40 
(n=7) 
0.73 ± 0.70 
(n=7) 
+15.9 0.760 
Septal nuclei 8.68 ± 4.57 
(n=7) 




Amygdala 3.44 ± 3.29 
(n=6) 





0.22 ± 0.18 
(n=5) 





0.58 ± 0.30 
(n=6) 
0.34 ± 0.25 
(n=9) 
-41.4 0.126 
Raphé 8.18 ± 5.21 
(n=6) 






16.83 ± 12.42 
(n=7) 




Table 6.3. Effects of chronic corticosterone on oxytocin concentration in discrete rat 
brain regions and plasma. Animals were treated with corticosterone in the same way as 
that outlined in figure 6.1. Data are shown as mean ± SD (n=5-9 per treatment group). 
Statistical analysis was carried out using 2-way ANOVA for treatment effects and 
regional effects followed by a Bonferroni post hoc test for multiple comparisons, with a 

























53.35 ± 23.57 
(n=8) 




Hypothalamus Above 1280 pg/mL 
 
Above 1280 pg/mL - - 
Prefrontal 
cortex 
1.34 ± 0.75 
(n=7) 




Septal nuclei 9.43 ± 5.48 
(n=6) 
11.95 ± 4.66 
(n=7) 
+26.7 0.390 
Amygdala 5.09 ± 2.70 
(n=6) 





2.06 ± 1.90 
(n=6) 





3.67 ± 3.18 
(n=8) 
2.17 ± 1.03 
(n=10) 
-40.9 0.175 
Raphé 68.27 ± 53.64 
(n=7) 





172.51 ± 33.56  
(n=7) 




Table 6.4 Effects of chronic corticosterone on oxytocin concentration in discrete rat 
brain regions. Animals were treated with corticosterone in the same was as that outlined 
in figure 6.1. Data are shown as mean ± SD (n=6-10 per treatment group). Statistical 
analysis was carried out using 2-way ANOVA for treatment effects and regional effects. 
No statistical differences associated with corticosterone treatment were observed and 
therefore further statistical analysis by Student’s t-test with Bonferroni correction was 




In an attempt to assess the relationship between the concentration of 
plasma neuropeptide and of those measured in regional brain tissue, a correlation 
analysis was carried out between plasma and brain neuropeptide concentration 
measured. There was no significant correlation between plasma and tissue 
oxytocin/vasopressin levels in either treatment group. Neither was there any 
correlation between plasma corticosterone and plasma or tissue neuropeptide 






The present study demonstrates that chronic exposure to glucocorticoids 
resulted in changes within the central oxytocinergic and vasopressinergic 
systems. This is the first study to describe the direct influence of glucocorticoids 
on both oxytocin and vasopressin activity in the same material and also to this 
extent throughout the rat brain. Chronic treatment with corticosterone resulted in 
changes in oxytocin and vasopressin 1a receptor binding in the brain regions that 
are involved in the regulation responses to stress.  In addition, there was a 
significant increase in the oxytocin content of the hypothalamus after CORT 
treatment. No significant changes were observed in the vasopressin content of 
any brain region sampled. Likewise, there were no significant changes in plasma 
concentrations of either peptide in response to chronic CORT exposure.  
 
6.5.1 Plasma corticosterone concentration 
Plasma concentrations of corticosterone were significantly increased in 
CORT treated animals that were sacrificed at t=0 hr. This is in line with the 
previous reports where plasma CORT levels were measured immediately after 
exogenous CORT administration (Karten et al., 1999; Bush et al., 2003) or after 
exposure to stress (McKitterick et al., 1995). However, the CORT treated 
animals that were sacrificed at t=24 hr had a plasma corticosterone concentration 
which was significantly lower than the t=0 hr group. This may be attributed to 
suppression of the HPA axis (van Gemert et al., 2006) and is also consistent with 
the reduction in adrenal gland weight measured in the same animals (discussed 
in chapter 5).  
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It should be noted that whilst plasma corticosterone concentration in the 
CORT treated animals is in agreement with the available literature, the vehicle 
treated animals in the present study showed higher plasma CORT concentration 
than expected at both time points. This would imply that there may have been an 
acute release of corticosterone at around the time of sacrifice in vehicle treated 
rats although every attempt was made to reduce distress to animals. For example, 
the animals were sacrificed in a separate room to the one in which the remaining 
animals were housed and the duration between transport and sacrifice was 
minimised. However, a survey of the literature reveals that the mean value 
reported in this study (~100 ng/mL for the vehicle treated group) does not 
represent stress levels of corticosterone, which are reported to be 300-400 ng/mL 
in young adult male rats (Lister Hooded; body weight, 200-250g). In fact, the 
normal variation across the diurnal rhythm is between 37-65 ng/mL at the trough 
and 118-141 ng/mL at the peak in the same animals (Pinnock and Herbert, 
2001). Although the vehicle treated rats showed a higher plasma corticosterone 
concentration than expected at the time of sacrifice (diurnal trough), it is still 
considerably lower than after exposure to stress, and in line with what is seen at 
the diurnal peak rather than after stress. In addition, it is important to consider 
that corticosterone is present in plasma bound to corticosterone binding globulin 
(CBG) and only about 10% is ‘free’ and bioavailable (Qian et al., 2011). After 
an acute stress, where plasma corticosterone concentration is increased, there is a 
20-30 minute delay in the rise of free corticosterone in the brain (hippocampus 
and hypothalamus). This delay has been postulated to be a protective response 
and is related to an increase in the release of CBG from the liver rather than a 
delay due to transport across the BBB (Qian et al., 2011). Considering this in the 
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context of the data presented here, it is not expected that the short time between 
transport of animals and sacrifice (~3-4 minutes) would result in a sufficient 
increase in brain free corticosterone concentration to have impacted on the 
variables measured here. However, the possibility that this may have occurred 
cannot be completely excluded.  
 
6.5.2 Oxytocin receptor binding  
The regions selected for analysis of oxytocin receptor binding were 
selected as a mixture of limbic and extralimbic brain regions and also regions 
with overlapping vasopressin 1a and 5-HT1A receptor distribution. Receptor 
autoradiography studies presented here revealed a high binding of [
125
I]OVTA in 
regions consistent with the known receptor distribution of oxytocin receptors in 
the rat brain i.e. amygdala and septal nuclei, with lower levels of binding 
observed in cortical areas (Tribollet et al., 1988). In the present study, exogenous 
CORT administration resulted in a significant and marked increase in 
[
125
I]OVTA binding in the septal nuclei and raphé, with a concomitant decrease 
in the hypothalamus. In addition, there was a trend towards an increase in 
binding in the amygdala after CORT treatment. Taken together these changes 
suggest that chronic exposure to corticosterone influences oxytocin receptor 
binding in a region-dependent manner.  
The lateral septal nuclei are involved in regulating sexual behaviour, 
social recognition, learning and memory processes (Bielsky et al., 2005; 
Veenema et al., 2010; Curly et al., 2012). The septal nuclei primarily receives 
projections from the entorhinal cortex and hippocampus, therefore irregularities exist in 
mood disorders (Nolte, The Human Brain, 5th edn). The increase in oxytocin 
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receptor binding here is similar to that previously observed after dexamethasone 
treatment, where it was suggested that glucocorticoid modulation of oxytocin 
receptors may mediate the sexual dysfunction seen in depression (Patchev et al., 
1993). In addition, the oxytocin receptor in the septal nuclei is implicated in 
regulating social and affective behaviours which are improved after oxytocin 
administration in rodents (Curly et al., 2012) and humans (Kosfeld et al., 2005).  
As oxytocin is released in the septal nuclei in response to 
glucocorticoids, and has an inhibitory effect on the HPA axis thus terminating 
the stress response via attenuation of ACTH. This effect can be abolished by an 
oxytocin antagonist (Neumann et al., 2000; Neumann et al., 2002), and so our 
results indicate that upregulation of the oxytocin receptors is a compensatory 
event to initiate HPA re-activity.    
In addition, here I report a significant increase in [
125
I]OVTA binding in 
the raphé after chronic CORT treatment. The presence of oxytocin receptors in 
this region implicates links with serotonergic regulation and therefore disorders 
which involve the serotonin system i.e. mood disorders. Approximately 50% of 
the serotonergic neurons co-express oxytocin receptors and it is thought that they 
influence the release of 5-HT (Yoshida et al., 2009). It has been suggested that 
the release of oxytocin in the raphé could be part of a compensatory response to 
increase serotonin release in depression (Scantamburlo et al., 2007). Moreover, 
antidepressant treatments such as SSRIs have shown to cause a release of 
oxytocin in the brain, which may contribute to their efficacy (Uvnӓs-Moberg et 
al., 1999). Although speculative, it is possible that glucocorticoids induce an 
upregulation of oxytocin receptors in the raphé which may induce such 
serotonergic changes.  
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There was an increase in [
125
I]OVTA binding in the subiculum of the 
ventral hippocampus. This is consistent with Liberzon and Young (1997). The 
subiculum is one of the major sites of synaptic plasticity in the hippocampal 
formation. It connects the hippocampus to cortical regions and is associated with 
the inhibitory input to the HPA axis (O’Mara, 2005). Although, in the present 
study, the increase in [
125
I]OVTA binding did not reach statistical significance, it 
is likely that this may be due to the small sample size that remained after 
sections of an inferior quality were removed. The subiculum is rich in MR and 
GR, therefore the tendency towards an increase in oxytocin receptor binding 
after exposure to corticosterone is of biological significance. It suggests that 
oxytocin may be involved in the inhibition of the HPA axis, possibly via 
interaction between the glucocorticoid receptors and the oxytocin receptors in 
the subiculum (Herman et al., 1992; Liberzon and Young, 1997).  
Also in the present study, there was a tendency towards an increase in 
[
125
I]OVTA binding in the amygdala. The amygdala is part of the limbic brain 
system and is considered to be the emotional processing centre. This region 
receives afferents carrying a huge amount of sensory data from several locations and 
projects to the cerebral cortex and hypothalamus (Nolte, The Human Brain, 5th edn).   
A high density of oxytocin receptors is found in the CeA subnuclei (Tribollet et 
al., 1988) and oxytocinergic neurones project to the hypothalamus suggesting a 
mechanism by which oxytocin may regulate the HPA axis (Stoop, 2012). In 
addition, this is a key brain region involved in the regulation of many processes 
such as fear and anxiety (Koo et al., 2004), memory consolidation and retrieval 
processes (de Oliviera et al., 2007) and also in stress coping mechanisms (Ebner 
et al., 2005). All these processes are affected in depression and so the changes in 
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oxytocin receptor binding observed in this study may be relevant for stress 
induced mood disorders. The tendency towards an increase in oxytocin receptor 
binding presented here is consistent with a previously reported increase after 
dexamethasone treatment (Patchev et al., 1993). Interestingly, oxytocin is 
released in the amygdala after exposure to forced swim stress, an effect that was 
attributed to passive stress-coping strategies. However, this was reversed after 
administration of an oxytocin antagonist suggesting a role for the oxytocin 
receptor in mediating these effects (Ebner et al., 2005). Taken together, this 
implies that glucocorticoids could potentially influence behaviour by modulating 
the oxytocin receptor in the amygdala, although this is speculative as 
behavioural responses were not investigated in this study. 
Importantly, a bidirectional pathway between prefrontal cortex and 
amygdala has been described, through this the prefrontal cortex is able to exert 
an inhibitory influence on the amygdala (Miller et al., 2005). A neural 
mechanism has been postulated whereby the prosocial hormone oxytocin is 
responsible for governing prosocial behaviours by reducing feelings of fear in 
the amygdala (Debiec, 2007). It has been shown that oxytocin is released in 
response to stress and this results in an attenuation of ACTH release enforcing 
HPA re-activity (Neumann et al., 2000). Taken together with our results, this 
would suggest that the upregulation of oxytocin receptors in the amygdala may 
be a compensatory response to feelings of fear and anxiety and this could be 
mediated in part by the prefrontal cortex.  
Furthermore, the central amygdaloid nucleus is where the majority of 
CRH pathways originate and there are also bidirectional pathways between CRH 
neurones from the amygdala to the hypothalamus and raphé. In addition some of 
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the amygdala CRH neurones also connect with serotonergic neurones (Gray, 
1993). Therefore the amygdala CRH neurones are involved in the regulation of 
the HPA axis. Taken together with the results from this study, it is feasible that 
oxytocin receptors in the amygdala are part of the mechanism by which oxytocin 
exerts an inhibitory effect on the HPA axis in response to glucocorticoids.    
In the present study, I also observed a decrease in the hypothalamic 
oxytocin receptor binding after CORT treatment, consistent with Patchev et al. 
(1993). The hypothalamus and septal nuclei are heavily interconnected 
suggesting they control similar functions (Stoop et al., 2012).  The hypothalamus 
is also involved in the regulation of sexual behaviour and therefore the results 
presented here suggest that the sexual dysfunction seen in depression may be in 
part mediated via glucocorticoid modulation of the oxytocin receptor as also 
seen in the study of Patchev et al. (1999). More importantly, the decrease in 
oxytocin binding is significant considering that oxytocin inhibits the HPA axis. 
As mentioned above, the amygdala relays information to the hypothalamus and 
thus the observed reduction in binding at the oxytocin receptor in the 
hypothalamus, in response to glucocorticoids, may be part of the mechanism by 
which glucocorticoids influence HPA axis activity.  
  
6.5.3 Oxytocin concentrations 
The significant CORT-dependent decrease in oxytocin receptor binding 
in the hypothalamus demonstrated here was accompanied by a significant 
increase in oxytocin concentration in the region. This finding is important 
considering the tonic inhibitory role of oxytocin on the HPA axis (Neumann et 
al., 2000). The data presented here suggest that exposure to glucocorticoids leads 
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to an increase in oxytocin release in the hypothalamus, which in turn induces the 
known agonist stimulated internalisation of the oxytocin receptor, thus reducing 
the number of receptors available for binding. This may be part of the 
mechanism, by which oxytocin inhibits the HPA axis and is relevant to the 
anxiolytic function of oxytocin and in stress coping mechanisms (Neumann, 
2000). However, it is accepted that this is speculative as receptor internalisation 
was not measured in this study. 
The hypothalamus was the only brain region sampled to show a change 
in oxytocin content after CORT treatment. The fact that in the present study 
there was no effect of chronic glucocorticoid exposure on oxytocin content in the 
septal nuclei amygdala or raphé would suggest that glucocorticoids may be able 
to upregulate oxytocin receptors in these regions irrespective of peptide 
concentration. This was a somewhat surprising result considering the literature 
evidence that shows stress causes an increase in oxytocin release in the 
amygdala (Ebner et al., 2005) and septal nuclei (reviewed in Slattery and 
Neumann, 2010) as well as the hypothalamus (Wotjak et al., 1996). In addition, 
the present study did not show any significant changes in plasma oxytocin 
concentration after CORT treatment, although a ~40.5% increase was observed. 
It is possible that the plasma changes in oxytocin concentration may reach 
significance with a larger sample size. 
 
6.5.4 Vasopressin V1a receptor binding  
The regions selected for analysis of vasopressin 1a receptor binding were 
selected as a mixture of limbic and extralimbic brain regions and also regions 
with overlapping oxytocin and 5-HT1A receptor distribution. Autoradiography 
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studies presented here revealed a high binding of [
125
I]AVP in brain regions 
consistent with the  known distribution of the vasopressin 1a receptor i.e. 
hypothalamus, septal nuclei, amygdala and thalamus, with lower levels of 
binding in the cortical areas (Tribollet et al., 1988). In the present study, 
exogenous CORT administration resulted in a significant and marked increase in 
[
125
I]AVP binding in the LSD subregion of the septal nuclei and the PODG 
subregion of the dorsal hippocampus. In contrast, binding of [
125
I]AVP was 
significantly decreased in the hypothalamus, suggesting that exposure to chronic 
corticosterone affects vasopressin 1a receptor binding in a region-specific 
manner. Although it is known that glucocorticoids regulate the expression of the 
V1a receptor, until now there has been only limited evidence on the effects of 
glucocorticoids on the V1a receptor across the rat brain (Watters et al., 1996). 
The present study reports an increase in [
125
I]AVP binding in the septal 
nuclei implying that glucocorticoids are able to modulate the vasopressin 1a 
receptor in this region. This is in agreement with the previously reported 
increase in V1aR in the septal nuclei after dexamethasone treatment (Watters et 
al., 1996). The septal nucleus is densely innervated by vasopressinergic neurones 
originating from the amygdala and expresses a high density of vasopressin 1a 
receptors (Stoop, 2012). In this region, the V1aR regulate processes such as the 
generation of emotions and also those associated with learning and memory 
(Ebner et al., 2002). The activation of the V1aR in the septal nuclei has been 
shown to be anxiogenic (Bielsky et al., 2005). Whereas, administration of a V1a 
receptor antagonist into the lateral septum has produced anxiolytic behavioural 
changes (Liebsch et al., 1996). Taken together, this suggests that glucocorticoids 
may be able to regulate behaviours associated with anxiety through modulation 
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of the vasopressin 1a receptor in the septal nuclei, although this remains 
speculative as behaviour was not investigated in this study. 
This is the first report of the direct effects of chronic exposure to 
glucocorticoids on binding at the vasopressin 1a receptors in the dorsal 
hippocampus or raphé. The dorsal hippocampus, in particular the dentate gyrus 
complex, is involved in memory retrieval and learning processes (Matus-Amat et 
al., 2004). Vasopressin 1a receptor antagonism impairs memory retrieval, 
whereas agonists enhance memory retrieval (reviewed in Caldwell et al., 2008). 
Although speculative, chronic exposure to corticosterone may influence memory 
retrieval processes through an increase in expression of the vasopressin 1a 
receptor, however it is accepted that the dose of corticosterone used here was 
much higher than the physiological range.  
Also, in the present study, a reduction in [
125
I]AVP binding was observed 
in the hypothalamus. This is important when considered with the role of 
vasopressin as an activator of the HPA axis.  Both vasopressin and CRH are 
secretagogues for adrenocorticotrophic hormone (ACTH), which in turn results 
in the release of glucocorticoids (Scott and Dinan, 1998). Approximately 50% of 
CRH neurones also express vasopressin and this proportion is greatly increased 
after exposure to a stressor, during which, vasopressin is the main regulator of 
the HPA axis response (Scott and Dinan, 1998; Aguilera et al., 2007). There is 
some evidence to show that the ensuing HPA axis re-activity mediated via 
glucocorticoids may inhibit vasopressin-induced ACTH release (Raff, 1987). 
Also, in the hypothalamus, glucocorticoids inhibit vasopressin expression at a 
transcriptional level (Erkut et al., 1998; Kovacs et al., 2000). Taken together, this 
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suggests that a reduction in vasopressin 1a receptors in the hypothalamus, as 
seen in the present study may be part of this mechanism. 
 
6.5.5 Vasopressin concentrations 
In the present study, administration with corticosterone for 21 days did 
not affect vasopressin concentrations in any brain region analysed nor in plasma. 
This would suggest that the upregulation of vasopressin 1a receptors in the septal 
nuclei, raphé and dorsal hippocampus may be independent of vasopressin 
concentration in these regions. Conversely, the reduction in binding observed in 
the hypothalamus also represents a downregulation of the V1aR. Interestingly, 
although not seen here, an increase in vasopressin content in the hypothalamus 
has been previously reported in depressed patients, which has correlated with the 
severity of disease (Merali et al., 2006). Thus, the reduction in binding may be a 
result of agonist induced internalisation of V1aR, although this is speculative as 
in the present study no change on vasopressin content was measured.  However, 
it should be mentioned that the lack of effect on vasopressin content in both 
brain and plasma in the present study is a surprising result especially when 
extensive literature evidence suggests that exposure to stress (social defeat 
stress) results in a release of vasopressin as measured by microdialysis (Wotjak 
et al., 1996; reviewed in Scott and Dinan, 1998). Although technical and 
experimental differences are likely to provide an explanation for such 
discrepancies, the high variation seen in both the tissue and plasma analyses in 
this study may explain the lack of effect observed.  
In conclusion, the data presented in this chapter suggest that chronic 
exposure to glucocorticoids modulates oxytocin and vasopressin 1a receptor 
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expression in extrahypothalamic regions in a way that is independent of 
endogenous peptide concentration. Glucocorticoid responsive elements have 
been identified on the genes of the oxytocin and vasopressin 1a receptor, 
providing a means by which corticosterone may modulate the expression of 










Changes in binding at the 
cannabinoid receptor 1 after chronic 
exposure to glucocorticoids 
 There is increase evidence to suggest that the endocannabinoid system is 
involved in the regulation of the HPA axis either directly or through modulation 
of other neurotransmitter systems and therefore regulates responses to stress. 
Interestingly, patients treated with the anti-obesity drug Rimonabant (CB1 
receptor antagonist) developed depression and anxiety-related disorders, 
possibly through increased activity of the HPA axis (Doyon et al., 2006). Thus 
endocannabinoid signalling via the CB1 receptor is important for the regulation 
of the HPA axis. This chapter describes a study investigating changes in CB1 
receptor binding after chronic exposure to corticosterone in male rats and 




 Endocannabinoids are retrograde neuromodulators and are implicated in 
stress-related disorders (Roche and Finn, 2010). The endocannabinoid system 
has an inhibitory tone on the HPA axis, where disruption of endocannabinoid 
signalling leads to an increase in basal and stress-induced corticosterone release 
and an impairment of HPA axis reactivity (Di et al., 2003). Conversely, 
enhanced endocannabinoid signalling attenuates HPA axis activity (Di et al., 
2003). Thus, in the normal brain, a high endocannabinoid concentration is found 
in the hypothalamus, which is thought to contribute to the basal inhibition of the 
HPA axis (Patel et al., 2004). However, exposure to chronic stress is associated 
with a reduction of endocannabinoid concentration in the prefrontal cortex, 
striata, amygdala, hippocampus and hypothalamus (Patel et al., 2004; Hill et al., 
2008a) associated with an increase in serum corticosterone concentration and an 
increase in anxiety-like behaviour of rodents (Patel et al., 2004; reviewed in 
Roche and Finn, 2010). In contrast, a study by Di et al. (2005) found that 
endocannabinoid concentration was increased in the hypothalamus (PVN) after 
exposure to glucocorticoids and postulated that endocannabinoids are 
responsible for initiating the fast negative feedback mechanism of the HPA axis 
i.e. they mediate the nongenomic actions of glucocorticoids. Conventionally, it 
was thought that the glucocorticoid induced negative feedback mechanism is 
initiated by transcriptional control over the mediators of the HPA axis, however, 
it is now understood that a rapid action of glucocorticoids also exists that does 
not involve transcription and is therefore sometimes called ‘nongenomic 
mechanism’ or ‘fast feedback mechanism’ (Tasker et al., 2006). An elegant 
study by Di et al., 2003 postulates that glucocorticoids act on an as yet unknown 
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membrane bound G-protein coupled receptor on the PVN neurones. This results 
in an increase in endocannabinoid release which acts on the CB1 receptors on 
the glutamate neurones, inhibiting the release of glutamate and thus inhibiting 
the activity of the PVN and hormone secretion (see figure 7.1). This postulates a 
pivotal role for the CB1 receptor in the regulation of the HPA axis. 
 
 




7.1.1 The CB1 receptor and the stress response 
The CB1 receptor is localised in limbic brain regions that are involved in 
the stress response and thus implicated in its regulation (Herkenham et al., 
1991). CB1 receptors are also present in the adrenal gland where they can 
regulate the release of glucocorticoids peripherally (Galiegue et al., 1995). The 
most compelling evidence for an involvement of the CB1 receptor in the 
regulation of the HPA axis is that pretreatment with the CB1 antagonist 
SR141716A inhibits ∆
9
- tetrahydrocannabinol (THC, a CB1 receptor agonist) 
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induced ACTH release (Manzanares et al., 2009). In addition, the generation of 
CB1 receptor knockout mice has further enhanced the understanding of the 
relationship between the CB1 receptor and regulation of the HPA axis. Indeed 
CB1 receptor knockout mice display characteristic anxiogenic and depressive 
behaviours which cannot be ameliorated with antidepressants (Uriguen et al., 
2004). In addition, CB1 knockout mice have a flattening of the circadian rhythm 
whereby corticosterone concentration remain elevated throughout. This suggests 
that the inhibitory tone on HPA axis activity is diminished with the loss of CB1 
receptor signalling. Therefore the CB1 receptor is required for basal modulation 
of the HPA axis (Cota et al., 2007).  
 Further to this, the administration of several CB1 receptor antagonists to 
rats, leads to an increase in the secretion of corticosterone (Weidenfield et al., 
1994; Wenger et al., 1997). Also, corticosterone secretion is increased in the 
amygdala after in situ antagonism of the CB1 receptor, whereas administration 
of HU-210, a CB1 agonist decreases corticosterone release (Hill et al., 2009).  
More importantly in the context of this study, the CB1 receptor is under 
negative regulation by glucocorticoids. Chronic unpredictable stress, for 21 days 
downregulates CB1 receptors in the hippocampus (Hill et al., 2005). However, 
in contrast, adrenalectomy upregulates CB1 receptor mRNA in the striata which 
is reversed upon glucocorticoid replacement (Mailleux and Vanderhaeghen, 
1993). As mentioned above, this suggests that the fast glucocorticoid negative 
feedback mechanism of the HPA axis is modulated by the CB1 receptor (Di et 
al., 2003).  
In this chapter, I outline a study designed to investigate the effect of 
exposure to corticosterone via addition to drinking water for 21 days on CB1 
193 
 
receptor binding. The radioligand [
3
H]CP 55,940 was used which has an affinity 
between 0.5-5nM  and is extensively used to study the CB1 receptor (Pertwee, 
2005). It was not possible to measure the concentrations of endocannabinoids in 
discrete brain regions according to the design in chapters 5 and 6, due to their 
very short half-life and methodology; this would require analysis via mass 
spectrometry, a technique which fell outside of the scope of this study.  
 
 7.2 Aims and Hypothesis 
7.2.1 Aims 
 The endocannabinoid system has a tonic inhibitory control over the HPA 
axis (Cota et al., 2007) an effect which is mediated via the CB1 receptor. In fact, 
CB1 receptor knockout mice as well as administration of a CB1 receptor 
antagonist resulted in an increase in corticosterone secretion (Cota et al., 2007; 
Hill et al., 2005). Stressful paradigms have been shown to reduce 
endocannabinoid concentration in the brain (Patel et al., 2004; Hill et al., 2008a). 
Although exposure to glucocorticoids has also been shown to result in an 
increase after glucocorticoid administration (Di et al., 2005). However, the 
influence of glucocorticoids on CB1 receptor binding in extralimbic regions has 
been seldom studied. In this thesis, I aim to investigate the effects of 
glucocorticoids on CB1 receptor binding in regions that are involved in 
responses to stress. The endocannabinoid and in particular the CB1 receptor is 
involved in maintaining the GABA-Glutamate balance and is also involved in 
regulation of the serotonergic system via the raphé (Rossi et al., 2008; Haj-
Dahmane and Shen, 2009).  Due to the pivotal role of endocannabinoid 
regulation over two of the major systems involved in depression, an 
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investigation into the influence of glucocorticoids on binding to the CB1 
receptor is warranted. 
 
7.2.2 Hypothesis 
It is hypothesised that chronic exposure to high concentrations of 
glucocorticoid for 21 days will result in changes to CB1 receptor binding in 
brain regions that are involved in the regulation of responses to stress. The 
direction of changes in receptor binding is expected to reflect changes in the 
concentration of endocannabinoids, according to the previously published 
literature. More specifically, it is hypothesised that chronic exposure to 
glucocorticoids will result in an decrease in CB1 receptor binding in amygdala 
and hippocampus amongst other brain regions associated with the regulation of 
responses to stress.  
 
7.3 Materials and Methods 
All materials used for this study are given in chapter 4 Also, in chapter 4, 
are methodological details on in-vivo husbandry, dosing on animals, collection 
of post mortem samples, tissue sectioning and autoradiography methodology. 
 
7.4  Results 
Changes in CB1 receptor binding were quantified after chronic exposure 
to CORT. The quantitative data showing [
3
H]CP 55,940 specific binding to CB1 
receptors expressed as pmol/mg tissue are shown in table 7.1. A two way 
ANOVA was used to test for effects of treatment and also for region. Significant 
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differences were found for both treatment (F(1,248) = 3.88, P = 0.0499) and 
region. (F(18,248) = 82.88, P = <0.0001). The interaction was not significant. 
Further analysis between treatment groups in each region revealed significant 
differences in three regions sampled (two-tailed Student’s t-test with Bonferroni 
at P = 0.05). These are shown in figure 7.2. A significant difference in regional 
uptake was seen in , the striata and the raphé. The significant 34.7% decrease in 
the striata after CORT treatment held significance after post hoc correction. 
Likewise, the raphé showed a 46.5% decrease in CB1 receptor binding retaining 
significance after Bonferroni correction. In addition, there was a tendency 
towards a decrease in [
3
H]CP 55,940 binding in the PVN (P<0.1).  Figure 7.3 
shows representative autoradiograms of brain sections from vehicle and CORT 
treated rats labeled with [
3
H]CP 55,940. Alongside, are images from brain 
sections showing non-specific binding i.e. those which were incubated in the 







Figure 7.2 Effects of chronic corticosterone on [
3
H]CP 55,940 binding in rat brain. 
Animals were treated with either vehicle (0.8% ethanol) or corticosterone (400 µg/mL) 
for 21 days. Animals were sacrificed after a 24 hour hormone free period. Data from 
regions showing a differences after corticosterone treatment are shown and expressed as 
mean ± SEM (n=8 per treatment group, except hypothalamus and subiculum, where n=5 
per treatment group due to the tissue becoming damaged during the experiment which 
meant that the regions could not be sampled accurately). Abbreviations for regions are 
the same as in figure 4.5. Statistical analysis was carried out using 2-way ANOVA for 
treatment effects and regional effects followed by Bonferroni post hoc test for multiple 
comparisons, was applied with a significance level of 0.05. A statistically significant 














Table 7.1 Regional [
3
H]CP 55,940 binding in rat brain after chronic exposure to 
corticosterone. 
 














10.69 ± 4.38 
9.10 ± 1.51 
 
7.96 ± 2.15 













23.70 ± 5.84 
26.64 ± 3.54 
30.83 ± 4.61 
35.53 ± 9.73 
 
22.85 ± 6.18 
26.98 ± 4.99 
27.20 ± 5.54 
















15.05 ± 5.51 
15.05 ± 5.51 
 
18.09 ± 4.05  







Striata 36.53 ± 6.19 23.85 ± 3.50 * -34.7 0.0002 
Amygdala 
      
14.18 ± 1.86 
 









24.16 ± 6.54 
26.10 ± 3.94 
27.43 ± 5.98 
21.32 ± 3.78 
 
 
25.01 ± 6.26 
27.14 ± 7.86 
25.13 ± 7.69 



















30.74 ± 9.16 
29.52 ± 3.39 
 
 
32.80 ± 6.12 











147.5 ± 55.76 130.0 ± 33.54 -11.9 0.4580 
Raphé 16.55 ± 5.08 
 
8.86 ± 0.80 * -46.5 0.0008 
 
Entorhinal cortex      18.44 ± 5.67 
 
  15.43 ± 3.84 -16.3 0.2338 
 
Table 7.1 Animals were treated in the same way as described in figure 7.4. Data are 
expressed as mean ± SD (n=8 per treatment group, except hypothalamus and subiculum, 
where n=5 per treatment group due to the tissue becoming damaged during the 
experiment which meant that the regions could not be sampled accurately). 
Abbreviations used for regions are the same as in figure 4.5. Statistical analysis was 
carried out using 2-way ANOVA for treatment effects and regional effects followed by 
Bonferroni post hoc test for multiple comparisons, with a significance level of 0.05. A 













Figure 7.3 Representative [
3
H]CP 55,940 autoradiography images from rat brain. 
Measured after chronic exposure to corticosterone as described in figure 7.4. Images are 
from individual rats representing A = prefrontal cortex (PrL, CgL, M1, M2), B = Striata, 
Nucleus accumbens (shell and core), C = dorsal hippocampus (CA1 rad, CA2 rad, CA3 
rad, MODG, PODG, amygdala, VMDH), D = CA1 rad of ventral hippocampus, 
subiculum, substantia nigra (SNR), E =  raphé. Further details of ROI location and 










CA1 rad, CA2 rad, CA3 










The present study demonstrates that long-term exposure to exogenous 
corticosterone induces changes in endocannabinoid receptor binding. Here, I 
present data quantifying the effects of exogenous corticosterone on CB1 receptor 
binding throughout the brain, in both the limbic and cortical regions. 
Corticosterone treatment affected CB1 receptors in brain regions known to be 
involved in responses to stress. Receptor autoradiography studies presented here 
reveal a high binding of [
3
H]CP 55,940 in striatum, substantia nigra, CA3 and 
dentate gyrus subregion of dorsal hippocampus, which is consistent with the 
known receptor distribution of CB1 receptors in rat brain (Herkenham et al., 
1991). In the present study, exogenous CORT administration resulted in a 
significant decrease in [
3
H]CP 55,940 binding in the striatum and raphé.  
The striatum is an important region for regulating emotional and 
cognitive functions which are affected by stress. In addition, the striatum is 
particularly abundant in CB1 receptors (Herkenham et al., 1991) and these have 
been reported to be involved in mediating the anxiolytic effects of 
endocannabinoids (Rossi et al., 2008). Here, I report a reduction in striatal CB1 
receptor binding after chronic exposure to glucocorticoids. Since 
endocannabinoid concentration in this region was not achievable within the 
scope of this thesis, the interpretation of how the CB1 receptor is modulated by 
glucocorticoids is speculative. However, Hill et al. (2008a) showed a significant 
reduction in anandamide concentration (measured after extraction from dissected 
tissue) in the striata after 21 days of chronic unpredictable stress, and also a 
decrease in CB1 receptor density. Although it is accepted that in the present 
study chronic exposure to corticosterone may not result in an increase in 
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endocannabinoid concentration in the same way, the decrease in [
3
H]CP 55,940 
binding here is consistent with the above mentioned finding of Hill et al. 
(2008a).  In the striatum, the CB1 receptors are located on presynaptic neurones 
which influence both GABA and glutamate release (Rossi et al., 2010). 
Exposure of mice to chronic social defeat stress or corticosterone (10mg/kg for 3 
days) results in desensitisation of those CB1 receptors which regulate GABA 
release, but no change is seen in those CB1 receptors which regulate glutamate 
release (Rossi et al., 2008). This suggests that glucocorticoids disrupt the 
GABA-glutamate balance, which is implicated in depression, by altering 
endocannabinoid signalling in the striata (Rossi et al., 2008). Thus, the results 
from the present study and that of Hill et al. (2008) suggest that corticosterone 
induced desensitisation of CB1 receptors may result in  reduced expression of 
the CB1 receptors in the striatum.  
Also, in the present study, there was a reduction in [
3
H]CP 55,940 
binding in the raphé. The effect of glucocorticoids on the raphé CB1 receptor has 
not been reported previously. The location of CB1 receptors in the raphé implies 
that these are able to influence central serotonergic activity. Indeed, activation of 
the CB1 receptors in the raphé inhibits serotonin release, modulates the firing 
rate of raphé serotonergic neurons (Nakazi et al., 2000; Tzavara et al., 2003) and 
reduces serotonin content in projection regions such as the prefrontal cortex and 
hippocampus (Egashira et al., 2002). This has shown to be via retrograde 
inhibition of glutamate release (Haj-Dahmane and Shen, 2009). Furthermore, 
pharmacological blockade of the CB1 receptor enhances basal extracellular 5-
HT in the prefrontal cortex (Haj-Dahmane, 2011). The results from the present 
study indicate that chronic exposure to glucocorticoids impair the 
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endocannabinoid receptor activity in the raphé, which can putatively affect the 
regulation of the serotonergic system.  Although speculative, when considered 
with the lack of change in 5-HT, 5-HIAA and 5-HT turnover seen in this 
investigation (outlined in chapter 5), it suggests that the decrease in CB1 
receptor binding reported in this study could be the reason that no change in 5-
HT content was observed. That is, it may represent a mechanism by which 5-HT 
content is maintained in projection regions after exposure to corticosterone for 
21 days. 
Importantly, there was a tendency towards a decrease in [
3
H]CP 55,940 
binding in the PVN after corticosterone treatment. It is possible that this may 
reach significance with a larger sample size, bearing in mind that in this study, 
some of these sections were damaged during the autoradiography procedure. 
Therefore the final analysis here is from n=5 in both treatment groups. However, 
this finding is potentially relevant as it suggests that glucocorticoids may be able 
to modulate the expression of the CB1 receptor in the PVN. Di et al. (2003) have 
shown that corticosterone exerts an inhibitory effect on the HPA axis via 
endocannabinoid release resulting in reduced binding at the CB1 receptor 
possibly due to internalisation of the receptor. They also show that this effect is 
abolished by a CB1 receptor antagonist. Although speculative, it is possible that 
a downregulation of the CB1 receptor may be part of the mechanism of HPA 
axis dysfunction. However, it is accepted that a significant finding is needed to 
add strength to this. 
Against the hypothesis, the study presented in this chapter did not show a 
significant change in CB1 receptor binding in the hippocampus. There are a few 
reports demonstrating a decrease in CB1 receptors in the hippocampus after 
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stress (Hill et al., 2008a, b; Hill and McEwen, 2010b). The hippocampus is 
highly susceptible to stress induced structural and neurochemical changes 
(Magarinos et al., 1998) and hence the development of depression (McEwen, 
2003). There is a high density of CB1 receptors in the hippocampus which are 
located on GABAergic interneurons (Herkenham et al., 1991). The lack of 
glucocorticoid induced change in [
3
H]CP 55,940 binding in this study compared 
to that observed in Hill et al. (2008a and b) may be explained by different 
treatment conditions and differences in the strain of rat used. Studies by Hill et 
al. are in Long Evans or Sprague Dawley rats, whereas here, Wistar rats were 
used. Strain differences in the responses to stress and its mediators are well 
established (GÓmez et al., 1996; Wu and Wang, 2010). In addition there were 
differences in the autoradiography methodology between the two studies. 
Although the protocols were similar, the studies of Hill et al. have determined 
non-specific binding with unlabelled CP 55,940 whereas in the current study 
non-specific binding was determined using a saturating dose of the selective 
CB1 antagonist, rimonabant (SR141716A). It is expected that at the high dose 
used here it will also block the CB2 receptors. 
It should be taken into consideration that CP 55,940 binds with similar 
affinity to both CB1 and CB2 receptors, and the fact that both these receptors are 
present in the rat hippocampus which could impede the results presented here 
(Gong et al., 2006; Brusco et al., 2008). However, it is thought that the CB2 
receptor density is much lower than that of the CB1 receptor (Gong et al., 2006; 
Onaivi et al., 2006) as measured by a 100 fold lower expression of CB2 receptor 
mRNA. Although that study investigated the relative expression in mice, there is 
evidence to suggest the expression of CB2 receptor transcripts in the rat brain is 
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100 fold lower than that in the rat spleen (Onaivi et al., 2006). Therefore it is 
assumed that the specific binding of [
3
H]CP 55,940 seen in this study represents 
binding to the CB1 receptor as the relative contribution by CB2 receptors is 
minimal due to the much lower expression levels.  
The findings presented in this chapter suggest that CB1 receptor binding 
is reduced by glucocorticoid overload in a region specific manner and due to the 
interactions between the endocannabinoid and serotonergic systems, this may be 










Stress related mood disorders are common. It is estimated that 
approximately 1 in 6 people are affected by depression at any given time in the 
UK (The Office for National Statistics, 2000). Not only is depression 
widespread, but it is an extremely costly disorder (Sobocki et al., 2006), partly 
due to difficulties in accurate diagnosis and treatment. It is clear that a greater 
understanding of the underlying neurobiological dysfunction in depression is 
needed as well as more accurate diagnosis (Pajer et al., 2012). A common 
feature of depression is a hyperactivity of the HPA axis resulting from elevated 
glucocorticoid concentrations (Anacker et al., 2011) which has been shown to 
lead to neurological deficits associated with depression.  
In this thesis, I attempted to understand the impact of an increase in 
circulating glucocorticoid concentration on four neurotransmitter systems known 
205 
 
to regulate the HPA axis. In particular the effects of chronically elevated 
glucocorticoid concentrations on the neuropeptide and endocannabinoid systems 
is investigated and their influence on the serotonergic system. This is important 
as irregularities in each of these are associated with depressive symptoms and a 
lot of effort has been placed on determining the exact nature of these 
abnormalities with a view to improving patient diagnosis and treatment (Slattery 
and Neumann, 2010; Caldwell et al., 2008; Carrasco et al., 2003; Hill and 
McEwen, 2010). To that end, molecular imaging techniques such as PET and 
SPECT may be applied to further investigate the receptor systems in conditions 
of elevated glucocorticoid, however, the question remains as to what exactly 
needs to be imaged. It was envisaged that the neurotransmitter systems studied 
here may provide a biologically relevant target that could be imaged to provide 
information which could help in the management of depressed patients that also 
present with HPA axis abnormalities. 
Attempts to develop radioligands for imaging the glucocorticoid receptor 
have so far failed, and this approach is particularly challenging because of the 
low expression of the glucocorticoid receptors in the human brain (30-40 
fmol/mg protein) (reviewed in Steiniger et al., 2008). Therefore, in order to 
image these receptors, radioligands with an extremely high affinity (<1 nM) are 
required. This is problematic as it means that a very high specific activity is also 
required since competition of the binding sites by endogenous ligand needs to be 
considered (reviewed in Steiniger et al., 2008). In addition, a high specific 
activity radiopreparation is also required to avoid significant receptor occupancy 
by unlabelled compound that is co-administered (Hume at al., 1998; reviewed in 
Steiniger et al., 2008). Furthermore, the compounds investigated to date have 
206 
 
shown poor metabolic stability and/or a high degree of non specific binding 
hampering further their utility. Due to the above mentioned problems with 
imaging the glucocorticoid receptor directly, in this thesis, changes in the 5-
HT1A, oxytocin, vasopressin 1a and CB1 receptors were investigated after 
chronic exposure to corticosterone. Furthermore, as these neurotransmitter 
systems are known to be interconnected, the influence of glucocorticoid induced 
changes to the neuropeptidergic and endocannabinoid systems on the 
serotonergic system are discussed to determine if these interactions are relevant 
for the understanding of stress induced depression. I have attempted to describe 
the changes that I measured in this study in figure 8.1.  
 
 
Figure 8.1 A simple schematic diagram showing significant changes measured in 
receptor binding and neurotransmitter concentration for each of the systems studied in 
this study. The relevant regions and their interactions are shown. Abbreviations: 5-
HT1AR = 5-HT1A receptor, OXTR = oxytocin receptor, V1aR = vasopressin 1a 
receptor; CB1R = CB1 receptor. Arrows indicate the direction of change observed after 
chronic exposure to corticosterone. These changes may be relevant for the regulation of 




In summary, I measured an upregulation of the 5-HT1A receptor in the 
PRL and M2 subregion of the prefrontal cortex, amygdala, CA1 rad and CA2 
pyr subregions of the dorsal hippocampus. There was no associated change in 5-
HT turnover in any region. I also measured an upregulation of the oxytocin 
receptor in the septal nuclei and raphé, however, there was no change in the 
oxytocin concentration measured here. Interestingly, there was a decrease in 
oxytocin receptor binding in the hypothalamus which was associated with a 
decrease in oxytocin content in the same region. In addition, the vasopressin 1a 
receptor was upregulated in the PODG subregion of the dorsal hippocampus and 
septal nuclei without a concomitant increase in vasopressin content. However 
the vasopressin 1a receptor binding was decreased in the hypothalamus. 
Furthermore, the CB1 receptor was decreased in the striata and raphé. 
For the serotonergic system, I reported an increase in 5-HT1A receptor 
binding in postsynaptic regions; PRL and M2 subregion of the prefrontal cortex, 
amygdala, CA1 rad and CA2 pyr subregions of the dorsal hippocampus. This 
increase in [
3
H]WAY 100635 binding, measured using in vitro autoradiography 
was not associated with a change in serotonin concentration suggesting the 
possibility of an upregulation of the 5-HT1A receptor in response to elevated 
glucocorticoids. Although this is contradictory to the majority of the published 
literature, where a decrease in 5-HT1A receptor binding has been reported, there 
is one major difference between this study and those reported. That is, here an 
antagonist radioligand is used, whereas other studies used the agonist [
3
H]8-
OHDPAT. Thus, because [
3
H]WAY 100635 binds to both the low and high 
affinity states of the 5-HT1A receptor, the total receptor population is considered 
and not just a subpopulation. The results presented in this thesis suggest that 
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chronic exposure to glucocorticoid for 21 days is sufficient to cause an 
upregulation of the total number of 5-HT1A receptors which may represent an 
attempt to ‘prime’ the serotonergic system i.e. to ensure there are enough 
receptors present to easily convert to the high affinity state when needed 
(Strange, 2000).  
The upregulation of 5-HT1A receptors in the PRL and M2 subregion of 
the prefrontal cortex may represent prefrontal control over raphé serotonergic 
neurones as a bidirectional pathway is known to exist between these regions 
(Martin-Ruiz et al., 2001).  Whilst the upregulation of 5-HT1A receptors in the 
CA1 rad and CA2 pyr subregions of the dorsal hippocampus could represent a 
neuroprotective mechanism against a stress induced increase in glutamate during 
stress.  
At present, there is a successful antagonist radioligand for imaging the 5-
HT1A receptor; [
11
C]WAY 100635 (Pike et al., 1996; Bantick et al., 2004; Saigal 
et al., 2006; Tipre et al., 2006). However, the carbon-11 label limits its clinical 
utility. An F-18 radiolabelled antagonist has been developed; [
18
F]MPPF but its 
fast clearance and higher nonspecific binding component when compared to 
[
11
C]WAY 100635 hinders its use beyond a basic research tool (Wooten et al., 
2011). Interestingly, recent PET studies using [
11
C]WAY100635 have shown 
that those patients which responded to the SSRI, escitalopram had a 33% higher 
baseline 5-HT1A receptor baseline than those patients that did not respond to the 
therapy (Miller et al., 2013). Furthermore, depressed patients with a higher 5-
HT1A receptor binding potential showed remission after 3 months of 
psychopharmacotherapy (Lan et al., 2013). However, these studies did not look 
at HPA axis function in the subjects, so it remains possible that a glucocorticoid 
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induced increase in 5-HT1A receptor binding as measured here could predict 
therapy response and hence could also aid in therapy selection for depressed 
patients. There has been one PET study to date looking at the effect of 
glucocorticoids on 5-HT1A receptor binding, which failed to find a relationship, 
although it should be borne in mind that the subjects in the study were not 
considered to be clinically depressed (Montgomery et al., 2001). 
Investigation of the neuropeptide systems showed that chronic 
corticosterone exposure altered the expression of oxytocin receptors in a region 
specific manner. A decrease in oxytocin receptor binding observed in the 
hypothalamus, was also accompanied by an increase in oxytocin concentration. 
It is possible that this decrease in binding is due to downregulation of the 
oxytocin receptor, in response to the increase in oxytocin content of the 
hypothalamus after treatment with corticosterone. In other regions however, 
oxytocin receptor binding was increased (septal nuclei and raphe), without an 
associated change in peptide concentration suggesting that corticosterone may 
induce an upregulation in the expression of oxytocin receptors in these regions. 
This is an important finding when considered along with the fact that the 
oxytocin receptor is coexpressed on serotonergic neurones in the raphé and that 
this receptor is involved in the regulation of the serotonergic system (Yoshida et 
al., 2009). Moreover, SSRI administration is known to induce the release of 
oxytocin (Uvnäs-Moberg et al., 1999). Therefore, the upregulation measured in 
the current study after chronic glucocorticoid exposure may represent a 
compensatory mechanism to maintain forebrain serotonin concentrations and 
may explain the lack of effect on the concentrations of 5-HT, 5-HIAA and 5-HT 
turnover. Furthermore, the upregulation of oxytocin receptors in the septal 
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nuclei, is also significant as oxytocinergic neurones project from this region to 
the hypothalamus where they exert an inhibitory influence on the HPA axis 
(Neumann et al., 2000; 2002), thus this pathway may represent a mechanism by 
which HPA axis reactivity is initiated.   
With respect to the value of imaging the oxytocin receptor in depression, 
the significantly large increases in oxytocin receptor binding measured here in 
the raphé (+100%) and septal nuclei (+87.5%) after corticosterone treatment 
suggest that PET imaging of this receptor in response to glucocorticoids could be 
amenable. Attempts have already been made to generate F-18 and C-11 
radioligands for the oxytocin receptor. Smith et al. (2012) report the synthesis of 
four non-peptide small molecule antagonists for the oxytocin receptor. 
Unfortunately, all four compounds failed to show utility for imaging central 
oxytocin receptors in vivo due to low brain uptake and so further development 
was halted. However, the study by Smith et al. (2012) does provide a good 
chemistry starting point for the synthesis of related compounds with improved in 
vivo characteristics. 
As with oxytocin receptor binding, specific binding to the vasopressin 1a 
receptor measured after elevated circulating corticosterone concentration was 
also affected in a region-specific manner. A decrease in [
125
I]AVP binding was 
observed in the hypothalamus, but specific binding was increased in the septal 
nuclei and PODG subregion of the dorsal hippocampus. These changes were not 
associated with a change in vasopressin content in the same regions, suggesting 
that the vasopressin 1a receptor may also be upregulated or downregulated in 
response to glucocorticoids. These findings are relevant as vasopressin is a 
known activator of the HPA axis and therefore the downregulation of 
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vasopressin 1a receptors seen in this region here suggests that this is part of the 
mechanism by which HPA axis re-activity is initiated. Furthermore, raphé 
serotonergic neurones project to the hypothalamus and synapse with 
vasopressinergic neurones (Ferris and Deville, 1999). Bearing in mind that I did 
not measure a change in 5-HT1A receptor number or 5-HT turnover in the raphé 
suggests that serotonergic function is maintained in the region and thus may 
influence HPA axis reactivity via influencing the vasopressin 1a receptor in the 
hypothalamus.  In addition, activation of the vasopressin 1a receptor in the septal 
nuclei has an anxiogenic effect (Bielsky et al., 2005) and thus chronic 
glucocorticoid exposure may result in an increase in anxiogenic behaviours via 
an upregulation of vasopressin 1a receptors in the septal nuclei. However, the 
septal nuclei also projects to the hypothalamus and vasopressin neurones may be 
responsible for regulating the HPA axis (Stoop, 2012). Importantly, this is the 
first time that it has been shown that glucocorticoids affect the vasopressin 1a 
receptor response in the dorsal hippocampus. The increase in [
125
I]AVP binding 
in the PODG subregion of the dorsal hippocampus suggests that a glucocorticoid 
induced upregulation of the vasopressin 1a receptor may be involved in the 
learning and memory impairments seen during chronic stress (Caldwell et al., 
2008).  
As with the oxytocin receptor, the degree of increase in binding at the 
vasopressin 1a receptor demonstrated here in the septal nuclei (+30.0%) and 
PODG of the dorsal hippocampus (+78.6%) could be detected by PET, however, 
as far as I am aware, there are no published data on the evaluation of 
radioligands for the vasopressin 1a receptor. There is one confounding issue with 
imaging this target in stress induced depression which is related to the resolution 
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of the currently available PET scanners especially when used without associated 
MRI coregistration. Subregional analysis of the dorsal hippocampus, for 
example, to measure the vasopressin 1a receptor effect seen here in the PODG 
may need some methodology work up as the effect is likely be lost if the whole 
dorsal hippocampus volume of interest is sampled.  
Finally, chronic corticosterone treatment was also shown to influence 
endocannabinoid signalling through the CB1 receptor. Binding of [
3
H]CP 55,940 
was reduced in the striata and raphé suggesting that exposure to glucocorticoids 
may modulate CB1 receptor expression, and thus contribute to the serotonergic 
abnormalities seen in depression. The decreased binding to CB1 receptors in the 
striata may contribute to the GABA-Glutamate imbalance which is seen in 
depression. Furthermore, the reduced CB1 receptor binding seen in the raphé 
implies a link with the regulation of the serotonergic system. Indeed, activation of 
the CB1 receptors in the raphé inhibits serotonin release, modulates the firing rate of 
raphé serotonergic neurons (Nakazi et al., 2000; Tzavara et al., 2003) and reduces 
serotonin content in projection regions such as the prefrontal cortex and hippocampus 
(Egashira et al., 2002). This has shown to be via retrograde inhibition of glutamate 
release (Haj-Dahmane and Shen, 2009). This is the first time that the effects of 
glucocorticoids on raphé CB1 receptors has been reported and when considered 
alongside the lack of change in  5-HT, 5-HIAA and 5-HT turnover, suggests that the 
decrease in CB1 receptor binding reported in this study could be the reason that 
no change in 5-HT content was observed. That is, it may represent a mechanism 
by which 5-HT content is maintained in projection regions after exposure to 
corticosterone for 21 days.  
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Due to the fact that the decreases in CB1 receptor binding observed in 
the striata (-34.7%) and also in the raphé (-46.5%) are relatively large it would 
be interesting to see if these changes could be detected by PET imaging. The 
development of radiotracers for the CB1 receptor has progressed further than the 
neuropeptide systems. Initial attempts were hampered by a high degree of 
lipophilicity exhibited by the radioligands, which is problematic considering the 
brain has a ~60% lipid composition, thus reducing the brain uptake and specific 
signal of these radioligands (Yasuno et al., 2008). However, since then, two 




C]MEPPEP (Yasuno et al., 
2008) showed more promise. [
11
C]OMAR has only been tested in preclinical 
studies, and is yet to be evaluated in humans (Herance et al., 2011), whereas 
[
11
C]MEPPEP displays slow kinetics which is a major drawback for use in 
humans (Fan et al., 2009).  More recently, [
18
F]MK-9470, a CB1 receptor ligand 
was evaluated in rats, but development was halted due to the presence of 
radiolabelled metabolites, which cross the BBB and contaminate the signal 
(Casteels et al., 2012). 
 
9.1 Future work 
The results from the present study suggest that in vivo non-invasive 
dosing of animals with corticosterone via drinking water can be used for further 
preclinical studies investigating the influence of glucocorticoids on a number of 
neurotransmitter systems including the serotonergic, neuropeptidergic and 
endocannabinoid systems.  It would be interesting to understand the impact that 
this treatment had on the glucocorticoid receptor, however, at present this is 
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challenging due to the lack of suitable radioligands. Although a measurement of 
glucocorticoid receptor mRNA may provide some insight. 
In addition, it would be interesting to compare the results obtained here 
with those derived from stress paradigms i.e. HPA axis activation via application 
of a psycho-physical stressor such as restraint stress. Such a paradigm would 
offer a complete HPA axis effect, with CRF and ACTH rather than from 
glucocorticoid alone. In addition, as behavioural studies were not conducted 
here, it would be interesting and relevant to assess the behavioural effects of 
either paradigm in parallel to the neurobiological ones. Also, gender effects 
could be studied preclinically as these are known to exist for the oxytocin and 
vasopressin systems and are relevant as women are more susceptible to 
depression than males. Furthermore, it would be interesting to assess whether the 
reported changes in receptor expression are affected by SSRI treatment, 
particularly as these drugs have been shown to act partly via the oxytocinergic 
system (Uvnӓs-Moberg et al., 1999). This could be investigated preclinically by 
dosing rats with corticosterone as described here, followed by 31 days of 
fluoxetine treatment (Leventopoulos et al., 2009).  
The data presented herein suggest that the 5-HT1A, extrahypothalamic 
oxytocin and extrahypothalamic vasopressin 1a receptors respond to elevated 
levels of glucocorticoids and hence could be of relevance in disorders such as 
stress induced depression. Taking into consideration the multifaceted approach 
to understand depression and other related mood disorders, the ability to detect 
abnormalities in neurotransmitter systems other than the serotonergic system is 
attractive. The changes measured here in the oxytocinergic, vasopressinergic and 
endocannabinoid systems is important as these systems are known to interact 
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and influence serotonergic regulation (Ferris and Deville, 1999; Uvnäs Moberg 
et al., 1999; Haj-Dahmane, 2011) and therefore may be relevant in stress 
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Feasibility organ weights 
Parameter   
Table Analyzed SC adrenal (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=7.378 df=10 
    
How big is the difference?   
Mean ± SEM of column A 10.38 ± 0.6292 N=6 
Mean ± SEM of column B 3.681 ± 0.6544 N=6 
Difference between means 6.699 ± 0.9079 
95% confidence interval 4.676 to 8.721 
R square 0.8448 
 
Parameter   
Table Analyzed SC thymus (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=7.825 df=10 
    
How big is the difference?   
Mean ± SEM of column A 172.9 ± 6.431 N=6 
Mean ± SEM of column B 85.71 ± 9.091 N=6 
Difference between means 87.14 ± 11.14 
95% confidence interval 62.33 to 112.0 
R square 0.8596 
    
 
Parameter   
Table Analyzed drink adrenal (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=8.806 df=10 
    
How big is the difference?   
Mean ± SEM of column A 19.27 ± 1.374 N=6 
Mean ± SEM of column B 6.865 ± 0.3094 N=6 
Difference between means 12.40 ± 1.409 
95% confidence interval 9.265 to 15.54 
R square 0.8858 






Parameter   
Table Analyzed drink thymus (mg)/100 g body weight (g) 
Column A VEHICLE 
Vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0007 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.839 df=10 
    
How big is the difference?   
Mean ± SEM of column A 178.7 ± 7.659 N=6 
Mean ± SEM of column B 91.29 ± 16.36 N=6 
Difference between means 87.40 ± 18.06 
95% confidence interval 47.16 to 127.7 
R square 0.7007 
    
 
Feasibility weight gain 
Parameter         
Table Analyzed sc injection grp       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 21.04 < 0.0001     
Treatment 52.20 < 0.0001     
duration 17.79 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
Treatment **** Yes     
Duration **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 20 40753 2038 24.64 
Treatment 1 101120 101120 1223 
duration 20 34465 1723 20.84 
Residual 210 17364 82.68   
          
 
Parameter         
Table Analyzed drink grp       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 16.58 < 0.0001     
Treatment 49.35 < 0.0001     
Day 24.28 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
Treatment **** Yes     
Duration **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 20 40903 2045 17.80 
Treatment 1 121748 121748 1059 
Day 20 59907 2995 26.06 
Residual 210 24134 114.9   








Parameter         
Table Analyzed water consumed (ml/rat)       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 3.82 0.8548     
treatment 9.82 0.0010     
duration 37.33 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment *** Yes     
duration **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 9 218.5 24.27 0.5195 
treatment 1 561.8 561.8 12.02 
duration 9 2134 237.2 5.076 
Residual 60 2804 46.73   
          
 
Parameter         
Table Analyzed ml/kgwater consumed       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 7.63 < 0.0001     
treatment 18.34 < 0.0001     
duration 25.50 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
treatment **** Yes     
duration **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 9 43412 4824 5.242 
treatment 1 104344 104344 113.4 
duration 9 145047 16116 17.51 
Residual 300 276079 920.3   
          
 
Parameter   
Table Analyzed ttest (ml/rat) day3 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.5911 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5674 df=6 
    
How big is the difference?   
Mean ± SEM of column A 66.50 ± 2.723 N=4 
Mean ± SEM of column B 64.00 ± 3.464 N=4 
Difference between means 2.500 ± 4.406 
95% confidence interval -8.283 to 13.28 
R square 0.05092 










Parameter   
Table Analyzed ttest (ml/rat) day7 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.6291 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5087 df=6 
    
How big is the difference?   
Mean ± SEM of column A 64.00 ± 3.651 N=4 
Mean ± SEM of column B 61.75 ± 2.496 N=4 
Difference between means 2.250 ± 4.423 
95% confidence interval -8.573 to 13.07 
R square 0.04135 
    
 
Parameter   
Table Analyzed ttest (ml/rat) day9 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0825 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=2.082 df=6 
    
How big is the difference?   
Mean ± SEM of column A 66.25 ± 4.571 N=4 
Mean ± SEM of column B 56.00 ± 1.826 N=4 
Difference between means 10.25 ± 4.922 
95% confidence interval -1.795 to 22.29 
R square 0.4195 







Parameter   
Table Analyzed ttest (ml/rat) day5 
Column A VEHICLE 
Vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.1954 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.457 df=6 
    
How big is the difference?   
Mean ± SEM of column A 63.25 ± 3.521 N=4 
Mean ± SEM of column B 57.25 ± 2.136 N=4 
Difference between means 6.000 ± 4.118 
95% confidence interval -4.077 to 16.08 
R square 0.2613 
    
262 
 
Parameter   
Table Analyzed ttest (ml/rat) day11 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.4173 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.8709 df=6 
    
How big is the difference?   
Mean ± SEM of column A 63.50 ± 4.173 N=4 
Mean ± SEM of column B 59.25 ± 2.529 N=4 
Difference between means 4.250 ± 4.880 
95% confidence interval -7.691 to 16.19 
R square 0.1122 
    
 
Parameter   
Table Analyzed ttest (ml/rat) day13 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.4383 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.8299 df=6 
    
How big is the difference?   
Mean ± SEM of column A 60.25 ± 1.887 N=4 
Mean ± SEM of column B 57.50 ± 2.723 N=4 
Difference between means 2.750 ± 3.313 
95% confidence interval -5.358 to 10.86 
R square 0.1030 
    
 
Parameter   
Table Analyzed ttest (ml/rat) day15 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.2492 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.276 df=6 
    
How big is the difference?   
Mean ± SEM of column A 62.25 ± 2.136 N=4 
Mean ± SEM of column B 56.50 ± 3.969 N=4 
Difference between means 5.750 ± 4.507 
95% confidence interval -5.278 to 16.78 
R square 0.2134 









Parameter   
Table Analyzed ttest (ml/rat) day17 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0007 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=6.419 df=6 
    
How big is the difference?   
Mean ± SEM of column A 64.75 ± 1.702 N=4 
Mean ± SEM of column B 52.25 ± 0.9465 N=4 
Difference between means 12.50 ± 1.947 
95% confidence interval 7.735 to 17.26 
R square 0.8729 
    
 
Parameter   
Table Analyzed ttest (ml/rat) day19 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.6841 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.4273 df=6 
    
How big is the difference?   
Mean ± SEM of column A 75.50 ± 7.089 N=4 
Mean ± SEM of column B 72.00 ± 4.103 N=4 
Difference between means 3.500 ± 8.190 
95% confidence interval -16.54 to 23.54 
R square 0.02954 
    
 
Parameter   
Table Analyzed ttest (ml/rat) day21 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.5581 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.6200 df=6 
    
How big is the difference?   
Mean ± SEM of column A 73.75 ± 3.637 N=4 
Mean ± SEM of column B 70.50 ± 3.775 N=4 
Difference between means 3.250 ± 5.242 
95% confidence interval -9.577 to 16.08 
R square 0.06021 










Parameter   
Table Analyzed ttest (ml/kg) day3 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.1642 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.426 df=30 
    
How big is the difference?   
Mean ± SEM of column A 287.9 ± 5.569 N=16 
Mean ± SEM of column B 300.7 ± 7.106 N=16 
Difference between means -12.88 ± 9.029 
95% confidence interval -31.31 to 5.561 
R square 0.06349 
    
 
Parameter   
Table Analyzed ttest (ml/kg) day3 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.1642 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.426 df=30 
    
How big is the difference?   
Mean ± SEM of column A 287.9 ± 5.569 N=16 
Mean ± SEM of column B 300.7 ± 7.106 N=16 
Difference between means -12.88 ± 9.029 
95% confidence interval -31.31 to 5.561 
R square 0.06349 
    
 
Parameter   
Table Analyzed ttest (ml/kg) day7 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0005 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.912 df=30 
    
How big is the difference?   
Mean ± SEM of column A 251.4 ± 8.031 N=16 
Mean ± SEM of column B 288.9 ± 5.226 N=16 
Difference between means -37.48 ± 9.582 
95% confidence interval -57.05 to -17.92 
R square 0.3378 









Parameter   
Table Analyzed ttest (ml/kg) day9 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.5160 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.6573 df=30 
    
How big is the difference?   
Mean ± SEM of column A 253.4 ± 9.836 N=16 
Mean ± SEM of column B 261.0 ± 6.017 N=16 
Difference between means -7.578 ± 11.53 
95% confidence interval -31.12 to 15.97 
R square 0.01420 
    
 
Parameter   
Table Analyzed ttest (ml/rat) day11 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0021 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.367 df=30 
    
How big is the difference?   
Mean ± SEM of column A 236.1 ± 9.294 N=16 
Mean ± SEM of column B 274.0 ± 6.308 N=16 
Difference between means -37.82 ± 11.23 
95% confidence interval -60.76 to -14.88 
R square 0.2742 
    
 
Parameter   
Table Analyzed ttest (ml/kg) day13 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=5.100 df=30 
    
How big is the difference?   
Mean ± SEM of column A 215.3 ± 5.151 N=16 
Mean ± SEM of column B 262.1 ± 7.597 N=16 
Difference between means -46.81 ± 9.178 
95% confidence interval -65.56 to -28.07 
R square 0.4644 








Parameter   
Table Analyzed ttest (ml/kg) day15 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0009 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.687 df=30 
    
How big is the difference?   
Mean ± SEM of column A 215.8 ± 5.071 N=16 
Mean ± SEM of column B 255.9 ± 9.606 N=16 
Difference between means -40.05 ± 10.86 
95% confidence interval -62.23 to -17.87 
R square 0.3118 
    
 
Parameter   
Table Analyzed ttest (ml/kg) day17 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0271 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.323 df=30 
    
How big is the difference?   
Mean ± SEM of column A 220.2 ± 5.214 N=16 
Mean ± SEM of column B 235.6 ± 4.091 N=16 
Difference between means -15.40 ± 6.628 
95% confidence interval -28.93 to -1.863 
R square 0.1525 
    
 
Parameter   
Table Analyzed ttest (ml/kg) day19 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.352 df=30 
    
How big is the difference?   
Mean ± SEM of column A 251.8 ± 12.85 N=16 
Mean ± SEM of column B 324.5 ± 10.70 N=16 
Difference between means -72.77 ± 16.72 
95% confidence interval -106.9 to -38.63 
R square 0.3870 









Parameter   
Table Analyzed ttest (ml/kg) day21 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=6.896 df=30 
    
How big is the difference?   
Mean ± SEM of column A 240.5 ± 6.351 N=16 
Mean ± SEM of column B 317.3 ± 9.149 N=16 
Difference between means -76.81 ± 11.14 
95% confidence interval -99.55 to -54.06 
R square 0.6132 
    
 
Body weight 
Parameter         
Table Analyzed body weight (g)       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 10.85 < 0.0001     
treatment 51.17 < 0.0001     
duration 18.91 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
treatment **** Yes     
duration **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 10 49986 4999 18.77 
treatment 1 235825 235825 885.4 
duration 10 87138 8714 32.71 
Residual 330 87899 266.4   
          
 
Parameter   
Table Analyzed day 1 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0647 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.918 df=30 
    
How big is the difference?   
Mean ± SEM of column A 220.8 ± 0.9895 N=16 
Mean ± SEM of column B 213.8 ± 3.479 N=16 
Difference between means 6.938 ± 3.617 
95% confidence interval -0.4479 to 14.32 
R square 0.1092 








Parameter   
Table Analyzed day 3 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.393 df=30 
    
How big is the difference?   
Mean ± SEM of column A 231.2 ± 1.646 N=16 
Mean ± SEM of column B 213.3 ± 3.721 N=16 
Difference between means 17.88 ± 4.069 
95% confidence interval 9.566 to 26.18 
R square 0.3914 
 
Parameter   
Table Analyzed day 5 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=7.640 df=30 
    
How big is the difference?   
Mean ± SEM of column A 247.8 ± 3.024 N=16 
Mean ± SEM of column B 212.7 ± 3.452 N=16 
Difference between means 35.06 ± 4.589 
95% confidence interval 25.69 to 44.43 
R square 0.6605 
 
Parameter   
Table Analyzed day 7 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=8.139 df=30 
    
How big is the difference?   
Mean ± SEM of column A 255.7 ± 3.608 N=16 
Mean ± SEM of column B 214.2 ± 3.603 N=16 
Difference between means 41.50 ± 5.099 
95% confidence interval 31.09 to 51.91 











Parameter   
Table Analyzed day 9 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=8.618 df=30 
    
How big is the difference?   
Mean ± SEM of column A 263.1 ± 4.247 N=16 
Mean ± SEM of column B 215.5 ± 3.525 N=16 
Difference between means 47.56 ± 5.519 
95% confidence interval 36.29 to 58.83 
R square 0.7123 
 
Parameter   
Table Analyzed day 11 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=9.091 df=30 
    
How big is the difference?   
Mean ± SEM of column A 270.9 ± 4.706 N=16 
Mean ± SEM of column B 217.0 ± 3.614 N=16 
Difference between means 53.94 ± 5.933 
95% confidence interval 41.82 to 66.05 
R square 0.7337 
 
Parameter   
Table Analyzed day 13 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=9.321 df=30 
    
How big is the difference?   
Mean ± SEM of column A 281.4 ± 5.261 N=16 
Mean ± SEM of column B 220.5 ± 3.870 N=16 
Difference between means 60.88 ± 6.531 
95% confidence interval 47.54 to 74.21 











Parameter   
Table Analyzed day 15 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=11.12 df=30 
    
How big is the difference?   
Mean ± SEM of column A 289.8 ± 5.022 N=16 
Mean ± SEM of column B 221.9 ± 3.456 N=16 
Difference between means 67.81 ± 6.096 
95% confidence interval 55.36 to 80.26 
R square 0.8049 
 
Parameter   
Table Analyzed day 17 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=10.98 df=30 
    
How big is the difference?   
Mean ± SEM of column A 295.9 ± 5.679 N=16 
Mean ± SEM of column B 222.6 ± 3.497 N=16 
Difference between means 73.25 ± 6.669 
95% confidence interval 59.63 to 86.87 
R square 0.8008 
 
Parameter   
Table Analyzed day 19 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=11.08 df=30 
    
How big is the difference?   
Mean ± SEM of column A 302.7 ± 6.071 N=16 
Mean ± SEM of column B 223.1 ± 3.840 N=16 
Difference between means 79.56 ± 7.184 
95% confidence interval 64.89 to 94.23 
R square 0.8035 











Parameter   
Table Analyzed day 21 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=12.28 df=30 
    
How big is the difference?   
Mean ± SEM of column A 308.1 ± 5.966 N=16 
Mean ± SEM of column B 223.0 ± 3.519 N=16 
Difference between means 85.06 ± 6.927 
95% confidence interval 70.92 to 99.21 
R square 0.8341 
    
 
Organ weights 
Parameter   
Table Analyzed adrenal (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value 0.0017 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.444 df=30 
    
How big is the difference?   
Mean ± SEM of column A 22.22 ± 0.8250 N=16 
Mean ± SEM of column B 15.98 ± 1.613 N=16 
Difference between means 6.239 ± 1.812 
95% confidence interval 2.540 to 9.939 
R square 0.2834 
 
Parameter   
Table Analyzed thymus (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.560 df=30 
    
How big is the difference?   
Mean ± SEM of column A 162.6 ± 7.413 N=16 
Mean ± SEM of column B 110.8 ± 8.587 N=16 
Difference between means 51.73 ± 11.34 
95% confidence interval 28.57 to 74.90 
R square 0.4094 








Table Analyzed adrenal in mgs 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=7.686 df=30 
    
How big is the difference?   
Mean ± SEM of column A 67.16 ± 2.617 N=16 
Mean ± SEM of column B 34.69 ± 3.317 N=16 
Difference between means 32.48 ± 4.225 
95% confidence interval 23.85 to 41.10 
R square 0.6632 
 
Table Analyzed Thymus in mgs 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=8.124 df=30 
    
How big is the difference?   
Mean ± SEM of column A 493.2 ± 25.59 N=16 
Mean ± SEM of column B 242.1 ± 17.32 N=16 
Difference between means 251.1 ± 30.90 
95% confidence interval 188.0 to 314.2 
R square 0.6875 
 
 
5-HT1A receptor autoradiography 
Table Analyzed stats       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 5.85 0.0007     
treatment 7.04 < 0.0001     
region 55.74 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction *** Yes     
treatment **** Yes     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 15 17418 1161 2.740 
treatment 1 20976 20976 49.49 
region 15 166002 11067 26.11 










Parameter   
Table Analyzed CA1 rad 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0010 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.117 df=14 
    
How big is the difference?   
Mean ± SEM of column A 63.18 ± 2.275 N=8 
Mean ± SEM of column B 85.14 ± 4.824 N=8 
Difference between means -21.96 ± 5.334 
95% confidence interval -33.40 to -10.52 
R square 0.5476 
    
 
Parameter   
Table Analyzed CA2 rad 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0038 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.458 df=14 
    
How big is the difference?   
Mean ± SEM of column A 61.94 ± 5.875 N=8 
Mean ± SEM of column B 104.5 ± 10.82 N=8 
Difference between means -42.57 ± 12.31 
95% confidence interval -68.98 to -16.16 
R square 0.4606 




Parameter   
Table Analyzed CA2 pyr 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0017 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.874 df=14 
    
How big is the difference?   
Mean ± SEM of column A 45.35 ± 2.649 N=8 
Mean ± SEM of column B 81.65 ± 8.986 N=8 
Difference between means -36.29 ± 9.369 
95% confidence interval -56.39 to -16.20 
R square 0.5174 








Parameter   
Table Analyzed CA3 rad 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0112 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.920 df=14 
    
How big is the difference?   
Mean ± SEM of column A 55.29 ± 4.781 N=8 
Mean ± SEM of column B 111.2 ± 18.54 N=8 
Difference between means -55.91 ± 19.15 
95% confidence interval -96.98 to -14.83 
R square 0.3785 
    
 
Parameter   
Table Analyzed MODG 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.6589 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.4510 df=14 
    
How big is the difference?   
Mean ± SEM of column A 96.91 ± 8.687 N=8 
Mean ± SEM of column B 101.3 ± 4.381 N=8 
Difference between means -4.388 ± 9.729 
95% confidence interval -25.26 to 16.48 
R square 0.01432 
    
 
Parameter   
Table Analyzed Amygdala 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0027 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.627 df=14 
    
How big is the difference?   
Mean ± SEM of column A 28.31 ± 2.493 N=8 
Mean ± SEM of column B 51.28 ± 5.821 N=8 
Difference between means -22.97 ± 6.333 
95% confidence interval -36.55 to -9.385 









Parameter   
Table Analyzed pir3 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0177 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.686 df=14 
    
How big is the difference?   
Mean ± SEM of column A 26.17 ± 2.444 N=8 
Mean ± SEM of column B 54.85 ± 10.39 N=8 
Difference between means -28.68 ± 10.68 
95% confidence interval -51.58 to -5.776 
R square 0.3401 
    
 
 
Parameter   
Table Analyzed PrL 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0031 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.573 df=14 
    
How big is the difference?   
Mean ± SEM of column A 34.61 ± 1.196 N=8 
Mean ± SEM of column B 60.51 ± 7.149 N=8 
Difference between means -25.90 ± 7.249 
95% confidence interval -41.45 to -10.35 
R square 0.4770 




Parameter   
Table Analyzed CGL 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0317 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.386 df=14 
    
How big is the difference?   
Mean ± SEM of column A 40.69 ± 5.290 N=8 
Mean ± SEM of column B 57.32 ± 4.530 N=8 
Difference between means -16.62 ± 6.965 
95% confidence interval -31.56 to -1.681 
R square 0.2892 






Parameter   
Table Analyzed M2 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0006 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.437 df=14 
    
How big is the difference?   
Mean ± SEM of column A 37.50 ± 2.166 N=8 
Mean ± SEM of column B 62.73 ± 5.258 N=8 
Difference between means -25.23 ± 5.687 
95% confidence interval -37.43 to -13.04 
R square 0.5844 
    
 
Parameter   
Table Analyzed M1 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0442 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.210 df=14 
    
How big is the difference?   
Mean ± SEM of column A 37.49 ± 3.257 N=8 
Mean ± SEM of column B 54.54 ± 6.993 N=8 
Difference between means -17.05 ± 7.714 
95% confidence interval -33.60 to -0.5042 
R square 0.2587 
    
 
 
Parameter   
Table Analyzed Raphe 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.4407 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.7935 df=14 
    
How big is the difference?   
Mean ± SEM of column A 112.6 ± 6.890 N=8 
Mean ± SEM of column B 103.7 ± 8.830 N=8 
Difference between means 8.887 ± 11.20 
95% confidence interval -15.14 to 32.91 
R square 0.04304 








Parameter   
Table Analyzed ent ctx 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.2012 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.341 df=14 
    
How big is the difference?   
Mean ± SEM of column A 61.31 ± 5.232 N=8 
Mean ± SEM of column B 71.68 ± 5.701 N=8 
Difference between means -10.38 ± 7.738 
95% confidence interval -26.98 to 6.220 
R square 0.1139 
    
 
Parameter   
Table Analyzed Vhip CA1 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.9011 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.1266 df=14 
    
How big is the difference?   
Mean ± SEM of column A 93.94 ± 11.81 N=8 
Mean ± SEM of column B 96.25 ± 13.97 N=8 
Difference between means -2.315 ± 18.29 
95% confidence interval -41.55 to 36.92 
R square 0.001143 
    
 
Parameter   
Table Analyzed subiculum 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.2928 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.117 df=9 
    
How big is the difference?   
Mean ± SEM of column A 8.343 ± 1.128 N=5 
Mean ± SEM of column B 12.51 ± 3.243 N=6 
Difference between means -4.164 ± 3.727 
95% confidence interval -12.60 to 4.267 










Parameter   
Table Analyzed hypothalamus 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.3076 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.082 df=9 
    
How big is the difference?   
Mean ± SEM of column A 23.88 ± 4.734 N=5 
Mean ± SEM of column B 17.32 ± 3.890 N=6 
Difference between means 6.557 ± 6.063 
95% confidence interval -7.157 to 20.27 
R square 0.1150 
    
 
5HIAA concentration 
Parameter         
Table Analyzed 5HIAA stats layout       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 0.23 0.9992     
treatment 0.37 0.3518     
region 54.07 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment ns No     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 7 53.79 7.684 0.07851 
treatment 1 85.59 85.59 0.8746 
region 7 12599 1800 18.39 
Residual 108 10570 97.87   
          
          
 
5-HT content 
Parameter         
Table Analyzed 5HT stats layout       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 4.07 0.0166     
treatment 0.88 0.0507     
region 71.06 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction * Yes     
treatment ns No     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 7 732.3 104.6 2.587 
treatment 1 157.8 157.8 3.903 
region 7 12781 1826 45.15 







Parameter         
Table Analyzed turnover stats layout       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 6.25 0.1053     
treatment 0.08 0.6909     
region 38.56 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment ns No     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 7 1.106 0.1580 1.749 
treatment 1 0.01436 0.01436 0.1589 
region 7 6.820 0.9743 10.78 
Residual 108 9.761 0.09038   
          
 
Corticosterone concentration (RIA) 
Parameter         
Table Analyzed Corticosterone 2way ANOVA       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 26.17 < 0.0001     
Treatment 8.19 0.0051     
Timepoint 26.34 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
Treatment ** Yes     
Timepoint **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 1 400423 400423 28.04 
Treatment 1 125328 125328 8.775 
Timepoint 1 403080 403080 28.22 
Residual 41 585575 14282   
 
Parameter   
Table Analyzed 0hrs VEH vs Cort 
Column A Vehicle 0hrs 
vs vs 
Column B Corticosterone 0hrs 
    
Unpaired t test   
P value 0.0083 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.073 df=14 
    
How big is the difference?   
Mean ± SEM of column A 109.6 ± 37.99 N=7 
Mean ± SEM of column B 419.1 ± 83.20 N=9 
Difference between means -309.5 ± 100.7 
95% confidence interval -525.5 to -93.46 
R square 0.4028 







Parameter   
Table Analyzed 24hrsVEH vs Cort 
Column A Vehicle 24hrs 
vs vs 
Column B Corticosterone 24hrs 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=7.469 df=27 
    
How big is the difference?   
Mean ± SEM of column A 109.0 ± 12.19 N=13 
Mean ± SEM of column B 21.54 ± 3.748 N=16 
Difference between means 87.42 ± 11.71 
95% confidence interval 63.41 to 111.4 
R square 0.6738 
    
 
Parameter   
Table Analyzed veh 0&24hrs 
Column A Vehicle 0hrs 
vs vs 
Column B veh 24 hrs 
    
Unpaired t test   
P value 0.9838 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.02056 df=18 
    
How big is the difference?   
Mean ± SEM of column A 109.6 ± 37.99 N=7 
Mean ± SEM of column B 109.0 ± 12.19 N=13 
Difference between means 0.6575 ± 31.98 
95% confidence interval -66.54 to 67.86 
R square 2.347e-005 
    
 
 
Parameter   
Table Analyzed cort 0&24hrs 
Column A Corticosterone 0hrs 
vs vs 
Column B Corticosterone 24hrs 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=6.460 df=23 
    
How big is the difference?   
Mean ± SEM of column A 419.1 ± 83.20 N=9 
Mean ± SEM of column B 21.54 ± 3.748 N=16 
Difference between means 397.5 ± 61.54 
95% confidence interval 270.2 to 524.9 
R square 0.6447 








Oxytocin receptor autoradiography 
Table Analyzed veh vs cort all regions       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 6.42 < 0.0001     
treatment 2.74 < 0.0001     
region 75.47 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
treatment **** Yes     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 8 0.03396 0.004246 6.071 
treatment 1 0.01450 0.01450 20.74 
region 8 0.3991 0.04989 71.35 
Residual 114 0.07972 0.0006993   
 
Parameter   
Table Analyzed MS 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.4906 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.7079 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.04063 ± 0.004595 N=8 
Mean ± SEM of column B 0.04544 ± 0.005010 N=8 
Difference between means -0.004813 ± 0.006798 
95% confidence interval -0.01939 to 0.009769 
R square 0.03456 
    
 
Parameter   
Table Analyzed Raphe 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=5.582 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.03926 ± 0.005107 N=8 
Mean ± SEM of column B 0.08344 ± 0.006045 N=8 
Difference between means -0.04418 ± 0.007914 
95% confidence interval -0.06115 to -0.02720 
R square 0.6900 









Parameter   
Table Analyzed Dhipp 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.6119 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5189 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.02918 ± 0.003313 N=8 
Mean ± SEM of column B 0.02678 ± 0.003228 N=8 
Difference between means 0.0024 ± 0.004625 
95% confidence interval -0.007521 to 0.01232 
R square 0.01887 
    
 
Parameter   
Table Analyzed LSD 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0008 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.273 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.07584 ± 0.01298 N=8 
Mean ± SEM of column B 0.1532 ± 0.01263 N=8 
Difference between means -0.07736 ± 0.01811 
95% confidence interval -0.1162 to -0.03852 
R square 0.5660 
    
 
Parameter   
Table Analyzed insular cortex 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.9729 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.03455 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.02551 ± 0.002094 N=8 
Mean ± SEM of column B 0.02539 ± 0.002950 N=8 
Difference between means 0.0001250 ± 0.003617 
95% confidence interval -0.007634 to 0.007884 
R square 8.528e-005 









Parameter   
Table Analyzed amygdala 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0962 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.783 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.1719 ± 0.02137 N=8 
Mean ± SEM of column B 0.2233 ± 0.01927 N=8 
Difference between means -0.05131 ± 0.02877 
95% confidence interval -0.1130 to 0.01041 
R square 0.1851 
    
 
Parameter   
Table Analyzed vhipp 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0476 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.292 df=9 
    
How big is the difference?   
Mean ± SEM of column A 0.03383 ± 0.007683 N=6 
Mean ± SEM of column B 0.0574 ± 0.006416 N=5 
Difference between means -0.02357 ± 0.01028 
95% confidence interval -0.04682 to -0.0003128 
R square 0.3687 
    
 
Table Analyzed subiculum 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0924 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.948 df=7 
    
How big is the difference?   
Mean ± SEM of column A 0.0316 ± 0.009003 N=5 
Mean ± SEM of column B 0.05575 ± 0.008004 N=4 
Difference between means -0.02415 ± 0.01240 
95% confidence interval -0.05346 to 0.005165 









Vasopressin 1a receptor autoradiography 
Table Analyzed veh vs cort layout-use this one       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 9.33 0.0006     
treatment 3.73 0.0002     
regions 42.27 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction *** Yes     
treatment *** Yes     
regions **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 11 0.2140 0.01945 3.192 
treatment 1 0.08561 0.08561 14.05 
regions 11 0.9690 0.08809 14.46 
Residual 168 1.024 0.006094   
          
 
Parameter   
Table Analyzed LDDM 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.6717 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.4328 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.2850 ± 0.03482 N=8 
Mean ± SEM of column B 0.3078 ± 0.03949 N=8 
Difference between means -0.02279 ± 0.05265 
95% confidence interval -0.1357 to 0.09014 
R square 0.01321 
    
 
Parameter   
Table Analyzed MO-DG 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.1738 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.433 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.1562 ± 0.02165 N=8 
Mean ± SEM of column B 0.1934 ± 0.01426 N=8 
Difference between means -0.03715 ± 0.02593 
95% confidence interval -0.09276 to 0.01846 
R square 0.1279 









Parameter   
Table Analyzed PO-DG 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0036 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.486 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.1430 ± 0.01933 N=8 
Mean ± SEM of column B 0.2469 ± 0.02267 N=8 
Difference between means -0.1039 ± 0.02979 
95% confidence interval -0.1678 to -0.03996 
R square 0.4647 
    
 
Parameter   
Table Analyzed PO 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.1603 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.483 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.1933 ± 0.02440 N=8 
Mean ± SEM of column B 0.2540 ± 0.03288 N=8 
Difference between means -0.06071 ± 0.04094 
95% confidence interval -0.1485 to 0.02711 
R square 0.1357 
    
 
Parameter   
Table Analyzed VM 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.5727 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5776 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.2076 ± 0.02382 N=8 
Mean ± SEM of column B 0.2235 ± 0.01397 N=8 
Difference between means -0.01595 ± 0.02762 
95% confidence interval -0.07519 to 0.04329 
R square 0.02327 








Parameter   
Table Analyzed PEFLH 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.6572 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.4534 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.2077 ± 0.03069 N=8 
Mean ± SEM of column B 0.2254 ± 0.02386 N=8 
Difference between means -0.01763 ± 0.03887 
95% confidence interval -0.1010 to 0.06576 
R square 0.01447 
    
 
Parameter   
Table Analyzed VMDH 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0034 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.524 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.3771 ± 0.03655 N=8 
Mean ± SEM of column B 0.2223 ± 0.02436 N=8 
Difference between means 0.1548 ± 0.04392 
95% confidence interval 0.06059 to 0.2490 
R square 0.4701 
    
 
Parameter   
Table Analyzed GRDG 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0964 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.782 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.2470 ± 0.03423 N=8 
Mean ± SEM of column B 0.3439 ± 0.04224 N=8 
Difference between means -0.0969 ± 0.05437 
95% confidence interval -0.2135 to 0.01973 
R square 0.1849 









Parameter   
Table Analyzed Septal nuclei 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0026 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=3.650 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.3294 ± 0.02082 N=8 
Mean ± SEM of column B 0.4290 ± 0.01762 N=8 
Difference between means -0.09957 ± 0.02728 
95% confidence interval -0.1581 to -0.04106 
R square 0.4877 
    
 
Parameter   
Table Analyzed nucleus accumbens 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.1560 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.499 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.3879 ± 0.03036 N=8 
Mean ± SEM of column B 0.4496 ± 0.02782 N=8 
Difference between means -0.06175 ± 0.04118 
95% confidence interval -0.1501 to 0.02658 
R square 0.1384 
    
 
Parameter   
Table Analyzed raphe 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0140 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.808 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.2524 ± 0.02158 N=8 
Mean ± SEM of column B 0.3378 ± 0.02142 N=8 
Difference between means -0.08538 ± 0.03041 
95% confidence interval -0.1506 to -0.02015 
R square 0.3602 









Parameter   
Table Analyzed CeA 
Column A veh 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.1742 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.431 df=14 
    
How big is the difference?   
Mean ± SEM of column A 0.2084 ± 0.03316 N=8 
Mean ± SEM of column B 0.2683 ± 0.02552 N=8 
Difference between means -0.05989 ± 0.04184 
95% confidence interval -0.1496 to 0.02986 
R square 0.1277 
    
 
Oxytocin tissue RIA 
Parameter         
Table Analyzed Stats relayout       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 18.23 < 0.0001     
treatment 2.69 < 0.0001     
region 58.73 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction **** Yes     
treatment **** Yes     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 7 50880 7269 16.43 
treatment 1 7517 7517 16.99 
region 7 163938 23420 52.94 
Residual 94 41587 442.4   
          
 
 
Parameter   
Table Analyzed Hypothalamus 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.0019 
P value summary ** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.047 df=11 
    
How big is the difference?   
Mean ± SEM of column A 57.83 ± 17.30 N=6 
Mean ± SEM of column B 191.3 ± 26.58 N=7 
Difference between means -133.5 ± 32.98 
95% confidence interval -206.1 to -60.89 
R square 0.5982 







Parameter   
Table Analyzed Prefrontal cortex 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.7603 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.3121 df=12 
    
How big is the difference?   
Mean ± SEM of column A 0.6326 ± 0.1513 N=7 
Mean ± SEM of column B 0.7277 ± 0.2643 N=7 
Difference between means -0.09506 ± 0.3045 
95% confidence interval -0.7586 to 0.5685 
R square 0.008054 
    
 
Parameter   
Table Analyzed Septal nuclei 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.3354 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.000 df=13 
    
How big is the difference?   
Mean ± SEM of column A 8.684 ± 1.728 N=7 
Mean ± SEM of column B 11.55 ± 2.204 N=8 
Difference between means -2.863 ± 2.862 
95% confidence interval -9.044 to 3.319 
R square 0.07146 
    
 
Parameter   
Table Analyzed Amygdala 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.3506 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.9748 df=11 
    
How big is the difference?   
Mean ± SEM of column A 3.435 ± 1.345 N=6 
Mean ± SEM of column B 2.121 ± 0.4962 N=7 
Difference between means 1.314 ± 1.348 
95% confidence interval -1.653 to 4.281 
R square 0.07951 









Parameter   
Table Analyzed Dorsal hippocampus 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.3491 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.9780 df=11 
    
How big is the difference?   
Mean ± SEM of column A 0.2225 ± 0.07956 N=5 
Mean ± SEM of column B 0.3642 ± 0.1021 N=8 
Difference between means -0.1417 ± 0.1449 
95% confidence interval -0.4606 to 0.1772 
R square 0.08000 
    
 
Parameter   
Table Analyzed Ventral hippocampus 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.1257 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.636 df=13 
    
How big is the difference?   
Mean ± SEM of column A 0.5763 ± 0.1209 N=6 
Mean ± SEM of column B 0.3446 ± 0.08339 N=9 
Difference between means 0.2318 ± 0.1416 
95% confidence interval -0.07418 to 0.5377 
R square 0.1708 
    
 
Parameter   
Table Analyzed Raphe 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.3797 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.9152 df=11 
    
How big is the difference?   
Mean ± SEM of column A 8.176 ± 2.128 N=6 
Mean ± SEM of column B 13.76 ± 5.312 N=7 
Difference between means -5.580 ± 6.097 
95% confidence interval -19.00 to 7.839 
R square 0.07076 









Parameter   
Table Analyzed Plasma 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.2538 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.204 df=11 
    
How big is the difference?   
Mean ± SEM of column A 16.83 ± 4.695 N=7 
Mean ± SEM of column B 10.01 ± 2.656 N=6 
Difference between means 6.813 ± 5.658 
95% confidence interval -5.640 to 19.26 
R square 0.1165 
    
 
Vasopressin tissue content (RIA) 
Parameter         
Table Analyzed stats relayout       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 0.77 0.2175     
treatment 0.01 0.7391     
region 86.37 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment ns No     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 7 3834 547.8 1.388 
treatment 1 43.99 43.99 0.1115 
region 7 428805 61258 155.2 
Residual 110 43409 394.6   
          
 
Parameter   
Table Analyzed Pituitary gland 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.7713 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.2964 df=14 
    
How big is the difference?   
Mean ± SEM of column A 53.35 ± 8.334 N=8 
Mean ± SEM of column B 50.08 ± 7.250 N=8 
Difference between means 3.274 ± 11.05 
95% confidence interval -20.42 to 26.97 
R square 0.006237 








Parameter   
Table Analyzed Prefrontal cortex 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.7557 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.3169 df=15 
    
How big is the difference?   
Mean ± SEM of column A 1.341 ± 0.2826 N=7 
Mean ± SEM of column B 1.236 ± 0.1936 N=10 
Difference between means 0.1046 ± 0.3300 
95% confidence interval -0.5987 to 0.8079 
R square 0.006650 
    
 
Parameter   
Table Analyzed Septal nuclei 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.3891 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.8967 df=11 
    
How big is the difference?   
Mean ± SEM of column A 9.428 ± 2.237 N=6 
Mean ± SEM of column B 11.95 ± 1.760 N=7 
Difference between means -2.518 ± 2.808 
95% confidence interval -8.699 to 3.663 
R square 0.06812 
    
 
 
Parameter   
Table Analyzed Amygdala 
Column A Vehicle 
vs vs 
  
Column B Corticosterone 
    
Unpaired t test   
P value 0.0537 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=2.121 df=13 
    
How big is the difference?   
Mean ± SEM of column A 5.085 ± 1.103 N=6 
Mean ± SEM of column B 9.300 ± 1.435 N=9 
Difference between means -4.215 ± 1.987 
95% confidence interval -8.507 to 0.07694 
R square 0.2571 








Parameter   
Table Analyzed Dorsal hippocampus 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.5052 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.6839 df=14 
    
How big is the difference?   
Mean ± SEM of column A 2.062 ± 0.7749 N=6 
Mean ± SEM of column B 1.581 ± 0.2958 N=10 
Difference between means 0.4803 ± 0.7022 
95% confidence interval -1.026 to 1.986 
R square 0.03233 
    
 
Parameter   
Table Analyzed Ventral hippocampus 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.1753 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.418 df=16 
    
How big is the difference?   
Mean ± SEM of column A 3.674 ± 1.125 N=8 
Mean ± SEM of column B 2.165 ± 0.3253 N=10 
Difference between means 1.509 ± 1.064 
95% confidence interval -0.7462 to 3.764 
R square 0.1117 
    
 
Parameter   
Table Analyzed Raphe 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.2623 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.176 df=12 
    
How big is the difference?   
Mean ± SEM of column A 68.27 ± 20.27 N=7 
Mean ± SEM of column B 40.92 ± 11.37 N=7 
Difference between means 27.34 ± 23.25 
95% confidence interval -23.31 to 77.99 
R square 0.1034 









Parameter   
Table Analyzed Plasma 
Column A Vehicle 
vs vs 
Column B Corticosterone 
    
Unpaired t test   
P value 0.2823 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.115 df=15 
    
How big is the difference?   
Mean ± SEM of column A 172.5 ± 12.69 N=7 
Mean ± SEM of column B 188.9 ± 8.528 N=10 
Difference between means -16.37 ± 14.68 
95% confidence interval -47.64 to 14.91 
R square 0.07655 
    
 
 











Number of XY Pairs 5 7 7 6 5 5 6 
Pearson r 0.08548 0.3317 0.2519 0.2107 0.1371 0.08744 0.1716 















P value (two-tailed) 0.8913 0.4674 0.5859 0.6886 0.8260 0.8888 0.7452 
P value summary ns ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) No No No No No No No 
R square 0.007307 0.1100 0.06343 0.04439 0.01879 0.007646 0.02943 
 










Number of XY Pairs 6 7 7 8 8 8 8 
Pearson r -0.01458 -0.6178 -0.1508 -0.3480 -0.5356 -0.3153 -0.03550 















P value (two-tailed) 0.9781 0.1393 0.7469 0.3982 0.1712 0.4469 0.9335 
P value summary ns ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) No No No No No No No 
R square 0.0002126 0.3816 0.02275 0.1211 0.2869 0.09939 0.001260 
 










Number of XY Pairs 7 7 5 6 5 7 7 
Pearson r 0.8099 0.2979 0.07844 0.6514 -0.2900 0.1268 -0.1890 















P value (two-tailed) 0.0272 0.5164 0.9002 0.1611 0.6360 0.7864 0.6848 
P value summary * ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) Yes No No No No No No 















Number of XY Pairs 7 9 7 9 9 9 6 
Pearson r 0.6058 -0.3480 0.2985 0.07275 -0.1153 -0.1967 0.02719 















P value (two-tailed) 0.1494 0.3588 0.5155 0.8525 0.7678 0.6120 0.9592 
P value summary ns ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) No No No No No No No 
R square 0.3670 0.1211 0.08911 0.005292 0.01329 0.03868 0.0007391 
 












Number of XY Pairs 5 6 6 5 5 5 5 
Pearson r -0.8715 -0.3386 -0.2208 -0.3645 -0.2798 -0.05288 -0.5926 















P value (two-tailed) 0.0542 0.5116 0.6741 0.5464 0.6484 0.9327 0.2923 
P value summary ns ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) No No No No No No No 
R square 0.7595 0.1146 0.04876 0.1329 0.07830 0.002796 0.3512 
 
Plasma oxytocin and tissue oxytocin – CORT treated group 
Parameter hypothalamus 
prefrontal 





Number of XY Pairs 3 4 5 6 5 6 5 
Pearson r -0.9569 -0.5573 0.08840 0.3021 0.3084 -0.004846 -0.1889 













P value (two-tailed) ns 0.4427 0.8876 0.5607 0.6136 0.9927 0.7609 
P value summary No ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) 0.9157 No No No No No No 
R square   0.3106 0.007814 0.09125 0.09511 2.348e-005 0.03569 
 










Number of XY Pairs 7 6 5 5 5 7 6 
Pearson r -0.3861 0.2248 0.5953 0.4189 -0.4880 -0.2183 0.8532 















P value (two-tailed) 0.3923 0.6685 0.2895 0.4827 0.4043 0.6381 0.0307 
P value summary ns ns ns ns ns ns * 
Is the correlation significant? 
(alpha=0.05) No No No No No No Yes 




















Number of XY Pairs 8 10 7 9 10 10 7 
Pearson r 0.3861 0.2748 0.2291 -0.2152 -0.4061 -0.3406 -0.7133 















P value (two-tailed) 0.3448 0.4422 0.6212 0.5782 0.2442 0.3355 0.0719 
P value summary ns ns ns ns ns ns ns 
Is the correlation significant? 
(alpha=0.05) No No No No No No No 
R square 0.1491 0.07552 0.05249 0.04630 0.1649 0.1160 0.5087 
 
t=0hrs vs t=24hrs 
Parameter         
Table Analyzed VEHwater consumed (ml/rat)       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 8.43 0.5615     
treatment 3.34 0.0844     
Duration 23.22 0.0224     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment ns No     
Duration * Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 9 274.6 30.51 0.8643 
treatment 1 108.7 108.7 3.079 
Duration 9 756.6 84.07 2.381 
Residual 60 2118 35.30   
 
Parameter         
Table Analyzed CORTwater consumed (ml/rat)       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 8.39 0.3070     
treatment 0.52 0.4141     
Duration 44.82 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment ns No     
Duration **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 9 305.7 33.97 1.208 
treatment 1 19.01 19.01 0.6763 
Duration 9 1634 181.5 6.458 
Residual 60 1687 28.11   











Parameter         
Table Analyzed VEHbody weight (g)       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 0.55 0.8666     
treatment 0.85 0.0044     
Day 62.04 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment ** Yes     
Day **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 10 1353 135.3 0.5321 
treatment 1 2104 2104 8.273 
Day 10 152859 15286 60.11 
Residual 242 61542 254.3   
          
 
Parameter         
Table Analyzed 
CORTbody weight 
(g)       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 1.10 0.9674     
treatment 9.67 < 0.0001     
duration 5.22 0.0943     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment **** Yes     
duration ns No     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 10 847.9 84.79 0.3461 
treatment 1 7465 7465 30.47 
duration 10 4029 402.9 1.644 
Residual 264 64682 245.0   
          
 
Parameter   
Table Analyzed adrenal (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=7.078 df=15 
    
How big is the difference?   
Mean ± SEM of column A 12.88 ± 1.050 N=8 
Mean ± SEM of column B 4.127 ± 0.7018 N=9 
Difference between means 8.755 ± 1.237 
95% confidence interval 6.119 to 11.39 
R square 0.7696 







Parameter   
Table Analyzed thymus (mg)/100 g body weight (g) 
Column A VEHICLE 
vs vs 
Column B CORT 
    
Unpaired t test   
P value < 0.0001 
P value summary **** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=9.009 df=16 
    
How big is the difference?   
Mean ± SEM of column A 170.9 ± 7.931 N=8 
Mean ± SEM of column B 87.65 ± 5.329 N=10 
Difference between means 83.29 ± 9.245 
95% confidence interval 63.69 to 102.9 
R square 0.8353 
    
 
CB1 receptor autoradiography 
Parameter         
Table Analyzed fmol/mg tiss all       
          
Two-way ANOVA         
          
Source of Variation % of total variation P value     
Interaction 0.86 0.6498     
treatment 0.22 0.0499     
region 84.80 < 0.0001     
          
Source of Variation P value summary Significant?     
Interaction ns No     
treatment * Yes     
region **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Interaction 18 2222 123.4 0.8418 
treatment 1 569.6 569.6 3.884 
region 18 218766 12154 82.88 
Residual 248 36367 146.6   
          
 
 
Parameter   
Table Analyzed ttest striata 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0002 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=5.040 df=14 
    
How big is the difference?   
Mean ± SEM of column A 36.53 ± 2.190 N=8 
Mean ± SEM of column B 23.85 ± 1.238 N=8 
Difference between means 12.68 ± 2.515 
95% confidence interval 7.281 to 18.07 







Parameter   
Table Analyzed ttest vhip 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.6053 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5287 df=14 
    
How big is the difference?   
Mean ± SEM of column A 30.74 ± 3.239 N=8 
Mean ± SEM of column B 32.80 ± 2.164 N=8 
Difference between means -2.059 ± 3.895 
95% confidence interval -10.41 to 6.296 
R square 0.01958 
 
Parameter   
Table Analyzed ttest SNR 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.4580 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.7632 df=14 
    
How big is the difference?   
Mean ± SEM of column A 147.5 ± 19.72 N=8 
Mean ± SEM of column B 130.0 ± 11.86 N=8 
Difference between means 17.56 ± 23.01 
95% confidence interval -31.79 to 66.91 
R square 0.03994 
    
 
Parameter   
Table Analyzed ttest Dhipp CA1 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.7596 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.3120 df=14 
    
How big is the difference?   
Mean ± SEM of column A 24.16 ± 1.605 N=8 
Mean ± SEM of column B 25.01 ± 2.215 N=8 
Difference between means -0.8533 ± 2.735 
95% confidence interval -6.720 to 5.013 










Parameter   
Table Analyzed ttest Dhipp CA2 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.7438 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.3333 df=14 
    
How big is the difference?   
Mean ± SEM of column A 26.10 ± 1.393 N=8 
Mean ± SEM of column B 27.14 ± 2.778 N=8 
Difference between means -1.036 ± 3.108 
95% confidence interval -7.702 to 5.630 
R square 0.007873 
    
 
Parameter   
Table Analyzed ttest Dhipp CA3 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.5152 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.6677 df=14 
    
How big is the difference?   
Mean ± SEM of column A 27.43 ± 2.114 N=8 
Mean ± SEM of column B 25.13 ± 2.719 N=8 
Difference between means 2.299 ± 3.444 
95% confidence interval -5.088 to 9.687 
R square 0.03086 
 
Parameter   
Table Analyzed ttest PODG 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.8281 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.2213 df=14 
    
How big is the difference?   
Mean ± SEM of column A 21.32 ± 1.336 N=8 
Mean ± SEM of column B 21.93 ± 2.404 N=8 
Difference between means -0.6086 ± 2.751 
95% confidence interval -6.508 to 5.291 










Parameter   
Table Analyzed ttest Raphe 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0008 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.227 df=14 
    
How big is the difference?   
Mean ± SEM of column A 16.55 ± 1.796 N=8 
Mean ± SEM of column B 8.862 ± 0.2834 N=8 
Difference between means 7.684 ± 1.818 
95% confidence interval 3.784 to 11.58 
R square 0.5606 
    
 
Parameter   
Table Analyzed ttest Entorhinal cortex 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.2338 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.244 df=14 
    
How big is the difference?   
Mean ± SEM of column A 18.44 ± 2.004 N=8 
Mean ± SEM of column B 15.43 ± 1.358 N=8 
Difference between means 3.012 ± 2.421 
95% confidence interval -2.180 to 8.205 
R square 0.09959 
    
 
Parameter   
Table Analyzed ttest PrL 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.7824 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.2816 df=14 
    
How big is the difference?   
Mean ± SEM of column A 23.70 ± 2.064 N=8 
Mean ± SEM of column B 22.85 ± 2.184 N=8 
Difference between means 0.8461 ± 3.005 
95% confidence interval -5.599 to 7.291 
R square 0.005633 










Parameter   
Table Analyzed ttest CgL 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.8798 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.1540 df=14 
    
How big is the difference?   
Mean ± SEM of column A 26.64 ± 1.250 N=8 
Mean ± SEM of column B 26.98 ± 1.766 N=8 
Difference between means -0.3333 ± 2.164 
95% confidence interval -4.974 to 4.308 
R square 0.001691 
    
 
Parameter   
Table Analyzed ttest M1 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0112 
P value summary * 
Are means signif. different? (P < 0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.920 df=14 
    
How big is the difference?   
Mean ± SEM of column A 35.53 ± 3.440 N=8 
Mean ± SEM of column B 24.02 ± 1.927 N=8 
Difference between means 11.51 ± 3.943 
95% confidence interval 3.055 to 19.97 
R square 0.3785 
    
 
 
Parameter   
Table Analyzed ttest M2 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.1760 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.425 df=14 
    
How big is the difference?   
Mean ± SEM of column A 30.83 ± 1.630 N=8 
Mean ± SEM of column B 27.20 ± 1.960 N=8 
Difference between means 3.632 ± 2.549 
95% confidence interval -1.835 to 9.099 
R square 0.1267 








Parameter   
Table Analyzed ttest nucc shell 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.2291 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.258 df=14 
    
How big is the difference?   
Mean ± SEM of column A 15.05 ± 1.947 N=8 
Mean ± SEM of column B 18.09 ± 1.432 N=8 
Difference between means -3.039 ± 2.417 
95% confidence interval -8.223 to 2.145 
R square 0.1015 
    
 
Parameter   
Table Analyzed ttest nucc core 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.8780 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.1564 df=14 
    
How big is the difference?   
Mean ± SEM of column A 15.05 ± 1.947 N=8 
Mean ± SEM of column B 15.42 ± 1.328 N=8 
Difference between means -0.3685 ± 2.356 
95% confidence interval -5.423 to 4.686 
R square 0.001744 
    
 
Parameter   
Table Analyzed ttest amygdala 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.9644 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.04548 df=14 
    
How big is the difference?   
Mean ± SEM of column A 14.18 ± 0.6574 N=8 
Mean ± SEM of column B 14.24 ± 1.156 N=8 
Difference between means -0.06048 ± 1.330 
95% confidence interval -2.913 to 2.792 
R square 0.0001477 









Parameter   
Table Analyzed ttest VMDH 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.2456 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.253 df=8 
    
How big is the difference?   
Mean ± SEM of column A 10.69 ± 1.958 N=5 
Mean ± SEM of column B 7.955 ± 0.9608 N=5 
Difference between means 2.732 ± 2.181 
95% confidence interval -2.297 to 7.762 
R square 0.1640 
    
 
Parameter   
Table Analyzed ttest PVN 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.0841 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=1.972 df=8 
    
How big is the difference?   
Mean ± SEM of column A 9.101 ± 0.6733 N=5 
Mean ± SEM of column B 7.013 ± 0.8176 N=5 
Difference between means 2.088 ± 1.059 
95% confidence interval -0.3540 to 4.531 
R square 0.3270 
    
 
 
Parameter   
Table Analyzed ttest subiculum 
Column A vehicle 
vs vs 
Column B cort 
    
Unpaired t test   
P value 0.5896 
P value summary ns 
Are means signif. different? (P < 0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t=0.5619 df=8 
    
How big is the difference?   
Mean ± SEM of column A 29.52 ± 1.518 N=5 
Mean ± SEM of column B 30.78 ± 1.656 N=5 
Difference between means -1.262 ± 2.246 
95% confidence interval -6.442 to 3.918 











Brain/ Region Width (mm) Height (mm) 
Prefrontal cortex   
PrL 0.25 1.00 
CGL 0.25 1.00 
M2 0.25 1.00 
M1 0.25 1.00 
Striata 1.00 1.00 
Septal nuclei   
LSD 0.40 0.50 
MSD 0.50 0.80 
Nucleus Accumbens   
Shell 0.50 0.80 
Core   
Insular cortex 0.30 1.00 
Dorsal hippocampus   
CA1-rad 0.16 0.80 
CA2-rad 0.15 0.60 
CA2-pyr 0.15 0.60 
CA3-rad 0.16 0.80 
MODG 0.20 0.80 
PODG 0.20 0.80 
Thalamus   
LDDM 0.40 0.40 
VM 1.00 1.00 
PO 0.60 1.00 
Hypothalamus   
VMDH 0.40 1.00 
PEFLH 0.60 0.70 
PVN 0.10 0.60 
Amygdala   
CeA 0.60 0.60 
Ventral hippocampus   
CA1 rad 0.35 2.00 
Subiculum 0.30 0.60 
GRDG 0.35 1.00 
Piriform cortex 0.30 1.20 
Entorhinal cortex 0.70 0.35 
Raphé 0.50 0.25 
 
 
